Bifunctional protein degraders containing sulfur / oxygen substituted glutarimide-based isoindolinone skeleton, and use thereof

Abstract

Provided are a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug or polymorph thereof, and the use thereof. Also provided are a pharmaceutical composition containing a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug or polymorph thereof as an active ingredient, and the use thereof. Further provided is the use of a compound of formula (II) or a salt, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug or polymorph thereof.

Description

Bifunctional proteolysis targeting drugs containing sulfur / oxygen substituted glutarimide-based isoindolinone scaffolds and their uses TECHNICAL FIELD

[0001] The present disclosure relates to the use of compounds of Formula (II), compounds of Formula (I) containing the same, and the use of compounds of Formula (I). The sulfur / oxygen substituted glutarimide-based isoindolinone scaffold compounds of Formula (II) of the present disclosure are capable of binding to Cereblon (CRBN) E3 ubiquitin ligase and are used to prepare compounds of Formula (I). The compounds of Formula (I) of the present disclosure designed based on the compounds of Formula (II) and various target protein ligands can have a wide range of pharmacological activities through degradation / inhibition of various different pathogenic protein classes or families. BACKGROUND

[0002] Bifunctional proteolysis targeting drugs are composed of three parts, one end is a ligand head that can bind to a specific target protein, the other end is a small molecule ligand of E3 ubiquitin ligase, and the two parts are connected by a linker unit of different lengths and types in the middle. Bifunctional proteolysis targeting small molecule compounds can simultaneously bind to a specific target protein and E3 ubiquitin ligase by the binding of the two end ligands, thereby recruiting E3 ubiquitin ligase to the vicinity of the specific target protein and allowing the E3 ubiquitin ligase to ubiquitinate the target protein. The target protein ubiquitinated by multiple ubiquitins is recognized and degraded by proteasomes in the body. This bifunctional proteolysis targeting drug can fundamentally eliminate the disease progression caused by the abnormal expression of driver genes and the drug resistance caused by the acquired mutations of driver genes.

[0003] E3 ubiquitin ligases involved in the design of targeted protein degradation drugs include more than 600 different proteins, each with a different cellular expression profile, and can be divided into multiple classes according to the structural elements of their E3 functional activity. Only a few of the ligases have been successfully applied in preclinical and clinical studies of degrading agents, and CRBN E3 ubiquitin ligase is one of the most widely used E3 ubiquitin ligases. The known CRBN-type E3 ubiquitin ligase ligands (CRBN ligands) include thalidomide and its analogs pomalidomide and lenalidomide, all of which have a phthalimide skeleton. CRBN-type E3 ubiquitin ligase ligands can also act as molecular glue to induce the degradation of specific proteins. CRBN forms a functional E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cullin 4A, and in the complex CRBN functions as a substrate receptor. Molecular glue degraders such as thalidomide bind to CRBN and induce CRBN to recognize new substrate proteins for ubiquitination and further recognition by proteasomes for degradation. CRBN ligands can not only act as molecular glue degraders to induce the degradation of different substrate proteins, but also be used as part of a bifunctional protein degradation drug to achieve effective degradation of specific pathogenic proteins. The structural novelty of the known CRBN ligand candidate compounds is very limited, and the design of diversified scaffolds to develop more CRBN ligands has become a research and development hotspot in this field.

[0004] Therefore, there is an urgent need for a series of novel CRBN E3 ubiquitin ligase ligands that can be used as effective molecular glue degraders and can be further synthesized into corresponding bifunctional protein degradation agents for the treatment and / or prevention of protein-mediated or related diseases or disorders. SUMMARY

[0005] In view of the above, the purpose of the present disclosure is to provide novel E3 ubiquitin ligase small molecule ligands, bifunctional protein degradation molecules designed based on novel E3 ubiquitin ligase small molecule ligands and various target protein ligands, their uses, and methods of using them. The compounds provided herein have the advantage of having a wide range of pharmacological activities by degrading / inhibiting various different classes or families of pathogenic proteins.

[0006] To achieve the above and other related purposes, in one aspect, the present disclosure provides the use of a compound of formula (II) based on a sulfur / oxygen-substituted glutarimide-based isoindolinone scaffold in the preparation of a bifunctional protein degradation small molecule drug. The compound of formula (II) based on a sulfur / oxygen-substituted glutarimide-based isoindolinone scaffold can bind to CRBN E3 ubiquitin ligase as a molecular glue, be an E3 ubiquitin ligase small molecule ligand, have CRBN binding ability, have anti-tumor activity, and thus can be used in a bifunctional protein degradation small molecule drug.

[0007] The sulfur / oxygen-substituted glutarimide-based isoindolinone skeleton-based compounds of the present disclosure can be a compound of Formula (II) or a salt, stereoisomer (including an enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof: wherein Z represents C(O) or CH2; R a1 , R a2 , R a3 , and R a4 are the same or different and each independently represents hydrogen, deuterium, halogen, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1- 6alkyl, C 1-6 alkoxy, deuterated C 1-6 6alkoxy, or haloC 1-6 alkoxy; (R a5 ) m represents the isoindoline ring to which it is attached is optionally substituted with m R a5 groups, each R a5 is the same or different and each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, deuterated C 1- 6alkoxy, or haloC 1-6 alkoxy; m represents an integer of 0, 1, 2, or 3; L1 represents S or O; L2 represents substituted or unsubstituted straight-chained or branched alkylene, or L2 is absent; R E represents: wherein ring Y 1 represents arylene, heteroarylene, heterocyclylene, or cycloalkylene, (R d1 ) n1 represents ring Y 1 is optionally substituted with n1 R d1 groups, each R d1 is independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, or C 1-6 alkoxy, and n1 represents an integer of 0-20; w represents an integer of 0 or 1; and ring Y 3 represents a nitrogen-containing heterocyclyl, (R d2 ) n2 represents ring Y 3 is optionally substituted with n2 R d2 groups, each R d2each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, and n2 represents an integer from 0 to 20.

[0008] In another aspect, the bifunctional protein degrader molecules of the present disclosure designed based on E3 ubiquitin ligase small molecule ligands and various target protein ligands can be a compound of Formula (I) or a salt, stereoisomer (including enantiomeric), solvate, isotopically enriched analog, prodrug, or polymorph thereof: PBM-LIN-ULM (I) wherein PBM represents a targeting moiety capable of binding a protein, the PBM is covalently linked to ULM through a group LIN; ULM represents a ligand moiety capable of binding an E3 ubiquitin ligase, and represents a structure of the following Formula (ULM): wherein Z represents C(O) or CH2; R a1 , R a2 , R a3 , and R a4 are the same or different and each independently represents hydrogen, deuterium, halogen, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1- 6alkyl, C 1-6 alkoxy, deuterated C 1-6 alkoxy, or haloC 1-6 alkoxy; (R a5 ) m represents the isoindoline ring to which it is attached is optionally substituted with m R a5 each R a5 is the same or different and each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, deuterated C 1- 6alkoxy, or haloC 1-6 alkoxy; m represents an integer 0, 1, 2, or 3; L1 represents S or O; L2 represents substituted or unsubstituted straight-chained or branched alkylene, or L2 is absent; R a6 represents: wherein ring Y 1 represents arylene, heteroarylene, heterocyclylene, or cycloalkylene, (R d1 ) n1 represents ring Y 1 optionally substituted with n1 R d1 groups, each Rd1 each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, and n1 represents an integer from 0 to 20; w represents an integer 0 or 1 ; ring Y 2 represents a nitrogen-containing heterocyclyl, (R d2 ) n2 represents ring Y 2 is optionally substituted with n2 R d2 groups, each R d2 each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, and n2 represents an integer from 0 to 20; and the symbol ** indicates a point of attachment to LIN; and LIN represents a bond or a structure of the following formula: wherein R w2 connects PBM, R w1 connects R a6 ; R w2 represents a bond, C(O), C(O)NH, or NHC(O); each ring A 1 are the same or different and each independently represents a heterocyclylene, cycloalkylene, arylene, or heteroarylene, y1 represents an integer 0, 1, 2, or 3, (R y1 ) a1 represents each ring A 1 is independently optionally substituted with a1 R y1 groups, each R y1 is independently deuterium, C 1-6 alkyl, deuterated C 1- 6alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkoxy, halogen, amino, hydroxyl, thiol, cyano, carboxyl, C 2-6 alkenyl, and a1 represents an integer from 0 to 10; each ring A 2 are the same or different and each independently represents a heterocyclylene, cycloalkylene, arylene, or heteroarylene, y2 represents an integer 0, 1, 2, or 3, (R y2 ) a2 represents each ring A 2 each is independently optionally substituted with a2 Ry2 groups, each R y2 each independently deuterium, C 1-6 alkyl, deuterated C 1-6 alkyl, halo C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl or C 2-6 alkenyl, and a2 represents an integer from 0 to 10; each ring A 3 are identical or different and each independently represent a heterocyclylenyl, cycloalkylenyl, arylene or heteroarylene group, y3 represents an integer 0, 1, 2 or 3, (R y3 ) a3 represents each ring A 3 is independently optionally substituted by a3 R y3 groups, each R y3 is independently deuterium, C 1-6 alkyl, deuterated C 1- 6alkyl, halo C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl or C 2-6 alkenyl, and a3 represents an integer from 0 to 10; R w1 represents a bond, or represents an optionally substituted straight chain or branched C 1-20 alkylene group, wherein any one or more methylene groups of the main carbon chain skeleton of the straight chain or branched C 1-20 alkylene group are optionally replaced by one or more groups selected from R a , R b and any combination thereof, each group R a is independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 ), N(R a7 )S(O)2, C(O)N(R a7 ), N(R a7 )C(O), N(R a7 ) and N(R a7 )C(O)N(R a7 ), wherein each R a7 is independently H or C 1-3 alkyl, and when any two or more methylene groups of the main carbon chain skeleton of the straight chain or branched C 1-20 alkylene group are replaced by two or more groups R a , each group R aare not directly connected to each other; each group R b each is independently selected from the group consisting of optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclylene, optionally substituted heteroarylene, alkynylene, alkenylene, and any combination thereof.

[0009] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I) or a salt, stereoisomer (including an enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof, and at least one pharmaceutically acceptable carrier.

[0010] In another aspect, the present disclosure also provides a kit or a pharmaceutical kit comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same.

[0011] In another aspect, the present disclosure provides a compound of Formula (I) or a salt, stereoisomer (including an enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof or a pharmaceutical composition comprising the same as an active ingredient for use as a medicament.

[0012] In another aspect, the present disclosure provides a compound of Formula (I) or a salt, stereoisomer (including an enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof or a pharmaceutical composition comprising the same as an active ingredient for use as a medicament.

[0013] In another aspect, the present disclosure also provides the use of the compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer (including enantiomer, diastereomer), solvate, isotopically enriched analog, prodrug or polymorph thereof, or the pharmaceutical composition of the present disclosure for the preparation of a medicament for the treatment and / or prevention of a disease or disorder comprising: a tumor, an infectious disease, an autoinflammatory disease, an inflammatory disease, an autoimmune disease, a neurological disease, a respiratory disease, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, alopecia seborrheica, hirsutism, skin disease, functional uterine bleeding, anemia, pediatric aplastic anemia, endometriosis, polycystic ovary syndrome, and thyroid disease.

[0014] In another aspect, the present disclosure also provides a method of treating or preventing a disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof, or a pharmaceutical composition comprising the same, wherein the disease or disorder comprises: a tumor, an infectious disease, an autoinflammatory disease, an inflammatory disease, an autoimmune disease, a neurological disease, a respiratory disease, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, alopecia seborrheica, hirsutism, skin disease, functional uterine bleeding, anemia, pediatric aplastic anemia, endometriosis, polycystic ovary syndrome, and thyroid disease.

[0015] In another aspect, the present disclosure provides the use of a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof for the preparation of a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof of the present disclosure.

[0016] In another aspect, the present disclosure provides a method of making a compound of Formula (I) of the present disclosure, or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug, or polymorph thereof, comprising making said compound of Formula (I), or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug, or polymorph thereof, using a compound of Formula (II), or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof.

[0017] The following detailed description is provided as exemplary embodiments to assist those skilled in the art in understanding and practicing the present disclosure. It is to be understood that the description is not intended to limit the scope of the present disclosure, and various modifications and changes can be made thereto without departing from the spirit and scope of the present disclosure. I. Compound

[0018] The compound of Formula (I) of the present disclosure, or a salt (including a pharmaceutically acceptable salt), stereoisomer (including an enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof, can bind to a target protein, recruit the target protein to an E3 ubiquitin ligase for ubiquitination marking and degradation. The compound of Formula (I) of the present disclosure can specifically target a particular class or family of target proteins, presenting a broad pharmacological activity through degradation / inhibition of various different classes or families of target proteins.

[0019] In some embodiments, the PBM can be a small molecule ligand that binds to a particular target protein, including but not limited to, epidermal growth factor receptor (EGFR), Cyclin-dependent kinase 4 / 6 (CDK4 / 6), Androgen receptor (AR), anaplastic lymphoma kinase (ALK), Interleukin-1 receptor-associated kinase 4 (IRAK4), or breakpoint cluster region (BCR)-Abelson leukemia virus (ABL) (BCR-ABL) tyrosine kinase.

[0020] In some embodiments, the PBM in the compound of Formula (I) comprises a structure selected from the following formulae: wherein X1in Formula (PBM-1) represents CR 1e or a fragment wherein the symbol # represents the point of attachment of N adjacent to X1, the symbol ## represents the point of attachment of X2, and each R 1e each independently represents deuterium, hydrogen, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, -C(O)-C 1-6 alkyl, -C(O)-deuterated C 1-6 alkyl, or -C(O)NR 1 fR 1g , wherein R 1f , R 1g are the same or different and each independently represents hydrogen, C 1-6 alkyl, or deuterated C 1-6 alkyl, and R 1f , R 1g are not simultaneously hydrogen; X2in Formula (PBM-1) represents N or CR 1h , wherein R 1h represents hydrogen, deuterium, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl, or halogenated C 1-6 alkyl; X3and X4each independently represents CH or N; R 1a represents a bond or an optionally substituted heteroarylene (e.g., halogen or deuterium substituted heteroarylene); R 1b represents hydrogen, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, or an optionally substituted C 3-12 cycloalkyl; (R 1c ) p1a represents the pyridine ring to which it is attached is optionally substituted with p1aR 1c , each R 1c is the same or different and each independently represents deuterium, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy, p1arepresents an integer 0, 1, 2, or 3; (R 1d ) p1b represents the nitrogen-containing bicyclic heteroaryl ring to which it is attached is optionally substituted with p1bR 1d , each R 1dthe same or different and each independently represent deuterium, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy, p1b represents an integer of 0 or 1 ; ring A in formula (PBM-2) represents C 6-10 aryl or 5- to 20-membered heteroaryl (e.g., 5- to 20-membered heteroaryl containing 1 or 2 5- to 7-membered rings and 1-4 heteroatoms selected from N, O, and S), said ring A is optionally substituted with one or more R 2a , and each R 2a the same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy, C 2-6 alkenyl, or C 2-6 alkynyl; ring B in formula (PBM-2) represents C 3-15 cycloalkyl or 4- to 20-membered heterocyclyl (e.g., 4- to 20-membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S), wherein said ring B is optionally substituted with one or more R 2b , and each R 2b the same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy; ring C in formula (PBM-2) represents 5- to 20-membered heteroaryl (e.g., 5- to 20-membered monocyclic or bicyclic heteroaryl containing 1-4 heteroatoms selected from N, O, and S), said ring C is optionally substituted with one or more R 2c , and each R 2c the same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy; X5, X6, X7, X8, and X9 in formula (PBM-3) are the same or different and each independently represent N or CH; R 3a represents a bond or optionally substituted methylene (e.g., halogen substituted methylene); R 3brepresents -C(O)N(R 3f )R 3e , -N(R 3f )C(O)R 3e , -S(O)2N(R 3f )R 3e , -N(R 3f )S(O)2R 3e , -S(O)2R 3e or -P(O)(R 3e )2, wherein each R 3e is the same or different and each independently represents C 1-6 alkyl or deuterated C 1-6 alkyl, each R 3f independently represents hydrogen or C 1-6 alkyl; (R 3c ) p3a in formula (PBM-3) represents a six-membered ring containing X6and X7to which it is attached, optionally substituted with p3a R 3c , each R 3c is the same or different and each independently represents deuterium, halogen, hydroxyl, amino, cyano, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkyl, deuterated C 1- 6alkyl or haloC 1-6 alkyl; p3a represents an integer 0, 1, 2, 3 or 4; R 3d represents deuterium, halogen, hydroxyl, amino, cyano, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkyl, deuterated C 1-6 alkyl or haloC 1-6 alkyl; (R 4a ) p4a in formula (PBM-4) represents the phenyl ring to which it is attached, substituted with p4a R 4a , each R 4a is the same or different and each independently represents deuterium, halogen, hydroxyl, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, NO2, NH2or cyano; p4a represents an integer 0, 1, 2, 3, 4 or 5; R 4b represents substituted or unsubstituted C 3-15 cycloalkyl, for example cyclopentyl; R 5a , R 5b , R 5ceach independently represents CH or N; R 5d represents -C(O)NHR 5h , -NHC(O)R 5h , -S(O)2NHR 5h , -NHS(O)2R 5h , -S(O)2R 5h or -P(O)(R 5h )2, wherein each R 5h is the same or different and each independently represents C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl; (R 5e ) p5a represents p5a substituents R 5e , each R 5e is the same or different and each independently represents halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy; p5a represents an integer 0, 1, 2, 3 or 4; (R 5f ) p5b represents p5b substituents R 5f , each R 5f is the same or different and each independently represents halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy; p5b represents an integer 0, 1 or 2; (R 5g ) p5c represents that the phenyl ring to which it is attached is optionally substituted with p5c R 5g , and each R 5g each independently represents halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy; p5c represents an integer 0, 1, 2, 3 or 4; Ring D in formula (PBM-6) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroarylene group containing 1 to 4 heteroatoms selected from N, O and S; R 6b represents an optionally substituted 5- to 15-membered heteroaryl group, an optionally substituted 5- to 15-membered heterocyclyl group, deuterium, halogen, hydroxyl, cyano, amino, C1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; R 6a Indicates hydrogen, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkyl group; R in formula (PBM-7) x1 Represents a bond or C(O), or R x1 It represents -C(O)NH-R x2 -C(O)-***, where the symbol *** indicates that it is related to R c The connection point, and R x2 C represents optional substitution 3-15 Cycloalkylene; (R 7a ) p7a This indicates that the 1H-pyrrolo[2,3-b]pyridine ring connected thereto is optionally replaced by a p7a R 7a Replacement, and each R 7a Each can be independently represented by cyano, halogen, hydroxyl, amino, nitro, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkyl groups and p7a represent integers 0, 1, 2, 3, 4, or 5; (R 7b ) p7b This indicates that the pyridine ring connected to it is optionally replaced by p7b R 7b Replacement, and each R 7b Each can be independently represented by cyano, halogen, hydroxyl, nitro, or C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy or NR 7c R 7d , where R 7c R 7d The same or different and each independently represents hydrogen and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, optional substituted C 3-15 Cycloalkyl or optionally substituted 4- to 15-membered heterocyclic groups, and p7b represents an integer 0, 1, 2, or 3; R in formula (PBM-8) 8arepresents N or CH; R 8b represents NHC(O), C(O)NH, NHS(O)2, or S(O)2NH; (R 8c ) p8a represents a six-membered ring containing R 8a substituted with p8a R 8c each R 8c is the same or different and each independently represents halogen, hydroxyl, thiol, cyano, amino, nitro, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or haloC 1-6 alkoxy, and p8a represents an integer 0, 1, 2, 3, or 4; ring E represents a 5- to 15-membered heteroaryl, (R 8d ) p8b represents ring E optionally substituted with p8b R 8d each R 8d is the same or different and each independently represents halogen, hydroxyl, thiol, cyano, amino, nitro, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, hydroxyl-substituted C 1-6 alkyl, amino-substituted C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, or optionally substituted C 3-15 cycloalkyl, and p8b represents an integer 0, 1, 2, or 3; R 9a represents -NHC(O)- or -C(O)NH-; R 9b represents -NH-, -N(C 1-6 alkyl)-, or ethynylene; ring F in formula (PBM-9) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl containing 1-4 heteroatoms selected from N, O, and S, (R 9c ) p9a represents said ring F optionally substituted with p9a R 9c , and each R 9c is the same or different and each independently represents an optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or haloC 1-6 alkoxy; p9a represents an integer 0, 1, 2, or 3; each (R 9d) p9b Each of the benzene rings to which it is attached represents an independent and optional p9b R group. 9d Replace, each R 9d The same or different and each independently represents deuterium, halogen, hydroxyl, cyano, amino, NO2, and C. 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 Alkyl group; each p9b may be the same or different and each independently represents an integer 0, 1, 2, 3 or 4; (R) in formula (PBM-10 10a ) p10a This indicates that the benzene ring connected to it is surrounded by p10a R 10a Replace, each R 10a The same or different and each independently represents deuterium, halogen, hydroxyl, cyano, amino, NO2, and C. 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 Alkyl group; p10a indicates an integer of 1, 2, 3, 4, or 5; R 10b Indicates halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 Alkyl; R 10c Represents -NHC(O)- or -C(O)NH-; R 10d and R 10 e independently represents N or CH; and R in each general formula c Each independently represents a bond, -O-, -N(R) d )-, -NHC(O)-*, -C(O)NH-*, -N(R d )-R f -N(R e -*、-R f - C(O)NH-*、-R f -NHC(O)-*、-R f -C(O)O-*、-R f -OC(O)-*, -C(O)O-*, -OC(O)-*, -R f -、-R f -N(R d -*、-OR f -N(R d )-*、 Among them, each ring W 1the same or different and each independently represent a nitrogen-containing heterocyclylene, cycloalkylene, arylene or heteroarylene, t1represents an integer 0, 1 or 2, (R c1 ) m2 each ring W 1 is independently optionally substituted with m1R c1 groups, each R c1 is independently deuterium, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, deuterated C 1-6 alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl, C 2-6 alkenyl, optionally deuterated C 3-6 cycloalkyl, or R c4 -R c3 -, wherein R c3 is optionally substituted C 1-6 alkylene or optionally substituted C 2-6 alkenylene, R c4 represents halogen, R c5 R c6 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c5 and R c6 are the same or different and each independently represent hydrogen or C 1-3 alkyl, and m1represents an integer from 0 to 20; each ring W 2 is the same or different and each independently represents a nitrogen-containing heterocyclylene, cycloalkylene, arylene or heteroarylene, t2represents an integer 0 or 1, (R c2 ) m3 each ring W 2 is independently optionally substituted with m2R c2 groups, each R c2 is independently deuterium, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, deuterated C 1-6 alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl, C 2-6 alkenyl, optionally deuterated C 3-6 cycloalkyl, or R c8 -R c7 -, wherein R c7 is optionally substituted C 1-6 alkylene or optionally substituted C2-6 alkylene, R c8 represents halogen, R c9 R c10 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c9 and R c10 are identical or different and each independently represent hydrogen or C 1-3 alkyl, and m2 represents an integer from 0 to 20; and R d and R e each independently represent hydrogen or C 1-6 alkyl, R f and R g each independently represent optionally substituted C 1-6 alkylene or optionally substituted C 2-6 alkenylene, and the symbol * indicates the point of attachment to LIN.

[0021] In embodiments of the present disclosure, the number of substituents is in principle not limited by any restriction, or is automatically limited by the size of the building unit (i.e. the total number of hydrogen atoms of the building unit which can be replaced), or as explicitly defined herein.

[0022] In embodiments of the present disclosure, each R c is as defined herein.

[0023] In some embodiments, PBM represents a small molecule ligand of EGFR.

[0024] In some embodiments, PBM represents a structure of the following formula (PBM-4): wherein (R 4a ) p4a represents that the phenyl ring to which it is attached is substituted by p4a R 4a each R 4a is identical or different and each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, C 1-6 alkyl (e.g. C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 alkyl (e.g. halogenated C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), C 1-6Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), NO2, NH2, or cyano; p4a represents the integer 0, 1, 2, 3, 4, or 5; R 4b C indicates whether it is substituted or not substituted. 3-15 Cycloalkyl (e.g., substituted or unsubstituted C) 3-10 cycloalkyl or C 3-6 Cycloalkyl groups, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, the C... 3-15 The cycloalkyl group is optionally selected from one or more (e.g., 1-3, 1, 2, or 3) groups selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen (e.g., fluorine, chlorine, bromine, or iodine), cyano, C 1-6 Alkyl (e.g., C10) 1- 4 alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl), deuterated C 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-, optionally halogenated C 3-6 cycloalkyl, C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 1-6 Alkyl-NH-, NH2-C 1-6alkylene, C 1-6 alkyl-NHC(O)-, C 1-6 alkyl-C(O)NH-, or any combination thereof.

[0025] In some embodiments, PBM represents the non-limiting example of the following structure (PBM-4), including structures of formula (PBM-4-1):

[0026] In some embodiments, PBM represents the following structure of formula (PBM-5): wherein R 5a , R 5b , R 5c each independently represents CH or N; R 5d represents -C(O)NHR 5h , -NHC(O)R 5h , -S(O)2NHR 5h , -NHS(O)2R 5h , -S(O)2R 5h , or -P(O)(R 5h )2, wherein each R 5h is the same or different and each independently represents C 1-6 alkyl (e.g., C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-5 alkyl, perdeuterated C 1-4 alkyl, or perdeuterated C 1-3 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), or halogenated C 1-6 alkyl (e.g., halogenated C 1-5 alkyl, or halogenated C 1-3 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-); (R 5e ) p5a represents p5a substituents R 5e , each R 5e is the same or different and each independently represents halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (e.g., C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), halogenated C 1-6 alkyl (e.g., halogenated C 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-5 Alkyl, fully deuterated C 1-4 Alkyl or fully deuterated C 1-3 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-5 Alkoxy, C 1-4 Alkoxy or C 1-3 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as trifluoromethoxy groups; p5a represents an integer 0, 1, 2, 3, or 4; (R 5f ) p5b Indicates p5b substituents R 5f Each R 5f The same or different and each independently represents a halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g., C10) 1-4 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-5 Alkyl, fully deuterated C 1-4 Alkyl or fully deuterated C 1-3 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-5 Alkoxy, C 1-4 Alkoxy or C 1-3 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as trifluoromethoxy groups; p5b represents the integer 0, 1, or 2; (R 5g ) p5crepresents optionally substituted phenyl, wherein the phenyl ring to which it is attached is optionally substituted with p5cR 5g substituents, and each R 5g each independently represents halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (e.g. C 1-4 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl (e.g. perdeuterated-C 1-5 alkyl, perdeuterated-C 1-4 alkyl or perdeuterated-C 1-3 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-5 alkoxy, C 1-4 alkoxy or C 1-3 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or t-butyloxy), or halo-C 1-6 alkoxy (e.g. halo-C 1-4 alkoxy, e.g. trifluoromethoxy); and p5c represents an integer 0, 1, 2, 3 or 4.

[0027] In some embodiments, R 5a and R 5b each independently represents CH or N. In some sub-embodiments, R 5a represents CH, R 5b represents N. In some sub-embodiments, R 5a represents CH, R 5b represents CH. In some sub-embodiments, R 5a represents N, R 5b represents CH. In some sub-embodiments, R 5a represents N, R 5b represents N.

[0028] In some embodiments, R 5c represents CH or N. In some sub-embodiments, R 5c represents N. In some sub-embodiments, R 5c represents CH.

[0029] In some embodiments, R 5drepresents -C(O)NHR 5h , -NHC(O)R 5h , -S(O)2NHR 5h , -NHS(O)2R 5h , -S(O)2R 5h , or -P(O)(R 5h )2, wherein each R 5h is the same or different and each independently represents C 1-6 alkyl (e.g., C 1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-5 alkyl, perdeuterated C 1-4 alkyl, or perdeuterated C 1-3 alkyl such as CD3, CD3CD2-, CD3CD2CD2-, etc.), or halogenated C 1-6 alkyl (e.g., halogenated C 1-5 alkyl, or halogenated C 1-3 alkyl such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-). In some sub-embodiments, R 5d represents -P(O)(R 5h )2, wherein each R 5h is the same or different and each independently represents C 1-6 alkyl (e.g., C 1-4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-5 alkyl, perdeuterated C 1-4 alkyl, or perdeuterated C 1-3 alkyl such as CD3, CD3CD2-, CD3CD2CD2-, etc.), or halogenated C 1-6 alkyl (e.g., halogenated C 1-5 alkyl, or halogenated C 1-3 alkyl such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-). In some sub-embodiments, R 5d represents -P(O)(CH3)2.

[0030] In some embodiments, p5crepresents an integer 0, 1, 2, 3, or 4. In some sub-embodiments, p5erepresents an integer 2.

[0031] In some embodiments, PBM represents a structure of Formula (PBM-5-1), Formula (PBM-5-2), Formula (PBM-5-3), Formula (PBM-5-4), or Formula (PBM-5-5):

[0032] In some embodiments, PBM represents a small molecule ligand of CDK4 / 6.

[0033] In some embodiments, PBM represents a structure of Formula (PBM-1): wherein X1in Formula (PBM-1) represents CR 1e or a fragment wherein the symbol # represents a point of attachment of N adjacent to X1, the symbol ## represents a point of attachment of X2, and each R 1e each independently represents deuterium, hydrogen, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, -C(O)-C 1-6 alkyl, -C(O)-deuterated C 1-6 alkyl, or -C(O)NR 1f R 1g , wherein R 1f , R 1g are the same or different and each independently represents hydrogen, C 1-6 alkyl, or deuterated C 1-6 alkyl, and R 1f , R 1g are not simultaneously hydrogen; X2in Formula (PBM-1) represents N or CR 1h , wherein R 1h represents hydrogen, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.) or halogenated C 1-6 alkyl (e.g., halogenated C 1-4 alkyl, or halogenated C 1-3alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2CICH2-); X3and X4each independently represent CH or N; R 1a represents a bond or an optionally substituted heteroarylene (e.g., an optionally substituted 5- to 20-membered monocyclic or bicyclic or polycyclic aromatic ring radical containing one or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur); R 1b represents hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, deuteratedC 1-6 alkyl, or optionally substitutedC 3-12 cycloalkyl; (R 1c ) p1a represents an optionally substituted pyridine ring with p1aR 1c substituents, each R 1c is the same or different and each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuteratedC 1-6 alkyl (e.g., perdeuteratedC 1-6 alkyl, perdeuteratedC 1-5 alkyl, or perdeuteratedC 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2CICH2-), C 1-6 alkoxy (e.g., C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), or haloC 1-6 alkoxy (e.g., haloC 1-4alkyl (e.g., C1-C6-alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl), deuterated C1-C6-alkyl (e.g., perdeuterated C1-C6-alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, and the like), halo-C1-C6-alkyl (e.g., halo-C1-C6-alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), C1-C6-alkoxy (e.g., C1-C6-alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halo-C1-C6-alkoxy (e.g., halo-C1-C6-alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), p1a represents an integer 0, 1, 2, or 3; and (R 1d ) p1b represents a nitrogen-containing bicyclic heteroaromatic ring, which is optionally substituted with p1bR 1d , each R 1d is the same or different and each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, and the like), halo-C 1-6 alkyl (e.g., halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), C 1-6 alkoxy (e.g., C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halo-C 1-6 alkoxy (e.g., halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), p1b represents an integer 0 or 1.

[0034] In some embodiments, X1represents CR 1e , wherein R 1e represents deuterium, hydrogen, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3alkyl (e.g. haloC 1-6 alkyl (e.g. haloC 1-4 alkyl (e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl (e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), -C(O)-C 1-6 alkyl (e.g. -C(O)-C 1-5 alkyl or -C(O)-C 1-3 alkyl (e.g. -C(O)-CH3, -C(O)-CH2CH3), -C(O)-deuterated C 1-6 alkyl (e.g. -C(O)-deuterated C 1-5 alkyl or -C(O)-deuterated C 1-3 alkyl (e.g. -C(O)-CD3) or -C(O)NR 1f R 1g wherein R 1f , R 1g are the same or different and each independently represent hydrogen, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl) or deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl (e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), and R 1f , R 1g are not simultaneously hydrogen.

[0035] In some embodiments, X1represents a fragment wherein the symbol # represents the point of attachment of N adjacent to X1, the symbol ## represents the point of attachment to X2, and R 1e represents deuterium, hydrogen, halogen (e.g. fluorine, chlorine, bromine or iodine), C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3alkyl (e.g., haloC 1-6 alkyl (e.g., haloC 1-4 alkyl (e.g., F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2CICH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), -C(O)-C 1-6 alkyl, -C(O)-deuterated C 1-6 alkyl or -C(O)NR 1f R 1g wherein R 1f , R 1g are the same or different and each independently represents hydrogen, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl) or deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.).

[0036] In some embodiments, R 1a represents a bond or an optionally substituted heteroarylene (e.g., an optionally substituted 5- to 20-membered monocyclic or bicyclic or polycyclic aromatic ring radical containing one or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur), wherein the heteroarylene is optionally substituted with one or more (e.g., 1 to 4, e.g., 1, 2, 3, or 4) groups each independently selected from halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4alkyl (e.g. perdeuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl (e.g. perdeuterated C 1-5 alkyl (e.g. perdeuterated C 1-4 alkyl (e.g. perdeuterated C 1-6 alkyl (e.g. perdeuterated C 1-4 alkoxy (e.g. C 1-6 alkoxy (e.g. C 1-4 alkoxy (e.g. C

[0037] In some embodiments, R 1arepresents optionally substituted heteroaryl, for example optionally substituted 5- to 14- membered monocyclic or bicyclic or polycyclic heteroaryl containing one or more (e.g., one to six, alternatively one to five, alternatively one to four, alternatively one to three) heteroatoms independently selected from oxygen, nitrogen, and sulfur. Examples of heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, iso-benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadia- zolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphthylidinyl, cinnolinyl, quinazolinyl, quinoxalinyl, pteridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1 H-pyrrolo[3,2-b]pyridinyl, 1 H-pyrrolo[2,3-b]pyridinyl, 4H-fluoro[3,2-b]pyrrolyl, pyrrolo[2,1 -b]thiazolyl, and imidazo[2,1 -b]thiazolyl. The heteroaryl group is optionally substituted with one or more (e.g., one to four, e.g., one, two, three, or four) substituents selected from the group consisting of halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl (e.g., C 1-6 alkyl (e.g., C 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2CICH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 alkoxy (e.g., halogenated C 1-4alkyl (e.g., haloC1-C6-alkyl such as CF3, CF2H, CHF2, or CH2F), deuterated C1-C6-alkyl (e.g., perdeuterated C1-C6-alkyl such as CD3, CD3CD2-, CD3CD2CD2-, and the like), or optionally substituted C3-C8-cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, or cycloheptyl, which is optionally substituted with, for example, substituents selected from the group consisting of halogen, C1-C6-alkyl, haloC1-C6-alkyl, C1-C6-alkoxy, haloC1-C6-alkoxy, oxo, and deuterated C1-C6-alkyl).

[0038] In some embodiments, R 1b represents hydrogen, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, and the like), or optionally substituted C 3-12 cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, or cycloheptyl, which is optionally substituted with, for example, substituents selected from the group consisting of halogen, C 1-6 alkyl, haloC 1-6 alkyl or haloC 1-6 alkyl).

[0039] In some embodiments, PBM represents a non-limiting example of the structure of Formula (PBM-1), i.e., a structure of Formula (PBM-1-1A), Formula (PBM-1-1B), Formula (PBM-1-1C), or Formula (PBM-1-1D): wherein each R 1e each independently represents deuterium, hydrogen, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl or haloC 1-3Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., -C(O)-C 1-6 Alkyl groups (e.g., -C(O)-C) 1-5 Alkyl or -C(O)-C 1-3 Alkyl groups, such as -C(O)-CH3, -C(O)-CH2CH3, and -C(O)-deuterated C 1-6 Alkyl groups (e.g., -C(O)-deuterated C) 1-5 Alkyl or -C(O)-deuterated C 1-3 Alkyl groups, such as -C(O)-CD3) or -C(O)NR 1f R 1g , where R 1f R 1g The same or different and each independently represents hydrogen and C. 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups (such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl) or deuterated C 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and R 1f R 1g They are not all hydrogen at the same time; each X2 independently represents N or CR. 1h , where R 1h Indicates hydrogen, deuterium, halogens (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., or halogenated C1-6 alkyl (e.g., haloC 1-4 alkyl or haloC 1-3 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-); each of X3and X4independently represents CH or N; R 1a each independently represents an optionally substituted heteroarylene (e.g., an optionally substituted 5- to 20-membered monocyclic or bicyclic or polycyclic aromatic ring group containing one or more (e.g., 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen, and sulfur), wherein the heteroarylene is optionally substituted with one or more (e.g., 1 to 4, e.g., 1, 2, 3, or 4) substituents each independently selected from halo (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuteratedC 1-6 alkyl (e.g., perdeuteratedC 1-6 alkyl, perdeuteratedC 1-5 alkyl or perdeuteratedC 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy, e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), or any combination thereof; each R 1b each independently represents hydrogen, C 1-6 alkyl (e.g., C 1-5 alkyl, C1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., or optionally substituted C4 groups. 3-12 Cycloalkyl groups (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, or cycloheptyl, optionally selected, for example, from halogens, C 1-6 Alkyl, Halogenated C 1-6 Alkyl or deuterated C 1-6 Alkyl substituents); each (R 1c ) p1a Each independently represents the pyridine ring to which it is connected, optionally represented by p1a R 1c Replace, each R 1c The same or different and each independently represents deuterium, halogens (e.g., fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), deuterated C 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., or halogenated C 1-6Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-. p 1a represents the integer 0, 1, 2, or 3; and each (R) 1d ) p1b Each independently represents the bicyclic nitrogen-containing heteroaryl ring connected to it, optionally represented by p1b R. 1d Replace, each R 1d The same or different and each independently represents deuterium, halogens (e.g., fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), deuterated C 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., or halogenated C 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), where p1b represents the integer 0 or 1.

[0040] In some implementations, R in formulas (PBM-1-1B) and (PBM-1-1D) 1aeach independently represents an optionally substituted heteroaryl group, for example an optionally substituted 5- to 14-membered monocyclic or bicyclic or polycyclic heteroaryl group containing one or more (for example 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of heteroaryl groups include, but are not limited to, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuryl, isobenzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadia- zolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphthylidinyl, cinnolinyl, quinazolinyl, quinoxalinyl, pteridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1 H-pyrrolo[3,2-b]pyridinyl, 1 H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1 -b]thiazolyl and imidazo[2,1 -b]thiazolyl. The heteroaryl group is optionally substituted by one or more (for example 1 to 4, for example 1, 2, 3, or 4) substituents selected from halo (for example fluoro, chloro, bromo or iodo), hydroxyl, cyano, amino, C 1-6 alkyl (for example C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (for example haloC 1-4 alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, CI2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (for example perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, for example CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (for example C 1-4 alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or t-butyloxy), or haloC 1-6 alkoxy (for example haloC 1-4alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-).

[0041] In some embodiments, PBM represents a structure of Formula (PBM-1-1), Formula (PBM-1-2), or Formula (PBM-1-3):

[0042] In some embodiments, PBM represents a small molecule ligand of ALK.

[0043] In some embodiments, PBM represents a structure of Formula (PBM-3): wherein X5, X6, X7, X8, and X9in Formula (PBM-3) are the same or different and each independently represent N or CH; R 3a represents a bond or optionally substituted methylene (e.g., halogen substituted methylene); R 3b represents -C(O)N(R 3f )R 3e , -N(R 3f )C(O)R 3e , -S(O)2N(R cf )R 3e , -N(R 3f )S(O)2R 3e , -S(O)2R 3e , or -P(O)(R 3e )2, wherein each R 3e is the same or different and each independently represents C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), or deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), each R 3f is the same or different and each independently represents hydrogen or C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl); (R3c ) p3a represents a six-membered ring containing X6and X7to which it is attached, which is optionally substituted by p3aR 3c , each R 3c is the same or different and each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, amino, cyano, C 1-6 alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. haloC 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), or haloC 1-6 alkyl (e.g. haloC 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-); p3a represents an integer 0, 1, 2, 3 or 4; and R 3d represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, amino, cyano, C 1-6 alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. haloC 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), C 1-6 alkyl (e.g. C 1-5alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, and the like), or halogenated C 1-6 alkyl (e.g., halogenated C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-).

[0044] In some embodiments, R 3a represents a bond. In other words, the six-membered ring containing X8and X9in formula (PBM-3) is directly connected to -NH-.

[0045] In some embodiments, R 3a represents an optionally substituted methylene (e.g., halogen substituted methylene).

[0046] In some embodiments, PBM represents a structure of formula (PBM-3-1A): wherein X5, X6, and X7are the same or different and each independently represents N or CH; R 3b represents -C(O)N(R 3f )R 3e , -N(R 3f )C(O)R 3e , -S(O)2N(R 3f )R 3e , -N(R 3f )S(O)2R 3e , -S(O)2R 3e , or -P(O)(R 3e )2, wherein each R 3e is the same or different and each independently represents C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), or deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), each R 3f each independently represents hydrogen or C 1-6 alkyl, such as C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl); (R 3c ) p3a represents a six-membered ring containing X6and X7optionally substituted with p3aR 3c each R 3c are identical or different and each independently represent deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, amino, cyano, C 1-6 alkoxy, such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halogenated C 1-6 alkoxy, such as halogenated C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 1-6 alkyl, such as C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl, such as perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), or halogenated C 1-6 alkyl, such as halogenated C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-); p3arepresents an integer 0, 1, 2, 3 or 4; and R 3d represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, amino, cyano, C 1-6 alkoxy, such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halogenated C1-6 alkoxy (e.g., haloC 1-4 alkoxy, e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), C 1-6 alkyl (e.g., haloC 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), or haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-).

[0047] In some embodiments, PBM represents a structure of formula (PBM-3-1B): wherein X6and X7are the same or different and each independently represents N or CH; R 3b represents -C(O)N(R 3f )R 3e , -N(R 3f )C(O)R 3e , -S(O)2N(R 3f )R 3e , -N(R 3f )S(O)2R 3e , -S(O)2R 3e , or -P(O)(R 3e )2, wherein each R 3e is the same or different and each independently represents C 1-6 alkyl (e.g., haloC 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), or deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), each R 3f each independently represents hydrogen or C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl); (R 3c ) p3a represents a six-membered ring containing X6and X7optionally substituted with p3aR 3c each R 3c are the same or different and each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, amino, cyano, C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t- butyloxy), haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy (e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), or haloC 1-6 alkyl (e.g., haloC 1-4 alkyl (e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-); and p3a represents an integer 0, 1, 2, 3, or 4.

[0048] In some embodiments, PBM represents a structure of formula (PBM-3-1):

[0049] In some embodiments, PBM represents a small molecule ligand of IRAK4.

[0050] In some embodiments, PBM represents a structure of formula (PBM-6): wherein ring D in formula (PBM-6) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl group containing 1-4 heteroatoms selected from N, O, and S; R 6b represents an optionally substituted 5- to 15-membered heteroaryl group, an optionally substituted 5- to 15-membered heterocyclyl group, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 alkyl (e.g., halogenated C 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), or halogenated C 1-6 alkoxy (e.g., halogenated C 1-4 alkoxy, e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-); R 6 a represents hydrogen, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-);

[0051] In some embodiments, ring D in formula (PBM-6) represents a 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, O, and S. In some embodiments, the 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroaryl group is a divalent aromatic ring group containing 1 to 4 (e.g., 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some sub-implementations, examples of 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroaryl groups include, but are not limited to, imidazolyl, imidazolyl, imidazolyl, imidadiazolyl, imidaphenyl, imidazolyl, imidazolyl, imidadiazolyl, imidaroxyl, imidazoly ... [2,1,3]oxadiazole subunit, benzo[2,1,3]thiadiazole subunit, benzo[1,2,3]thiadiazole subunit, quinoline, isoquinoline, naphthinyl, cinnamoline, quinoline, quinoline, quinolineyl, phthalazinyl, pyrazolo[1,5-a]pyridine subunit, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridine subunit, 1H-pyrrolo[3,2-b]pyridine subunit, 1H-pyrrolo[2,3-b]pyridine subunit, pyrrolo[2,1-b]thiazolium subunit, imidazo[2,1-b]thiazolium subunit, or imidazo[1,2-b]pyridazinium subunit. The 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroaryl group may optionally be further substituted by one or more (e.g., 1-3, such as 1, 2, or 3) substituents, each substituent independently representing deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-).

[0052] In some embodiments, R 6b represents an optionally substituted 5- to 15-membered heteroaryl. In some embodiments, the 5- to 15-membered heteroaryl is a 5- to 15-membered monocyclic or bicyclic or polycyclic aromatic ring radical containing 1-4 (e.g., 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some sub-embodiments, examples of heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, iso-benzofuranyl, benzothienyl, indazolyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazyolyl, benzo[1,2,3]thiadiazyolyl, quinolinyl, isoquinolinyl, naphthylidinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, or imidazo[1,2-b]pyridazinyl. R 6b The heteroaryl groups represented by R 6c -C 1-6 alkylene- optionally substituted C 3-8 cycloalkyl, -N(R 6c -C 1-6 alkyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3alkyl (e.g., haloC 1-6 alkyl (e.g., haloC 1-4 alkyl (e.g., F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2CICH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2CICH2-O-), wherein each R6c independently represents hydrogen or C 1-6 alkyl (e.g., haloC 1-4 alkyl (e.g., F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2CICH2-), deuterated C 1-3 alkyl. In some embodiments, R 6b substituents of the heteroaryl groups represented by -N(R 6c )-C 1-6 alkylene-substituted C 3-8 cycloalkyl, wherein R6crepresents hydrogen or C 1-3 alkyl (e.g., methyl). In some embodiments, C 1-6 Examples of alkylene groups include, but are not limited to, C 1-3 alkylene. In some embodiments, C 3-8 Examples of cycloalkyl groups include, but are not limited to, C 3- 6cycloalkyl. In some embodiments, C 3-8 Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. C 3-8 The cycloalkyl group is optionally further substituted with one or more (e.g., 1-3, e.g., 1, 2, or 3) substituents each independently selected from the group consisting of C1-C3alkyl, C 3-6 cycloalkyl, hydroxyl, amino, mercapto, halogen, C1-C3alkoxy, C1-C3alkylamino, haloC1-C3alkyl, amino-substituted C 1-3 substituents of the alkylene or cyano groups. In some embodiments, R 6bThe substituent represented by the heteroaryl group is -N(R) 6c )-Optional halogenated C 1-6 Alkyl, wherein R 6c Indicates hydrogen or C 1-3 Alkyl (e.g., methyl). In some embodiments, a halogenated C may be used. 1-6 Examples of alkyl groups include, but are not limited to, optional halogenated C. 1-4 Alkyl, optional halogenated C 1-3 Alkyl and optional halogenated C 1-2 Alkyl group. In some embodiments, a halogenated C may be used. 1-6 Representative examples of alkyl groups include, but are not limited to, -CH2-CF3.

[0053] In some implementations, R in formula (PBM-6) 6b The term indicates a substituted 5- to 15-membered heterocyclic group. In some sub-implementations, "5- to 15-membered heterocyclic group" refers to a saturated or partially unsaturated (i.e. having one or more double bonds, but not fully conjugated) cyclic hydrocarbon group containing one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen, of a monocyclic, bicyclic, tricyclic, or polycyclic form. In some sub-implementations, examples of heterocyclic groups include, but are not limited to, azirrobutyl, oxacyclobutyl, pyrrolidinyl, imidazoalkyl, pyrazolyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolyl, thiazoalkyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxacyclohexyl, azirroheptyl, azirrooctyl, diazacycloheptyl (e.g., 1,4-diazacycloheptane-1-yl), and diazacyclooctyl. The heterocyclic group is optionally selected from one or more (e.g., 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) independently of deuterium, hydroxyl, amino, mercapto, nitro, halogen (e.g., fluorine, chlorine, bromine, or iodine), cyano, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 3-6 cycloalkyl, C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, are substituted with substituents.

[0054] In some implementations, PBM represents the structure of the following formulas (PBM-6-1), (PBM-6-2), (PBM-6-3), or (PBM-6-4):

[0055] In some implementations, the structure of the PBM representation (PBM-7) is as follows: In equation (PBM-7), R x1 Represents a bond or C(O), or R x1 It represents -C(O)NH-R x2 -C(O)-***, where the symbol *** indicates that it is related to R c The connection point, and R x2 C represents optional substitution 3-15 Cycloalkylene; (R 7a ) p7a This indicates that the 1H-pyrrolo[2,3-b]pyridine ring connected thereto is optionally replaced by a p7a R 7a Replacement, and each R 7a Each can be independently represented by a cyano group, a halogen (e.g., fluorine, chlorine, bromine, or iodine), a hydroxyl group, an amino group, a nitro group, or a C group. 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), and p7a represent integers 0, 1, 2, 3, 4, or 5; (R 7b ) p7b This indicates that the pyridine ring connected to it is optionally replaced by p7b R 7b Replacement, and each R 7b Each can independently represent a cyano group, a halogen (e.g., fluorine, chlorine, bromine, or iodine), a hydroxyl group, a nitro group, or a C group. 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 7c R 7d , wherein R 7c , R 7d are identical or different and each independently represent hydrogen, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 alkyl (e.g. halogenated C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 3-15 cycloalkyl or optionally substituted 4- to 15-membered heterocyclyl, and p7b represents an integer 0, 1, 2 or 3.

[0056] In some embodiments, R x1 in formula (PBM-7) represents a bond.

[0057] In some embodiments, R x1 in formula (PBM-7) represents C(O).

[0058] In some embodiments, R x1 in formula (PBM-7) represents -C(O)NH-R x2 -C(O)-***, wherein the symbol *** represents the point of attachment to R c , and R x2 represents optionally substituted C 3-15 cycloalkylene. Examples of optionally substituted C 3-15 cycloalkylene include, but are not limited to, optionally substituted C 3-11 cycloalkylene and optionally substituted C 3-8Cycloalkylene, for example optionally substituted cyclopropylene, optionally substituted cyclobutylene, optionally substituted cyclopentylene, optionally substituted cyclohexylene, optionally substituted cycloheptylene, or optionally substituted cyclooctylene. In some embodiments, C 3-15 Cycloalkylene is optionally substituted with one or more (e.g. 1 to 3, 1, 2, or 3) substituents each independently selected from deuterium, hydroxyl, amino, thiol, nitro, halogen (e.g. fluorine, chlorine, bromine, or iodine), cyano, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 Alkyl (e.g. haloC 1-4 Alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2CICH2-), deuterated C 1-6 Alkyl (e.g. perdeuterated C 1-6 Alkyl, perdeuterated C 1-5 Alkyl or perdeuterated C 1-4 Alkyl, for example CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy (e.g. C 1-4 Alkoxy, for example methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), or haloC 1-6 Alkoxy (e.g. haloC 1-4 Alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, F2CIC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2CICH2-O-).

[0059] In some embodiments, (R 7a ) p7a represents that the 1H-pyrrolo[2,3-b]pyridine ring in Formula (PBM-7) is optionally substituted with p7a R7a, and each R 7a each independently is cyano, halogen (e.g. fluorine, chlorine, bromine, or iodine), hydroxyl, amino, nitro, C 1-6 Alkyl (e.g. C 1-5 Alkyl, C 1-4 Alkyl or C 1-3Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, and p7a represent integers 0, 1, 2, 3, 4, or 5.

[0060] In some implementation schemes, (R 7a ) p7a In the expression (PBM-7), the 1H-pyrrolo[2,3-b]pyridine ring connected to it is p7a R 7a Replace, where p7a represents the integer 1, and R 7a It is a cyano group.

[0061] In some implementation schemes, (R 7b ) p7b This indicates that the pyridine ring connected to it is optionally replaced by p7b R 7b Replacement, and each R 7b Each of these groups is independently a cyano group, a halogen (e.g., fluorine, chlorine, bromine, or iodine), a hydroxyl group, a nitro group, or a C group. 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-5 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 7c R 7d wherein R 7c , R 7d are identical or different and each independently represent hydrogen, C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-5 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-3 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-5 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), optionally substituted C 3-15 cycloalkyl, e.g. optionally substituted C 3-12 cycloalkyl and optionally substituted C 3-8optionally substituted 4- to 15-membered heterocyclyl (e.g., optionally substituted 4- to 12-membered heterocyclyl or optionally substituted 4- to 10-membered heterocyclyl), and p7b represents an integer of 0, 1, 2, or 3. In some sub-embodiments, examples of optionally substituted C 3-15 Examples of optionally substituted cycloalkyl include, but are not limited to, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cycloheptyl, or optionally substituted cyclooctyl. In some sub-embodiments, examples of optionally substituted 4- to 15-membered heterocyclyl include, but are not limited to, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, azepanyl, diazepanyl, azocanyl, or diazocanyl. In some sub-embodiments, examples of optionally substituted C 3-15 Substituents of cycloalkyl and optionally substituted 4- to 15-membered heterocyclyl are each independently optionally selected from: deuterium, hydroxy, amino, thiol, nitro, halogen (e.g., fluorine, chlorine, bromine, or iodine), cyano, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), or haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy, e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-).

[0062] In some embodiments, (R 7b ) p7b represents a pyridine ring attached thereto which is substituted with p7b R 7b , wherein p7b represents an integer 1, and R 7b is NR 7c R 7d , wherein R 7c represents hydrogen, and R 7d represents C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl).

[0063] In some embodiments, PBM represents a structure of formula (PBM-7-1), formula (PBM-7-2), formula (PBM-7-3) or formula (PBM-7-4):

[0064] In some embodiments, PBM represents a structure of formula (PBM-8): wherein R 8a in formula (PBM-8) represents N or CH; R 8b represents NHC(O), C(O)NH, NHS(O)2 or S(O)2NH; (R 8c ) p8a represents a six-membered ring containing R 8a attached thereto which is substituted with p8a R 8c , each R 8c is the same or different and each independently represents halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, thiol, cyano, amino, nitro, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), and p8a represents an integer 0, 1, 2, 3, or 4; and cyclic E represents a 5- to 15-membered heteroaryl group, (R 8d ) p8b This indicates that the ring E connected to it can optionally be p8b R. 8d Replace, each R 8d The same or different and each independently represents a halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and hydroxyl-substituted C 1-6 alkyl and amino substituted C 1-6 Alkyl, C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, F2ClC-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, or optionally substituted C groups. 3-15 Cycloalkyl, and p8b represents the integer 0, 1, 2 or 3.

[0065] In some implementation schemes, R 8a N represents N. In some implementations, R represents N. 8a It represents CH.

[0066] In some implementation schemes, (R 8c ) p8a Indicates that it is connected to R 8a The six-membered ring can be optionally p8a R 8c Replace, each R 8c The same or different and each independently represents a halogen (e.g., fluorine, chlorine, bromine, iodine), hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4alkyl (e.g., C1-C6alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 8a The aromatic ring containing R 8a is a pyridine ring, R 8c represents F3C-, and p8arepresents the integer 1.

[0067] In some embodiments, ring E represents a 5- to 15-membered heteroarylene group, such as a 5- to 12-membered heteroarylene group, or a 5- to 10-membered heteroarylene group. In some embodiments, examples of ring E include, but are not limited to, phenylazoimidazolylene, phenylazothiazolylene, 2H-indazolylene, phenyl- oxazolylene, isoindolylene, phenylbenzofuranylene, iso-phenylbenzofuranylene, phenyl- benzothiophenylene, phenylbenzisoxazolylene, phenylbenzisothiazolylene, phenyl- benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, imidazo[2,1-b]thiazolylene, imidazo[1,2-b]pyridazinylene, or 6,7-dihydro-5H-pyrrolo[1,2-c]imidazolylene. Ring E is optionally substituted with p8bR 8d each R 8d is the same or different and each independently represents halogen (e.g., fluorine, chlorine, bromine, iodine), hydroxyl, thiol, cyano, amino, nitro, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl (e.g., C1-C6alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl (e.g., C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C1-5 alkyl or perdeuterated C 1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), hydroxy-substituted C 1-6 alkyl (e.g., hydroxy-substituted C 1-4 alkyl (e.g., hydroxy-substituted C 1-6 alkyl (e.g., amino-substituted C 1-4 alkyl (e.g., amino-substituted C 1-6 alkyl (e.g., amino-substituted C 1-4 alkoxy (e.g., C 1-6 alkoxy (e.g., halo-substituted C 1-4 alkoxy (e.g., halo-substituted C 3-15 cycloalkyl, and p8b represents an integer of 0, 1, 2, or 3. In some embodiments, R 8d represents hydroxypropyl or hydroxyisopropyl, and p8b represents an integer of 1. In some embodiments, R 8d represents optionally substituted C 3-15 cycloalkyl. C 3-15 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthyl, octahydropentalenyl, octahydro-lH-indenyl, 2,3-dihydro-lH-indenyl, spirocyclyl (e.g., C 5-15 spirocyclyl), adamantyl, noradamantyl, and norbornyl. C 3- 15 Optionally, the optional substituents of cycloalkyl are optionally selected from halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxy, thiol, cyano, amino, nitro, C 1-6 alkyl (e.g., C 1-4 alkyl or C 1-3 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), halo-substituted C 1-6 alkyl (e.g., halo-substituted C 1-4 alkyl or halo-substituted C 1-3 alkyl (e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-.

[0068] In some implementations, PBM represents the structure of the following formulas (PBM-8-1), (PBM-8-2), (PBM-8-3), (PBM-8-4), (PBM-8-5), (PBM-8-6), (PBM-8-7), (PBM-8-8), (PBM-8-9), (PBM-8-10), (PBM-8-11), (PBM-8-12), or (PBM-8-13):

[0069] In some implementations, PBM represents a small molecule ligand for AR.

[0070] In some implementations, the structure of the PBM representation (PBM-2) is as follows: Where ring A represents C 6-10 aryl or 5- to 20-membered heteroaryl (e.g., 5- to 20-membered heteroaryl comprising one or two 5- to 7-membered rings and 1 to 4 heteroatoms selected from N, O, and S), ring A optionally surrounded by one or more (e.g., 1 to 10, 1 to 8, or 1 to 6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 2a Replacement, and each R 2a The same or different and independent of each other are deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 2-6 alkenyl (e.g., vinyl, propenyl, or butenyl), or C 2-6 Alkyne group (e.g., ethynyl, propynyl, or butynyl); ring B represents C. 3-15 Cycloalkyl or 4- to 20-membered heterocyclic groups (e.g., 4- to 20-membered heterocyclic groups containing 1 to 4 heteroatoms selected from N, O, and S), wherein ring B is optionally surrounded by one or more (e.g., 1 to 10, 1 to 8, or 1 to 6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 2b Replacement, and each R 2b The same or different and independent of each other are deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-; and ring C representing a 5- to 20-membered heteroaryl group (e.g., a 5- to 20-membered monocyclic or bicyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, O, and S), wherein the ring C is optionally surrounded by one or more (e.g., 1 to 10, 1 to 8, or 1 to 6, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R groups. 2c Replacement, and each R 2c The same or different and independent of each other are deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-.

[0071] In some embodiments, PBM represents a structure of formula (PBM-2-1A): wherein the phenyl ring in formula (PBM-2-1A) is optionally substituted with one or more (e.g., 1-10, 1-8, or 1-6, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 2a , and each R 2a is the same or different, and each is independently deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl (e.g., per-deuterated C 1-6 alkyl, per-deuterated C 1-6 alkyl, or per-deuterated C 1-5 alkyl, or per-deuterated C 1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy (e.g., per-deuterated C 2-6 alkenyl (e.g., vinyl, propenyl, or butenyl), or C 2-6 alkynyl (e.g., ethynyl, propynyl, or butynyl); ring B represents C 3-15 cycloalkyl or 4- to 20-membered heterocyclyl (e.g., 4- to 20-membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S), wherein ring B is optionally substituted with one or more (e.g., 1-10, 1-8, or 1-6, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) R 2b , and each R 2bthe same or different and each independently deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl (e.g. perdeuterated-C 1-6 alkyl, perdeuterated-C 1-5 alkyl or perdeuterated-C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halo-C 1-6 alkoxy (e.g. halo-C 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-); Q1represents N or CH; and the heteroaryl group in formula (PBM-2-1A) containing Q1and the nitrogen atom is optionally substituted with one or more (e.g. 1 to 3, e.g. 1, 2 or 3) R 2c substituents, and each R 2c the same or different and each independently deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl (e.g. perdeuterated-C1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy, e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-).

[0072] In some embodiments, each instance of ring B in formula (PBM-2) and formula (PBM-2-1A) independently represents C 3-15 cycloalkyl or 4- to 20-membered heterocyclyl (e.g., 4- to 20-membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S).C 3-15 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, decahydronaphthalenyl, octahydropentalenyl, octahydro-1H-indenyl, 2,3-dihydro-1H-indenyl, spirocyclyl (e.g., C 5-15 spirocyclyl), adamantyl, noradamantyl, and norbornyl.C 3-15 Optional substituents of cycloalkyl are optionally selected from deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (e.g., C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl or haloC 1-3 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), perdeuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4Alkyl groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-). Examples of the 4- to 20-membered heterocyclic groups include, but are not limited to, azirrobutyl, oxacyclobutyl, pyrrolidinyl, imidazoalkyl, pyrazolyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolyl, thiazoalkyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxacyclohexyl, azirrohepyl, diazacyclohepyl (e.g., 1,4-diazacycloheptan-1-yl), azirrooctyl, diazacyclooctyl, azirbicyclo[3.1.1]heptyl. Alkyl, azabicyclo[2.2.1]heptyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, diazabicyclo[3.1.1]heptyl, diazabicyclo[2.2.1]heptyl, diazabicyclo[3.2.1]octyl (e.g., 3,8-diazabicyclo[3.2.1]octane-3-yl), diazabicyclo[2.2.2]octyl (e.g., 2,5-diazabicyclo[2.2.2]octane-2-yl). Optional substituents for the 4- to 20-membered heterocyclic group are optionally selected from deuterium, halogens (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, nitro, C 1-6 Alkyl (e.g., C10) 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl or halogenated C 1-3 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups, such as methoxy, CD3-O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C1-6 alkoxy (e.g., haloC 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-).

[0073] In some embodiments, PBM represents a structure of formula (PBM-2-1), formula (PBM-2-2), formula (PBM-2-3), formula (PBM-2-4), formula (PBM-2-5), formula (PBM-2-6), formula (PBM-2-7), or formula (PBM-2-8):

[0074] In some embodiments, PBM represents a small molecule ligand of BCR-ABL.

[0075] In some embodiments, PBM represents a structure of formula (PBM-9): wherein R 9a represents -NHC(O)- or -C(O)NH-; R 9b represents -NH-, -N(C 1-6 alkyl)-, or ethynylene; the ring F in formula (PBM-9) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl containing 1 to 4 heteroatoms selected from N, O, and S, 9c p9a represents that the ring F is optionally substituted with p9a R 9c , and each R 9c is the same or different and each independently represents an optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, NO2, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 ​Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-; p9a represents an integer 0, 1, 2, or 3; each (R) in formula (PBM-9) 9d ) p9b Each independently represents the benzene ring to which it is attached, and each can be optionally represented by a p9b R. 9d Replace, each R 9d The same or different and each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, NO2, C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., or halogenated C 1-6 Alkyl groups (e.g., halogenated C) 1-4alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-); and each p9b is the same or different and each independently represents an integer 0, 1, 2, 3, or 4.

[0076] In some embodiments, ring F in formula (PBM-9) represents a 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl containing 1-4 heteroatoms selected from N, O, and S. In a sub-embodiment, examples of the 5- to 20-membered monocyclic or bicyclic or polycyclic heteroaryl include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, iso-benzofuranyl, benzothienyl, indazolyl, benzoimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadia- zolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphthylidinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, or imidazo[1,2-b]pyridazinyl. The heteroaryl is optionally substituted with p2aR 2c substituted, p2a represents an integer 0, 1, 2, or 3, and each R 2c are the same or different and each independently represents: optionally substituted 5- to 15-membered heteroaryl, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, NO2, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-.

[0077] In some implementations, R in formula (PBM-9) 9c The 5- to 15-membered heteroaryl group is a 5- to 15-membered monocyclic or bicyclic aromatic ring group containing one or more (e.g., one to six, one to five, one to four, or one to three) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some sub-implementations, examples of heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrroleyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, indoleyl, isindoleyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indoleyl, benzimidazolyl, benzooxazolyl, benzoisooxazolyl, benzothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzyl... [2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphridyl, cenolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, or imidazo[1,2-b]pyridazinyl. The heteroaryl group is optionally substituted with one or more (e.g., 1-6, e.g., 1, 2, 3, 4, 5, or 6) substituents, wherein the substituents are optionally selected from: halogens (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-.

[0078] In some implementations, R in formula (PBM-9) 9b It represents -NH-.

[0079] In some implementations, PBM represents a non-limiting instance of the structure of the following formula (PBM-9), namely the structure of formula (PBM-9-1A): Where R 9a It represents -NHC(O)- or -C(O)NH-; (R 9c ) p9a This indicates that the pyrimidine group connected thereto is optionally replaced by p9a R 9c Replacement, and each R 9c The same or different, and each independently, represent optional substituted 5- to 15-membered heteroaryl, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, NO2, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halogenated C 1-6 alkoxy (e.g. halogenated C 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-); p9a denotes an integer 0, 1, 2, or 3; each (R 9d ) p9b each independently denotes that the respective phenyl ring is optionally substituted by p9b R 9d each R 9d are identical or different and each independently denotes deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, NO2, C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halogenated C 1-6 alkoxy (e.g. halogenated C 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), or halogenated C 1-6 alkyl (e.g. halogenated C 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-; and each p9b may be the same as or different from the integers 0, 1, 2, 3 or 4, and each p9b may be independent.

[0080] In some implementations, R in formula (PBM-9-1A) 9c The 5- to 15-membered heteroaryl group is a 5- to 15-membered monocyclic or bicyclic aromatic ring group containing one or more (e.g., one to six, one to five, one to four, or one to three) heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some sub-implementations, examples of heteroaryl groups include, but are not limited to, furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiophenyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrroleyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, indoleyl, isindoleyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indoleyl, benzimidazolyl, benzooxazolyl, benzoisooxazolyl, benzothiazolyl, benzotriazolyl, benzo[2,1,3]oxadiazolyl, benzyl... [2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolinyl, isoquinolinyl, naphridyl, cenolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-a]pyridyl, 1H-pyrrolo[3,2-b]pyridyl, 1H-pyrrolo[2,3-b]pyridyl, pyrrolo[2,1-b]thiazolyl, imidazo[2,1-b]thiazolyl, or imidazo[1,2-b]pyridazinyl. The heteroaryl group is optionally substituted with one or more (e.g., 1-6, e.g., 1, 2, 3, 4, 5, or 6) substituents, wherein the substituents are optionally selected from: halogens (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), or haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-).

[0081] In some embodiments, PBM represents a structure of formula (PBM-9-1) or formula (PBM-9-2):

[0082] In some embodiments, PBM represents a structure of formula (PBM-10): wherein (R 10a ) p10a represents a phenyl ring substituted with p10aR 10a , each R 10a is the same or different and each is independently deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkyl, deuterated C 1-6 alkyl, or haloC 1-6 alkyl; p10a represents an integer 1, 2, 3, 4, or 5; R 10b represents halogen, C 1-6 alkyl, deuterated C 1-6 alkyl, or haloC 1-6 alkyl; R 10c represents -NHC(O)- or -C(O)NH-; and R 10d and R 10e each independently represents N or CH.

[0083] In some embodiments, each R 10a each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, cyano, amino, NO2, C 1-6 alkoxy (e.g., C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), haloC 1-6 alkoxy (e.g., haloC1-4 alkyl (e.g. haloC 1-6 alkyl (e.g. haloC 1-5 alkyl, haloC 1-4 alkyl or haloC 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), or deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.).

[0084] In some embodiments, R 10b represents halo (e.g. fluorine, chlorine, bromine or iodine), C 1-6 alkyl (e.g. haloC 1-5 alkyl, haloC 1-4 alkyl or haloC 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), or deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.).

[0085] In some embodiments, R 10c represents -NHC(O)-.

[0086] In some embodiments, R 10c represents -C(O)NH-.

[0087] In some embodiments, R 10d represents N. In some embodiments, R 10d represents CH.

[0088] In some embodiments, R 10e represents N. In some embodiments, R 10e represents CH.

[0089] In some embodiments, R 10d represents N or CH, and R 10e represents N or CH.

[0090] In some embodiments, R 10d represents N, and R 10e represents N.

[0091] In some embodiments, R 10d represents N, and R 10e represents CH.

[0092] In some embodiments, R 10d represents CH, and R 10e represents N.

[0093] In some embodiments, R 10d represents CH, and R 10e represents CH.

[0094] In some embodiments, PBM represents a structure of Formula (PBM-10-1), Formula (PBM-10-2), Formula (PBM-10-3), or Formula (PBM-10-4):

[0095] In some embodiments, R c represents a bond, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, or -NH-.

[0096] In some embodiments, R c represents a structure of: -N(R d )-, -N(R d )-R f -N(R e )-*, -R f -C(O)NH-*, -R f -NHC(O)-*, -R f -C(O)O-*, -R f -OC(O)-*, -R f -, -Rf - N(R d )-*、-O-R f -N(R d )-*、 wherein each ring W 1 is the same or different and each independently represents a 4- to 20-membered nitrogen-containing heterocyclylidenyl group, a C 3-20 cycloalkylidene group, a C 5-20 arylidene group, or a 5- to 20-membered heteroarylidene group, t1 represents an integer of 0, 1 or 2, (R c1 ) m2 represents each ring W 1 is independently optionally substituted by m1 R c1 groups, each R c1 is independently deuterium, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy, deuterated C 1-6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl, C 2-6 alkenyl, optionally deuterated C 3-6 cycloalkyl, or R c4 -R c3 -, wherein R c3 is optionally substituted C 1-6 alkylene or optionally substituted C 2-6 alkenylene, R c4 represents halogen, R c5 R c6 N-, hydroxy, carboxy, ethynyl, or vinyl, wherein R c5 and R c6 are the same or different and each independently represents hydrogen or C 1-3 alkyl, and m1 represents an integer of 0 to 20; each ring W 2 is the same or different and each independently represents a 4- to 20-membered nitrogen-containing heterocyclylidenyl group, a C 3-20 cycloalkylidene group, a C 5-20 arylidene group, or a 5- to 20-membered heteroarylidene group, t2 represents an integer of 0 or 1, (R c2 ) m3 represents each ring W 2 is independently optionally substituted by m2 R c2 groups, each R c2 is independently deuterium, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, deuteratedC 1-6 alkoxy, halogen, amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl, C 2-6 alkenyl, optionally deuteratedC 3-6 cycloalkyl, or R c8 -R c7 -, wherein R c7 is optionally substituted C 1-6 alkylene or optionally substituted C 2-6 alkenylene, R c8 denotes halogen, R c9 R c10 N-, hydroxy, carboxy, ethynyl, or vinyl, wherein R c9 and R c10 are identical or different and each independently denotes hydrogen or C 1-3 alkyl, and m2 denotes an integer from 0 to 20; and R d and R e each independently denotes hydrogen or C 1-6 alkyl, R f and R g each independently denotes optionally substituted C 1-6 alkylene or optionally substituted C 2-6 alkenylene; the C 1-6 alkylene and C 2-6 alkenylene are each independently optionally substituted by one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, mercapto, cyano, amino, nitro, C 1-6 alkyl, haloC 1-6 alkyl, deuteratedC 1-6 alkyl, C 1-6 alkoxy or haloC 1-6 alkoxy; and the symbol * indicates the point of attachment to LIN.

[0097] In some embodiments, R d and R e each independently denotes hydrogen or C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl).

[0098] In some embodiments, R f and R g each independently denotes C 1-6 alkylene and C 2-6 alkenylene. C 1-6alkylene and C 2-6 Alkenylene is optionally substituted with one or more (e.g. one to five, e.g. one, two, three, four, or five) substituents each independently selected from deuterium, halogen, hydroxyl, thiol, cyano, amino, nitro, C 1-6 Alkyl, haloC 1-3 Alkyl, deuteratedC 1-6 Alkyl, C 1-6 Alkoxy or haloC 1-6 Alkoxy is substituted with one or more (e.g. one to five, e.g. one, two, three, four, or five) substituents each independently selected from deuterium, halogen, hydroxyl, thiol, cyano, amino, nitro, C

[0099] In some embodiments, t1 represents the integer 0.

[0100] In some embodiments, t1 represents the integer 1.

[0101] In some embodiments, t1 represents the integer 2.

[0102] In some embodiments, each ring W 1 are the same or different and each independently represents a 4- to 20-membered (e.g. 4 to 15 membered, 4 to 12 membered, 4-11 membered, 4 to 10 membered, 4 to 9 membered, 4 to 8 membered, 4 to 7 membered, 4 to 6 membered, 5 to 15 membered, or 5 membered to 9 membered) nitrogen-containing heterocyclyl, C 3-20 Cycloalkylene (e.g. C 3-15 Cycloalkylene or C 3-11 Cycloalkylene), C 5-20 Arylene (e.g. C 6-20 Arylene, C 5-15 Arylene or C 6-15heteroarylene) or 5- to 20-membered (e.g., 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heteroarylene. In some embodiments, the 4- to 20-membered nitrogen-containing heterocyclylene is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5-membered to 9-membered) heterocyclylene containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. Examples of nitrogen-containing heterocyclylenes include, but are not limited to, for example, piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, sulfomorpholinylene, azepanylene, diazepanylene, azocanylene, diazocanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2.2]octanylene, diazabicyclo[3.1.1]heptanylene, diazabicyclo[2.2.1]heptanylene, diazabicyclo[3.2.1]octanylene, diazabicyclo[2.2.2]octanylene, 3-azaspiro[5.5]undecanylene, 8-azaspiro[4.5]decanylene, 2-oxo-8-azaspiro[4.5]decanylene, or 3-methyl-2-oxo-8-azaspiro[4.5]decanylene. In some embodiments, the C 3-20 Examples of cycloalkylene (e.g., C 3-15 Examples of cycloalkylene (e.g., C 5-15In some embodiments, examples of 5- to 20-membered arylene groups include, but are not limited to, for example, phenylene or naphthylene. In some embodiments, a 5- to 20-membered heteroarylene group is a 5- to 20-membered (e.g., 5 to 15 membered, 5 to 12 membered, 5 to 9 membered, 5 to 8 membered, 5 to 7 membered, or 5 to 6 membered) heteroarylene group containing one nitrogen atom and optionally containing heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazyiene, benzo[1,2,3]thiadiazyiene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene. Each ring W 1 each independently optionally substituted by m1R d groups, each R c1 is independently deuterium, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., per-deuterated C 1-6 alkyl, per-deuterated C 1-5 alkyl or per-deuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), halo C 1-6 alkyl (e.g., halo C 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), C 1-6 alkoxy (e.g., C 1-4alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 2-6 alkyl, such as methyl, ethyl or propyl, and the C 2-4 alkyl, such as methyl, ethyl or propyl, and the C 2-6 alkyl, such as methyl, ethyl or propyl, and the C 2-4 alkyl, such as methyl, ethyl or propyl, and the C 3-6 alkyl, such as methyl, ethyl or propyl, and the C c4 alkyl, such as methyl, ethyl or propyl, and the C c3 alkyl, such as methyl, ethyl or propyl, and the C c3 alkyl, such as methyl, ethyl or propyl, and the C 1-6 alkyl, such as methyl, ethyl or propyl, and the C 1-4 alkyl, such as methyl, ethyl or propyl, and the C 2-6 alkyl, such as methyl, ethyl or propyl, and the C 2-4 alkyl, such as methyl, ethyl or propyl, and the C c4 alkyl, such as methyl, ethyl or propyl, and the C c5 alkyl, such as methyl, ethyl or propyl, and the C c6 alkyl, such as methyl, ethyl or propyl, and the C c5 and R c6 are identical or different and each independently represent hydrogen or C 1-3 alkyl, such as methyl, ethyl or propyl, and the C 1-6 alkyl, such as methyl, ethyl or propyl, and the C 2-6 alkyl, such as methyl, ethyl or propyl, and the C 1-6 alkyl, such as methyl, ethyl or propyl, and the C 1-5 alkyl, such as methyl, ethyl or propyl, and the C 1-4 alkyl, such as methyl, ethyl or propyl, and the C 1-3 alkyl, such as methyl, ethyl or propyl, and the C 1-3 alkyl, such as methyl, ethyl or propyl, and the C 1-2alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-5 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-3 alkoxy, e.g. methoxy, ethoxy, propoxy, or isopropoxy), or halogenated C 1-3 alkoxy, e.g. halogenated C 1-2 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-). m1 denotes an integer from 0 to 20, e.g. the integer 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not limited by any restriction or automatically by the size of the building block.

[0103] In some embodiments, each ring W 1 are identical or different and each independently represent the following optionally substituted group: each ring W 1 are each independently optionally substituted by m1 R c1 groups, each R c1 is independently deuterium, C 1-6 alkyl, e.g. C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-5 alkyl, or deuterated C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkoxy, e.g. C1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), deuterated C 1-6 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 2-6 alkynyl, such as ethynyl, propynyl, or butynyl), C 2-4 alkynyl, such as ethynyl, propynyl, or butynyl), C 2-6 alkenyl, such as ethenyl, propenyl, or butenyl), optionally deuterated C 2-4 alkenyl, such as ethenyl, propenyl, or butenyl), optionally deuterated C 3-6 cycloalkyl, such as optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl or optionally perdeuterated cyclohexyl), or R c4 -R c3 -, wherein R c3 is optionally substituted C 1-6 alkylene, such as optionally substituted methylene, ethylene or propylene), or optionally substituted C 1-4 alkylene, such as optionally substituted methylene, ethylene or propylene), or optionally substituted C 2-6 alkenylene, such as optionally substituted ethenylene, propenylene, butenylene), R 2-4 alkenylene, such as optionally substituted ethenylene, propenylene, butenylene), R c4 represents halogen (such as fluorine, chlorine, bromine or iodine), R c5 R c6 N-, hydroxy, carboxy, ethynyl, or ethenyl, wherein R c5 and R c6 are identical or different and each independently represent hydrogen or C 1-3 alkyl (such as methyl, ethyl or propyl), and the C 1-6 alkylene and the C 2-6 alkylene and the C 1-6 alkyl (such as C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-2alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-5 alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-4 alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-3 alkoxy (for example methoxy, ethoxy, propyloxy, or isopropoxy), or halogenated C 1-3 alkoxy (for example halogenated C 1-2 alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-). m1 denotes an integer from 0 to 20, for example the integer 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not limited in any way or is automatically limited by the size of the building block.

[0104] In some embodiments, each ring W 2 are identical or different and each independently denote a 4- to 20-membered (for example 4- to 15-membered, 4 to 12 membered, 4-11 membered, 4 to 10 membered, 4 to 9 membered, 4 to 8 membered, 4 to 7 membered, 4 to 6 membered, 5 to 15 membered, or 5 membered to 9 membered) nitrogen-containing heterocyclyl, C 3-20 cycloalkylene (for example C 3-15 cycloalkylene or C 3-11 cycloalkylene), C 5-20 arylene (for example C 6-20 arylene, C 5-15 arylene or C 6-15heteroarylene) or 5- to 20-membered (e.g., 5- to 15-membered, 5- to 12-membered, 5- to 11-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, or 5- to 6-membered) heteroarylene. In some embodiments, the 4- to 20-membered nitrogen-containing heterocyclylene is a 4- to 20-membered (e.g., 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, or 5- to 9-membered) heterocyclylene containing one nitrogen atom and optionally containing a heteroatom selected from nitrogen, oxygen, and sulfur. Examples of 4- to 20-membered nitrogen-containing heterocyclylenes include, but are not limited to, for example, piperidinylene, piperazinylene, morpholinylene, azetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, sulfomorpholinylene, azepanylene, diazepanylene, azocanylene, diazocanylene, azabicyclo[3.1.1]heptanylene, azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene, azabicyclo[2.2.2]octanylene, diazabicyclo[3.1.1]heptanylene, diazabicyclo[2.2.1]heptanylene, diazabicyclo[3.2.1]octanylene, diazabicyclo[2.2.2]octanylene, 3-azaspiro[5.5]undecanylene, 8-azaspiro[4.5]decanylene, 2-oxo-8-azaspiro[4.5]decanylene, or 3-methyl-2-oxo-8-azaspiro[4.5]decanylene. In some embodiments, the C 3-20 cycloalkylene (e.g., C 3-15 Examples of cycloalkylene groups include, but are not limited to, for example, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydrocyclopenta-dienylene, octahydro-lH-indenylene, 2,3-dihydro-lH-indenylene, spirocyclylene (e.g., C 5-15In some embodiments, examples of 5- to 20-membered arylene groups include, but are not limited to, for example, phenylene or naphthylene. In some embodiments, a 5- to 20-membered heteroarylene group is a 5- to 20-membered (e.g., 5 to 15 membered, 5 to 12 membered, 5 to 9 membered, 5 to 8 membered, 5 to 7 membered, or 5 to 6 membered) heteroarylene group containing one nitrogen atom and optionally containing heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazyiene, benzo[1,2,3]thiadiazyiene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene. Each ring W 2 is independently optionally substituted with m2 R c2 groups, each R c2 is independently deuterium, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), halo C 1-6 alkyl (e.g., halo C 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), C 1-6 alkoxy (e.g., C 1-4alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-4 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 2-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 2-4 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 2-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 2-4 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 3-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c8 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c7 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c7 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-4 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 2-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 2-4 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c8 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c9 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c10 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c9 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC c10 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-3 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 2-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC 1-6substituted by substituents selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, deuterated alkyl, deuterated alkoxy, deuterated haloalkyl, deuterated haloalkoxy, deuterated cycloalkyl, deuterated cycloalkylalkyl, deuterated aryl, deuterated aralkyl, deuterated heteroaryl, deuterated heteroaralkyl, deuterated heterocyclyl, deuterated heterocyclylalkyl, halogen, cyano, nitro, oxo, hydroxyl, amino, and carboxyl. m2represents an integer from 0 to 20, for example the integer 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, 12, 13, 14, 15, or 20. The number of substituents is in principle not limited by any or is automatically limited by the size of the building block.

[0105] In some embodiments, each ring W 2 are identical or different and each independently represent: each ring W 2 is independently optionally substituted by m2R c2 groups, each R c2 is independently deuterium, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, for example CD3, CD3CD2-, CD3CD2CD2-, etc.), halo C 1-6 alkyl (e.g. halo C 1-4 alkyl, for example F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), C 1-6 alkoxy (e.g. C 1-4 alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo C 1-6 alkoxy (e.g. halo C 1-4 alkoxy, for example F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), deuterated C 1-6 alkoxy, halogen (e.g. fluorine, chlorine, bromine or iodine), amino, hydroxyl, thiol, cyano, carboxyl, C 2-6 alkynyl (e.g. C 2-4 alkynyl, for example ethynyl, propynyl, or butynyl), C 2-6 alkenyl (e.g. C 2-4 alkenyl, for example ethenyl, propenyl, or butenyl), optionally deuterated C 3-6cycloalkyl (e.g. optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl or optionally perdeuterated cyclohexyl), or R c8 -R c7 - wherein R c7 is optionally substituted C 1-6 alkylene (e.g. optionally substituted C 1-4 alkylene, e.g. optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 alkenylene (e.g. optionally substituted C 2-4 alkenylene, e.g. optionally substituted ethenylene, propenylene, butenylene), R c8 represents halogen (e.g. fluorine, chlorine, bromine or iodine), R c9 R c10 N-, hydroxy, carboxy, ethynyl, or vinyl, wherein R c9 and R c10 are identical or different and each independently represent hydrogen or C 1-3 alkyl (e.g. methyl, ethyl, or propyl); and each of said C 1-6 alkylene and said C 2-6 alkenylene is independently optionally substituted with one or more (e.g. 1 to 5, e.g. 1, 2, 3, 4 or 5) substituents selected from the group consisting of deuterium, halogen, hydroxy, thiol, cyano, amino, nitro, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy or haloC 1-6 alkoxy. m2 represents an integer from 0 to 20, e.g. the integer 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not limited by any or is automatically limited by the size of the building block.

[0106] In some embodiments, t2 represents the integer 0.

[0107] In some embodiments, t2 represents the integer 1.

[0108] In some embodiments, the moiety c in each of the general formulae for R represents a group of the following: wherein each of said groups is independently optionally further substituted with one or more (e.g. 1 to 5, e.g. 1, 2, 3, 4 or 5) substituents selected from the group consisting of deuterium, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl, e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), halo-C 1-6 alkyl, e.g. halo-C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 alkoxy, e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 alkoxy, e.g. halo-C 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), deuterated C 1-6 alkoxy, e.g. perdeuterated C 1-4 alkoxy, e.g. CD3-O-, CD3CD2-O-, or CD3CD2CD2-O-), halogen (e.g. fluorine, chlorine, bromine or iodine), amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl, e.g. C 2-4 alkynyl, e.g. ethynyl, propynyl, or butynyl), C 2-6 alkenyl, e.g. C 2-4 alkenyl, e.g. ethenyl, propenyl, or butenyl), optionally deuterated C 3-6 cycloalkyl, e.g. optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl or optionally perdeuterated cyclohexyl), R c12 -R c11 , or any combination thereof, wherein R c11 is optionally substituted C 1-6 alkylene, e.g. optionally substituted C 1-4 alkylene, e.g. optionally substituted methylene, ethylene or propylene) or optionally substituted C 2-6 alkenylene, e.g. optionally substituted C 2-4 alkenylene, e.g. optionally substituted ethenylene, propenylene, butenylene), R c12 denotes halogen (e.g. fluorine, chlorine, bromine or iodine), Rc13 R c14 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c13 and R c14 The same or different and each independently represents hydrogen or C. 1-3 Alkyl (e.g., methyl, ethyl, or propyl), the C 1-6 Alkylene and C 2-6 Each of the alkenyl groups is independently and optionally selected from one or more groups selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Substitution of alkoxy groups.

[0109] In some embodiments, the R of compound (I) c Represents the following groups: bond, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, -CH2C(O)O-*, -CH2OC(O)-*, -NH-, - N(CH3)-, -NH-CH2-*, -N(CH3)-CH2-*, -N(CH3)-(CH2)2-N(CH3)-*, -N(CH3)-(CH2)3-N(CH3)-*, -NH-(CH2)2-N(CH3)-*, -N(C or Each of the said groups is optionally and independently further selected from deuterium, C, and C. 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-; halogens (e.g., fluorine, chlorine, bromine, or iodine); amino groups; hydroxyl groups; mercapto groups; cyano groups; C 2-6 alkynyl groups (e.g., C) 2-4 Alkyne group, such as ethynyl, propynyl, or butynyl), C 2-6 alkenyl (e.g., C) 2-4 Alkenyl (e.g., vinyl, propenyl, or butenyl), optionally deuterated C 3-6 Cycloalkyl groups (e.g., optionally fully deuterated cyclopropyl, optionally fully deuterated cyclobutyl, optionally fully deuterated cyclopentyl, or optionally fully deuterated cyclohexyl), R c12 -R c11 - or any combination of substituents thereof, wherein R c11 It is an optional replacement for C 1-6 Alkylenes (e.g., optionally substituted C) 1-4 Alkylenes (e.g., optionally substituted methylene, ethylene, or propylene) or optionally substituted C 2-6 alkenyl groups (e.g., optionally substituted C) 2-4 alkenyl groups, such as optionally substituted vinylidene, propenylidene, or butenylidene groups, R c12 Indicates halogen (e.g., fluorine, chlorine, bromine, or iodine), R c13 R c14 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c13 and R c14 The same or different and each independently represents hydrogen or C. 1-3 Alkyl groups (e.g., methyl, ethyl, or propyl), and the C 1-6 alkylene and the C 2-6 Each of the alkenyl groups is independently and optionally replaced by one or more deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C group, etc. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6alkoxy or halogenated C 1-6 Substituents of alkoxy groups; and the symbol * indicates the connection point with LIN.

[0110] In some embodiments, the ULM of the compound of formula (I) represents the ligand moiety capable of binding to E3 ubiquitin ligases, and represents the structure of the following formula (ULM): Where Z represents C(O) or CH2; R a1 R a2 R a3 and R a4 The same or different and each independently represents hydrogen, deuterium, halogens (e.g., fluorine, chlorine, bromine or iodine), C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, or deuterated C 1-6 Alkoxy; (R a5 ) m This indicates that the isoindoline ring connected to it is optionally surrounded by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl (e.g. perdeuterated-C 1-6 alkyl, perdeuterated-C 1-5 alkyl or perdeuterated-C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or t-butyloxy), halo-C 1-6 alkoxy (e.g. halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), or deuterated-C 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; L1represents S or O; L2represents substituted or unsubstituted straight-chain or branched-chain alkylene (e.g. substituted or unsubstituted straight-chain or branched-chain C1-C 10 alkylene), or L2is absent; R a6 represents: wherein ring Y 1 represents arylene, heteroarylene, heterocyclylene, or cycloalkylene, (R d1 ) n1 represents ring Y 1 optionally substituted by n1R d1 groups, each R d1 each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxy, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy) or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, and n1 represents an integer from 0 to 20; w represents an integer 0 or 1; cyclic Y 2 Indicates a nitrogen-containing heterocyclic group, (R) d2 ) n2 Represents ring Y 2 Optionally, it can be used by n2 R d2 Group substitution, each R d2 Each can independently represent deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4alkyl (e.g., C1-C5alkyl, C1-C3alkyl, or C1-C2alkyl), or substituted or unsubstituted straight- chain or branched-chain C1-C5alkyl, or substituted or unsubstituted straight- chain or branched-chain C1-C3alkyl, etc. 1-6 alkyl (e.g., C1-C5alkyl, C1-C3alkyl, or C1-C2alkyl), or substituted or unsubstituted straight- chain or branched-chain C1-C5alkyl, or substituted or unsubstituted straight- chain or branched-chain C1-C3alkyl, etc. 1-4 alkyl (e.g., C1-C5alkyl, C1-C3alkyl, or C1-C2alkyl), or substituted or unsubstituted straight- chain or branched-chain C1-C5alkyl, or substituted or unsubstituted straight- chain or branched-chain C1-C3alkyl, etc.

[0111] In some embodiments, Z of the structure of Formula (ULM) represents C(O).

[0112] In some embodiments, Z of the structure of Formula (ULM) represents CH2.

[0113] In some embodiments, L1of the structure of Formula (ULM) represents S.

[0114] In some embodiments, L1of the structure of Formula (ULM) represents O.

[0115] In some embodiments, R a1 , R a2 , R a3 , and R a4 represent hydrogen.

[0116] In some embodiments, m of the structure of Formula (ULM) represents the integer 0.

[0117] In some embodiments, m of the structure of Formula (ULM) represents the integer 1, 2, or 3.

[0118] In some embodiments, each R a5 is the same or different and each independently represents halogen (e.g., fluorine, chlorine, bromine, or iodine).

[0119] In some embodiments, L2of the structure of Formula (ULM) is substituted or unsubstituted straight-chain or branched-chain alkylene. When L2is substituted or unsubstituted straight-chain or branched-chain alkylene, the L2represents substituted or unsubstituted straight-chain or branched-chain C1-C 10 alkyl (e.g., C1-C5alkyl, C1-C3alkyl, or C1-C2alkyl), or substituted or unsubstituted straight- chain or branched-chain C1-C5alkyl, or substituted or unsubstituted straight- chain or branched-chain C1-C3alkyl, etc.

[0120] In some embodiments, when L2of the structure of formula (ULM) is a substituted or unsubstituted straight or branched C1-C5 alkylene, the straight or branched C1-C5 alkylene can be methylene, ethylene, propylene, n-propylene, iso-propylene, butylene, n-butylene, iso-butylene, t-butylene, sec-butylene, 1-methyl-butylene, 1-ethyl-butylene, pentylene, n-pentylene, iso-pentylene, neopentylene, or t-pentylene, and the like.

[0121] In some embodiments, when L2of the structure of formula (ULM) is a substituted or unsubstituted straight or branched C1-C3 alkylene, the straight or branched alkylene can be, for example, methylene, ethylene, propylene, or iso-propylene.

[0122] In some embodiments, L2of the structure of formula (ULM) is selected from methylene.

[0123] In some embodiments, the substituents of the substituted L2are optionally selected from deuterium, halogen, cyano, nitro, hydroxyl, thiol, carbonyl, ester, imide, amino, phosphine oxide group, alkoxy, haloalkoxy, aryloxy, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, silyl, boron group, alkyl, cycloalkyl, alkenyl, aryl, aralkyl, aralkenyl, alkylaryl, alkylamino, aralkylamino, heteroaryl amino, arylamino, aryl phosphine group, and heteroaryl, acenyl, and the like, or any combination thereof. Alternatively, the substituents of the substituted L2may be, for example, one or more substituents selected from D (i.e., deuterium), halogen, hydroxyl, cyano, C1-C3 alkyl, C1-C3 alkoxy, trifluoromethyl, heterocyclyl (e.g., four- to eight-membered heterocycle), nitro, thiol, carbonyl, ester, imide, amino, phosphine oxide group, alkoxy, deuterated alkoxy, trifluoromethoxy, aryloxy, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, silyl, boron group, alkyl, deuterated alkyl, haloalkyl, amino-substituted alkylene, alkyl-NHC(O)-, alkyl-C(O)NH-, cycloalkyl, deuterated cycloalkyl, alkenyl, aryl, aralkyl, aralkenyl, alkylaryl, alkylamino, aralkylamino, heteroaryl amino, arylamino, aryl phosphine group, heteroaryl, acenyl, oxo, or any combination thereof. Further alternatively, the substituents of the substituted L2may be, for example, selected from deuterium, halogen, nitro, thiol, hydroxyl, cyano, C1-C3 alkyl, C1-C3 alkoxy, halo-substituted C1-C3 alkoxy, halo-substituted C1-C3 alkyl, amino, silyl, boron group, or any combination thereof. Further alternatively, the “substituted” substituents may, for example, be selected from deuterium, F, Cl, methoxy, methyl, hydroxyl, or any combination thereof.

[0124] In some embodiments, L2of the structure of formula (ULM) is absent.

[0125] In some embodiments, R of the structure of Formula (ULM) is a6 represents: wherein ring Y 1 represents C5-C 30 arylene, 5- to 30-membered heteroarylene, 4- to 30-membered heterocyclylene, or C3-C 30 cycloalkylene, (R d1 ) n1 represents ring Y 1 optionally substituted with n1 R d1 groups, each R d1 each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), or haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy, e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), and n1 represents an integer from 0-20 (e.g., 0-10 or 0-5, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20); w represents an integer 0 or 1; and ring Y 2 represents 4- to 30-membered nitrogen-containing heterocyclylene, (R d2 ) n2 represents ring Y 2optionally substituted by n2R d2 each R d2 each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or haloC 1-6 alkoxy (e.g. haloC 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), and n2 represents an integer from 0 to 20 (e.g. 0 to 10 or 0 to 5, e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20); and the symbol ** indicates the point of attachment to LIN.

[0126] In some embodiments, R a6 represents: wherein ring Y 1 represents C5-C 20 arylene (e.g. C5-C 15 arylene), 5- to 20-membered heteroarylene (e.g. 5- to 15-membered heteroarylene), 4- to 20-membered heterocyclylene (e.g. 4- to 15-membered heterocyclylene), or C3-C 20 cycloalkylene (e.g. C3-C 15 cycloalkylene), (R d1 )n1 represents a 4- to 20-membered nitrogen-containing heterocyclyl ring (e.g., a 4- to 15-membered nitrogen-containing heterocyclyl ring), (R 1 optionally substituted by n1 R d1 groups, each R d1 each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, thio, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or t-butyloxy) or haloC 1-6 alkoxy (e.g., haloC 1-4 alkoxy, e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n1 represents an integer of 0 to 20; w represents an integer of 0 or 1 ; and ring Y 2 represents a 4- to 20-membered nitrogen-containing heterocyclyl ring (e.g., a 4- to 15-membered nitrogen-containing heterocyclyl ring), (R d2 ) n2 represents a 4- to 20-membered nitrogen-containing heterocyclyl ring (e.g., a 4- to 15-membered nitrogen-containing heterocyclyl ring), (R 2 optionally substituted by n2 R d2 groups, each R d2 each independently represents deuterium, halogen (e.g., fluorine, chlorine, bromine or iodine), hydroxy, thio, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g., haloC1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy) or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, and n2 represents an integer from 0 to 20; and the symbol ** indicates the connection point with LIN.

[0127] In some implementations, the R of the structure of formula (ULM) a6 The ring Y in 1non-limiting examples include, but are not limited to: azetidinylene, oxetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, dihydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, dioxanylene, dioxolanylene, azepanylene, azocanylene, diazepanylene, diazocanylene, bridged heterocyclylene (e.g., 5- to 15-membered bridged heterocyclylene, such as azabicyclohexanylene, azabicycloheptanylene, or azabicyclooctanylene), or spiroheterocyclylene (e.g., 5- to 15-membered spiroheterocyclylene, such as 3-azaspiro[5.5]undecanylene or 7-azaspiro[3.5]nonanylene); or furanylene, oxanylene, isoxanylene, oxadiazanylene, thienylene, thiazanylene, isothiazanylene, thiadiazanylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothiophenylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,l,3]oxadiazolylene, benzo[2,l,3]thiadiazolylene, benzo[l,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[l,5-a]pyridinylene, pyrazolo[l,5-a]pyrimidinylene, imidazo[l,2-a]pyridinylene, lH-pyrrolo[3,2-b]pyridinylene, lH-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,l-b]thiazolylene, and imidazo[2,l-b]thiazolylene; or cyclopropylylene, cyclobutylylene, cyclopentylylene, cyclopentenylylene, cyclohexylylene, cyclohexenylylene, cycloheptylylene, cyclooctanylene, decahydronaphthylylene, octahydrobenzo[a]cyclopentylylene, octahydro-lH-indenylene, spirocycloalkanylene (e.g., C5-C 15 spirocycloalkanylene, such as spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, or spiro[5.5]undecanylene), or bridged cycloalkanylene (e.g., C5-C 15 bridged cycloalkanylene, such as adamantylylene, noradamantylylene, menthylylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[2.2.1]heptanylene, or bicyclo[2.2.1]heptenylylene); or phenylylene or naphthylylene; wherein the ring Y 1 is optionally substituted with n1R d1 groups, each R d1each independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, deuterated C 1-6 alkyl, deuterated C 1-6 alkoxy or C 1-6 alkoxy; n1 represents an integer from 0-20 (e.g., 0-10 or 0-5, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20).

[0128] In some embodiments, R a6 in the structure of Formula (ULM) is a ring Y 2non-limiting examples include, but are not limited to: azetidinylene, diazetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinylene, thiazolidinylene, piperidinylene, tetrahydropyridinylene, piperazinylene, 1,2,3,4-tetrahydropyrazinylene, hexahydropyrimidinylene, hexahydropyridazinylene, morpholinylene, sulfomorpholinylene, azepinylene, azocinylene, dioxepinylene, azepinylene, azocinylene, diazepinylene, diazocinylene, nitrogen-containing bridged heterocyclylene groups (e.g., 5- to 20-membered nitrogen-containing bridged heterocyclylene groups, such as azabicyclo[3.1.1]heptanylene (e.g., 6-azabicyclo[3.1.1]heptanylene), azabicyclo[2.2.1]heptanylene, azabicyclo[3.2.1]octanylene (e.g., 3-azabicyclo[3.2.1]octanylene), azabicyclo[2.2.2]octanylene, diazabicyclo[3.1.1]heptanylene (e.g., 3,6-diazabicyclo[3.1.1]heptanylene), diazabicyclo[2.2.1]heptanylene (e.g., 2,5-diazabicyclo[2.2.1]heptanylene), diazabicyclo[3.2.1]octanylene (e.g., 3,8-diazabicyclo[3.2.1]octanylene), diazabicyclo[2.2.2]octanylene (e.g., 2,5-diazabicyclo[2.2.2]octanylene)), or 5- to 20-membered azaspiroalkylene groups (e.g., azaspiro[2.3]hexanylene, azaspiro[3.3]heptanylene, azaspiro[2.4]heptanylene, azaspiro[3.4]octanylene, azaspiro[3.5]nonanylene, azaspiro[4.4]nonanylene, azaspiro[4.5]decanylene, diazaspiro[2.3]hexanylene, diazaspiro[3.3]heptanylene, diazaspiro[2.4]heptanylene, diazaspiro[3.4]octanylene, diazaspiro[3.5]nonanylene, diazaspiro[4.4]nonanylene, diazaspiro[4.5]decanylene, diazaspiro[5.5]undecanylene, octahydrocyclopenta[c]pyrrolylene, octahydropyrrolo[3,4-c]pyrrolylene, or decahydronaphthyridinylene); wherein the ring Y 2 is optionally substituted with n2R d2 groups, each R d2 is independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy, or C 1-6alkyl, haloC

[0129] In some embodiments, R a6 Non-limiting examples of R wherein R d3 , R d4 each independently is selected from hydrogen, deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkyl, or C 1-6 alkoxy; and R d3 , R d4 are not simultaneously hydrogen.

[0130] In some embodiments, ULM of the compound of Formula (I) represents a structure of Formula (ULM-1-1), Formula (ULM-1-2), Formula (ULM-1-3), or Formula (ULM-1-4): wherein Z represents C(O) or CH2; R a1 , R a2 , R a3 and R a4 are the same or different and each independently represents hydrogen, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy, e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or t-butyloxy), haloC1-6 alkoxy (e.g. haloC 1-4 alkoxy (e.g. haloC 1-6 alkoxy; (R a5 ) m represents an isochromane ring optionally substituted with m R a5 , each R a5 are the same or different and each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxy, thiohydroxy, nitro, amino, cyano, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC 1-4 alkyl (e.g. haloC 1-6 alkyl (e.g. perdeuteroC 1-6 alkyl, perdeuteroC 1-5 alkyl or perdeuteroC 1-4 alkyl (e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy (e.g. C 1-6 alkoxy (e.g. haloC 1-4 alkoxy (e.g. haloC 1-6 alkoxy; m represents an integer 0, 1, 2 or 3; L1represents S or O; L2represents substituted or unsubstituted straight-chain or branched alkylene, or L2is absent; R a6 represents: wherein ring Y 1 represents arylene, heteroarylene, heterocyclylene, or cycloalkylene, (Rd1 ) n1 represents a ring Y 1 optionally substituted by n1 R d1 groups, each R d1 each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxy, thio, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or t-butyloxy) or haloC 1-6 alkoxy (e.g. haloC 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), and n1 represents an integer from 0 to 20; w represents an integer 0 or 1 ; ring Y 2 represents a nitrogen-containing heterocyclyl ring, (R d2 ) n2 represents a ring Y 2 optionally substituted by n2 R d2 groups, each R d2 each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxy, thio, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy, sec-butyloxy or tert-butyloxy) or halogenated C 1-6 alkoxy (e.g. halogenated C 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), and n2 represents an integer from 0 to 20; and the symbol ** indicates the point of attachment to LIN.

[0131] In some embodiments, ULM of the compound of formula (I) represents one of the following structures of formula: wherein Z, (R a5 ) m , L1, L2and R a6 are as defined herein.

[0132] In some embodiments, LIN of the compound of formula (I) represents: wherein R w2 connects PBM, R w1 connects R a6 ; R w2 represents a bond, C(O), C(O)NH or NHC(O); each ring A 1 is the same or different and each independently represents heterocyclylene (e.g. 4- to 20-membered heterocyclylene), cycloalkylene (e.g. C 3-20 cycloalkylene), arylene (e.g. C 5-20 arylene), or heteroarylene (e.g. 5- to 20-membered heteroarylene), y1 represents an integer 0, 1, 2 or 3, (R y1 ) a1 represents each ring A 1 is independently optionally substituted by a1 R y1 groups, each R y1 is independently deuterium, C 1-6alkyl, deuterated C 1- 6alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, halo, amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl or C 2-6 alkenyl, and a1 represents an integer of 0 to 10; each ring A 2 are the same or different and each independently represents a heterocyclylene group (e.g., 4- to 20-membered heterocyclylene group), a cycloalkylene group (e.g., C 3-20 cycloalkylene group), an arylene group (e.g., C 5-20 arylene group), or a heteroarylene group (e.g., 5- to 20-membered heteroarylene group), y2 represents an integer of 0, 1, 2, or 3, (R y2 ) a2 represents each ring A 2 is independently optionally substituted by a2 R y2 groups, each R y2 is independently deuterium, C 1-6 alkyl, deuterated C 1- 6alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, halo, amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl or C 2-6 alkenyl, and a2 represents an integer of 0 to 10; each ring A 3 are the same or different and each independently represents a heterocyclylene group (e.g., 4- to 20-membered heterocyclylene group), a cycloalkylene group (e.g., C 3-20 cycloalkylene group), an arylene group (e.g., C 5-20 arylene group), or a heteroarylene group (e.g., 5- to 20-membered heteroarylene group), y3 represents an integer of 0, 1, 2, or 3, (R y3 ) a3 represents each ring A 3 is independently optionally substituted by a3 R y3 groups, each R y3 is independently deuterium, C 1-6 alkyl, deuterated C 1- 6alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, halo, amino, hydroxy, mercapto, cyano, carboxy, C 2-6 alkynyl or C 2-6 alkenyl, and a3 represents an integer of 0 to 10; R w1 represents a bond, or represents an optionally substituted straight or branched C 1-20 alkylene group, wherein the straight or branched C1-20 Any one or more methylene groups in the main carbon chain backbone of the alkylene group may optionally be replaced by one or more groups selected from the following: R a R b And any combination thereof, each group R a Each is independently selected from O, C(O), OC(O), S, S(O), S(O)2, and S(O)2N(R). a7 ), N(R a7 S(O)2、C(O)N(R) a7 ), N(R a7 C(O), N(R) a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each can be represented independently as H or C. 1-3 Alkyl groups, and when the straight-chain or branched C 1-20 Any two or more methylene groups in the main carbon chain backbone of an alkylene group may optionally be separated by two or more R groups. a During substitution, each group R a They are not directly connected to each other; each group R b Each is independently selected from optional substituted cycloalkylene groups (e.g., optional substituted C14 groups). 3-20 Cycloalkylene, optionally substituted arylene (e.g., optionally substituted C464), 5-20 arylene), optionally substituted heterocyclic groups (e.g., optionally substituted 4- to 20-membered heterocyclic groups), optionally substituted heteroarylene groups (e.g., optionally substituted 5- to 20-membered heteroarylene groups), alkynyl groups (e.g., C... 2-6 (e.g., C-ynyl), (e.g., C-yl) 2-6 (alkenyl groups) and any combination thereof.

[0133] In some implementations, R in the LIN of compound (I) w2 Indicates a key.

[0134] In some implementations, R in the LIN of compound (I) w2 It represents C(O).

[0135] In some implementations, R in the LIN of compound (I) w2 It represents C(O)NH or NHC(O).

[0136] In some embodiments, the rings A in the LIN of compound (I) 1The same or different and each independently represents a heterocyclic group (e.g., 4- to 20-membered heterocyclic group, such as 4 to 18-membered, 4 to 15-membered, 4 to 12-membered, 4 to 11-membered, 4 to 10-membered, 4 to 9-membered, 4 to 8-membered, 4 to 7-membered, 4 to 6-membered, 5 to 15-membered, or 5 to 9-membered heterocyclic group), or a cycloalkyl group (e.g., C...). 3-20 Cycloalkylene, arylene (e.g., C164-) 5-20 aryl, such as C 6-20 Alpha-aryl, C 5-15 aryl or C 6-15 (e.g., 5- to 20-membered heteroaryl, e.g., 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered or 5- to 6-membered heteroaryl). In some embodiments, the 4- to 20-membered heterocyclic group is a saturated or partially unsaturated (i.e. having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of 4- to 20-membered heterocyclic groups include, but are not limited to, monocyclic heterocyclic groups (e.g., 4- to 20-membered monocyclic heterocyclic groups), bridged heterocyclic groups (e.g., 5- to 20-membered bridged heterocyclic groups or 7- to 15-membered bridged heterocyclic groups), fused heterocyclic groups, and spirocyclic heterocyclic groups (e.g., 5- to 20-membered spirocyclic heterocyclic groups), such as azapyrocyclyl, oxazolidinyl, pyrazolealkyl, imidazoalkyl, pyrazolalkyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolalkyl, thiazoalkyl, piperidinyl, piperazine, morpholinyl, thiomorpholinyl, azapyrocyclyl heptyl, and azapyrocyclyl octane. The compounds include 6-azabicyclo[3.1.1]heptane, 2,5-azabicyclo[2.2.1]heptane, 3,6-azabicyclo[3.1.1]heptane, 3-azabicyclo[3.2.1]octane, 3,8-azabicyclo[3.2.1]octane, 3,8-azabicyclo[3.2.1]octane, 2,5-azabicyclo[2.2.2]octane, and azaspirocyclic groups (e.g., 5- to 20-membered azaspirocyclic groups, such as 3-azaspiro[5.5]undecane). In some embodiments, C 3-20Examples of cycloalkylene groups include, but are not limited to, for example, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydro naphthylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclylene (e.g., C 5-15 spirocyclylene), adamantylene, noradamantylene, and norbornylene. In some embodiments, examples of 5- to 20-membered arylene groups include, but are not limited to, for example, phenylene or naphthylene. In some embodiments, the 5- to 20-membered heteroarylene is a 5- to 20-membered (e.g., 5 to 15 membered, 5 to 12 membered, 5 to 9 membered, 5 to 8 membered, 5 to 7 membered, or 5 to 6 membered) heteroarylene containing one nitrogen atom and optionally containing heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothiophenylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene. Each ring A 1 is independently optionally substituted with a1R y1 groups, each R y1 is independently deuterium, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), halo C 1-6 alkyl (e.g., halo C 1-4Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl. a1 represents an integer from 0 to 10, such as the integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The number of substituents is in principle unrestricted or automatically limited by the size of the building blocks.

[0137] In some implementations, y1 in LIN of compound (I) represents an integer 0, 1, 2 or 3.

[0138] In some embodiments, the rings A in the LIN of compound (I) 1 The same or different, and each independently, represent the following optional substituted groups: Each ring A 1 Independently and optionally by a1 R y1 Group substitution, each R y1 Independent of deuterium and C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6Alkyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl groups (e.g., C) 2-4 Alkyne group (e.g., ethynyl, propynyl, or butynyl) or C 2-6 alkenyl (e.g., C) 2-4 Alkenyl groups, such as vinyl, propenyl, or butenyl. a1 represents an integer from 0 to 10, such as the integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The number of substituents is not limited in principle or is automatically limited by the size of the building blocks.

[0139] In some embodiments, the rings A in the LIN of compound (I) 2 The same or different and each independently represents a heterocyclic group (e.g., 4- to 20-membered heterocyclic group, such as 4 to 18-membered, 4 to 15-membered, 4 to 12-membered, 4 to 11-membered, 4 to 10-membered, 4 to 9-membered, 4 to 8-membered, 4 to 7-membered, 4 to 6-membered, 5 to 15-membered, or 5 to 9-membered heterocyclic group), or a cycloalkyl group (e.g., C...). 3-20 Cycloalkylene, arylene (e.g., C164-) 5-20 aryl, such as C 6-20 Alpha-aryl, C 5-15 aryl or C 6-15(e.g., 5- to 20-membered heteroaryl, e.g., 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered or 5- to 6-membered heteroaryl). In some embodiments, the 4- to 20-membered heterocyclic group is a saturated or partially unsaturated (i.e. having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of 4- to 20-membered heterocyclic groups include, but are not limited to, monocyclic heterocyclic groups (e.g., 4- to 20-membered monocyclic heterocyclic groups), bridged heterocyclic groups (e.g., 5- to 20-membered bridged heterocyclic groups or 7- to 15-membered bridged heterocyclic groups), fused heterocyclic groups, and spirocyclic heterocyclic groups (e.g., 5- to 20-membered spirocyclic heterocyclic groups), such as azapyrocyclyl, oxazolidinyl, pyrazolealkyl, imidazoalkyl, pyrazolalkyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolalkyl, thiazoalkyl, piperidinyl, piperazine, morpholinyl, thiomorpholinyl, azapyrocyclyl heptyl, and azapyrocyclyl octane. The compounds include 6-azabicyclo[3.1.1]heptane, 2,5-azabicyclo[2.2.1]heptane, 3,6-azabicyclo[3.1.1]heptane, 3-azabicyclo[3.2.1]octane, 3,8-azabicyclo[3.2.1]octane, 3,8-azabicyclo[3.2.1]octane, 2,5-azabicyclo[2.2.2]octane, and azaspirocyclic groups (e.g., 5- to 20-membered azaspirocyclic groups, such as 3-azaspiro[5.5]undecane). In some embodiments, C 3-20 Examples of cycloalkylene compounds include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydrocyclopentadienylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, and spirocyclic compounds (e.g., C16). 5-15In some embodiments, examples of 5- to 20-membered arylene groups include, but are not limited to, for example, phenylene or naphthylene. In some embodiments, a 5- to 20-membered heteroarylene group is a 5- to 20-membered (e.g., 5 to 15 membered, 5 to 12 membered, 5 to 9 membered, 5 to 8 membered, 5 to 7 membered, or 5 to 6 membered) heteroarylene group containing one nitrogen atom and optionally containing heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazyiene, benzo[1,2,3]thiadiazyiene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene. Each ring A 2 is independently optionally substituted by a2 R y2 groups, each R y2 is independently deuterium, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., per-deuterated C 1-6 alkyl, per-deuterated C 1-5 alkyl or per-deuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), halo C 1-6 alkyl (e.g., halo C 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), C 1-6 alkoxy (e.g., C 1-4Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl. a2 represents an integer from 0 to 10, such as the integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The number of substituents is not limited in principle or is automatically limited by the size of the building blocks.

[0140] In some implementations, y2 of compound (I) represents an integer 0, 1, 2 or 3.

[0141] In some embodiments, the rings A in the LIN of compound (I) 2 The same or different, and each independently, represent the following optional substituted groups: Each ring A 2 Independently and optionally by a2 R y2 Group substitution, each R y2 Independent of deuterium and C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl groups (e.g., C) 2-4 Alkyne group (e.g., ethynyl, propynyl, or butynyl) or C 2-6 alkenyl (e.g., C) 2-4Alkenyl, such as vinyl, propenyl, or butenyl). a2 represents an integer from 0 to 10, such as the integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The number of substituents is not limited in principle or is automatically limited by the size of the building blocks.

[0142] In some embodiments, the rings A in the LIN of compound (I) 3 The same or different and each independently represents a heterocyclic group (e.g., 4- to 20-membered heterocyclic group, such as 4 to 18-membered, 4 to 15-membered, 4 to 12-membered, 4 to 11-membered, 4 to 10-membered, 4 to 9-membered, 4 to 8-membered, 4 to 7-membered, 4 to 6-membered, 5 to 15-membered, or 5 to 9-membered heterocyclic group), or a cycloalkyl group (e.g., C...). 3-20 Cycloalkylene, arylene (e.g., C164-) 5-20 aryl, such as C 6-20 Alpha-aryl, C 5-15 aryl or C 6-15(e.g., 5- to 20-membered heteroaryl, e.g., 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered or 5- to 6-membered heteroaryl). In some embodiments, the 4- to 20-membered heterocyclic group is a saturated or partially unsaturated (i.e. having one or more double bonds, but not fully conjugated) divalent cyclic hydrocarbon group containing one or more (e.g., containing 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1) heteroatoms independently selected from sulfur, oxygen, and nitrogen. Examples of 4- to 20-membered heterocyclic groups include, but are not limited to, monocyclic heterocyclic groups (e.g., 4- to 20-membered monocyclic heterocyclic groups), bridged heterocyclic groups (e.g., 5- to 20-membered bridged heterocyclic groups or 7- to 15-membered bridged heterocyclic groups), fused heterocyclic groups, and spirocyclic heterocyclic groups (e.g., 5- to 20-membered spirocyclic heterocyclic groups), such as azapyrocyclyl, oxazolidinyl, pyrazolealkyl, imidazoalkyl, pyrazolalkyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolalkyl, thiazoalkyl, piperidinyl, piperazine, morpholinyl, thiomorpholinyl, azapyrocyclyl heptyl, and azapyrocyclyl octane. The compounds include 6-azabicyclo[3.1.1]heptane, 2,5-azabicyclo[2.2.1]heptane, 3,6-azabicyclo[3.1.1]heptane, 3-azabicyclo[3.2.1]octane, 3,8-azabicyclo[3.2.1]octane, 3,8-azabicyclo[3.2.1]octane, 2,5-azabicyclo[2.2.2]octane, and azaspirocyclic groups (e.g., 5- to 20-membered azaspirocyclic groups, such as 3-azaspiro[5.5]undecane). In some embodiments, C 3-20 Examples of cycloalkylene compounds include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydrocyclopentadienylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, and spirocyclic compounds (e.g., C16). 5-15In some embodiments, examples of 5- to 20-membered arylene groups include, but are not limited to, for example, phenylene or naphthylene. In some embodiments, a 5- to 20-membered heteroarylene group is a 5- to 20-membered (e.g., 5 to 15 membered, 5 to 12 membered, 5 to 9 membered, 5 to 8 membered, 5 to 7 membered, or 5 to 6 membered) heteroarylene group containing one nitrogen atom and optionally containing heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, examples of 5- to 20-membered heteroarylene groups include, but are not limited to, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazyiene, benzo[1,2,3]thiadiazyiene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, or imidazo[2,1-b]thiazolylene. Each ring A 3 is independently optionally substituted by a3 R y3 group, each R y3 is independently deuterium, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., per-deuterated C 1-6 alkyl, per-deuterated C 1-5 alkyl or per-deuterated C 1-4 alkyl, e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), halo C 1-6 alkyl (e.g., halo C 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), C 1-6 alkoxy (e.g., C 1-4Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl. a3 represents an integer from 0 to 10, such as the integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The number of substituents is not limited in principle or is automatically limited by the size of the building blocks.

[0143] In some implementations, y3 of compound (I) represents an integer 0, 1, 2 or 3.

[0144] In some embodiments, the rings A of the compound of formula (I) 3 The same or different, and each independently, represent the following optional substituted groups: Each ring A 3 Independently and optionally by a3 R y3 Group substitution, each R y3 Independent of deuterium and C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkyl, halogen (e.g., fluorine, chlorine, bromine, or iodine), amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl groups (e.g., C) 2-4 Alkyne group (e.g., ethynyl, propynyl, or butynyl) or C 2-6 alkenyl (e.g., C) 2-4Alkenyl groups, such as vinyl, propenyl, or butenyl. a3 represents an integer from 0 to 10, such as the integers 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The number of substituents is not limited in principle or is automatically limited by the size of the building blocks.

[0145] In some embodiments, the portion of the general formula of LIN of compound (I) Examples include, but are not limited to, the following structures: The aforementioned groups may optionally be selected from deuterium, C 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; deuterated C 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl substituent substitution. In this document, unless otherwise expressly indicated, any end of the above general formulas may be connected to the R group of a compound of formula (I). w1 The other end is connected to R w2 .

[0146] In some embodiments, R in the general formula of LIN of compound (I) w1 Indicates a key.

[0147] In some embodiments, R in the general formula of LIN of compound (I) w1 C represents the alternative substitution of straight or branched chains. 1-20 Alkylene, wherein the straight-chain or branched C 1-20Any one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) methylenes of the main carbon chain backbone of the alkylene group are optionally replaced with one or more (e.g., 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2, or 1) groups selected from R a , R b , and any combination thereof, each group R a is independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R a7 ), N(R a7 )S(O)2, C(O)N(R a7 ), N(R a7 )C(O), N(R a7 ), and N(R a7 )C(O)N(R a7 ), wherein each R a7 each independently represents H or C 1-3 alkyl, and when two or more methylenes of the main carbon chain backbone of the straight-chain or branched-chain C 1-20 alkylene group are replaced with two or more groups R a , each group R a is not directly attached to each other; and each group R b is independently selected from optionally substituted cycloalkylene (e.g., optionally substituted C 3-20 cycloalkylene), optionally substituted arylene (e.g., optionally substituted C 5-20 arylene), optionally substituted heterocyclylene (e.g., optionally substituted 4- to 20-membered heterocyclylene), optionally substituted heteroarylene (e.g., optionally substituted 5- to 20-membered heteroarylene), alkynylene (e.g., C 2-6 alkynylene), alkenylene (e.g., C 2-6 alkenylene), and any combination thereof, wherein the cycloalkylene, the arylene, the heterocyclylene, and the heteroarylene are each independently optionally substituted with one or more groups selected from deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl, or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl, or perdeuterated C 1-4 alkyl), and any combination thereof.Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substituents of cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof, and the C-chain of said straight or branched groups. 1-20 One or more hydrogen atoms in the alkylene group may optionally be selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc., and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), C 3-6Cycloalkyl, haloC 3-6 Cycloalkyl, deuteratedC 3-6 Cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof, for the substituents.

[0148] In some embodiments, R w1 represents the following general formula: -C 1-15 alkylene-; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -(R a (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11)) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -((C(R a14 )(R a15 )) n7 R a ) m5 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -(R b (C(R a14 )(R a15)) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a1 0)(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -((C(R a14 )(R a15 )) n7 R b ) m5 -; -(C(R a8 )(R a9 )) n4 -(R a -R b -(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 )m4 -; -(C(R a8 )(R a9 )) n4 -; -(C(R b )(R a )) a10 -; -(C(R a11 )(R n5 )) m3 -; -(C(R a8 )(R a9 )) n4 -; -(C(R b )(R a10 )) a11 -; -(C(R n5 )(R m3 )) a -; -(C(R a12 )(R a13 )) n6 -; -(C(R m4 )(R a8 )) a9 -; -(C(R n4 )(R a10 )) a11 -; -(C(R n5 )(R a )) b -; -(C(R m3 )(R a8 )) a9 -; -(C(R n4 )(R a10 )) a11 -; -(C(R n5 )(R a )) m3 -; -(C(R a12 )(R a13 )) n6 -; -(C(R b )(R m4 )) a8 -; -(C(R a9 )(R n4 )) a10 -; -(C(R a11 )(R n5 )) b -; -(C(R a )(R m3 )) a8 -; -(C(R a9 )(R n4 )) a10 -; -(C(R a11 )(R n5 )) b -; -(C(R m3-((C(R a12 (R) a13 )) n6 R a ) m4 -; where each group R a Independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R) a7 ), N(R a7 S(O)2、 C(O)N(R) a7 ), N(R a7 C(O), N(R) a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each can be represented independently as H or C. 1-3 Alkyl groups; R groups b Independently selected from optional substituted cycloalkylene groups (e.g., optional substituted C14-C ... 3-20 Cycloalkylene, optionally substituted arylene (e.g., optionally substituted C464), 5-20 arylene), optionally substituted heterocyclic groups (e.g., optionally substituted 4- to 20-membered heterocyclic groups), optionally substituted heteroarylene groups (e.g., 5- to 20-membered heteroarylene groups), alkynyl groups (e.g., C... 2-6 (e.g., C-ynyl), (e.g., C-yl) 2-6 (alkenyl groups) and any combination thereof, wherein the cycloalkyl group, the aryl group, the heterocyclic group, and the heteroaryl group are each independently and optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substituents including cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof; R a8 R a9 R a10 R a11 R a12 R a13 R a14 and R a15 Each of these groups independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, and halogenated C. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6alkyl, deuterated C 3-6 cycloalkyl, haloC 3- 6cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof. In this context, unless explicitly indicated otherwise, any one of the above general formulae can be connected to R 1-15 any one or more hydrogens of the main carbon chain skeleton of the alkylene group are optionally replaced by a substituent selected from the group consisting of deuterium, hydroxy, amino, mercapto, nitro, halogen, cyano, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof. In this context, unless explicitly indicated otherwise, any one of the above general formulae can be connected to R a6 of the compound of formula (I) at one end and to ring A 1 at the other end. The number of carbon atoms of each of the above general formulae, i.e. the sum of n4+n5*m3, the sum of n4+n5*m3+n6*m4, the sum of n4+n5*m3+n6*m4+n7*m5, is each independently an integer less than or equal to 20.

[0149] In some embodiments, R w1 represents -C 1-15 alkylene-, wherein the C 1-15 any one or more hydrogens of the main carbon chain skeleton of the alkylene group are optionally replaced by a substituent selected from the group consisting of deuterium, hydroxy, amino, mercapto, nitro, halogen, cyano, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0150] In some embodiments, R w1 represents the following groups: -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10-,-(CH2)11-,-(CH2) 12 -,-(CH2) 13 -,-(CH2) 14 -,-(CH2) 15 -; wherein any one or more hydrogens of said groups are optionally replaced by a substituent selected from the group consisting of deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, haloC 1-6 alkyl, deuteriumC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuteriumC 3-6 cycloalkyl, 4- to 10-membered heterocyclyl and any combination thereof.

[0151] In some embodiments, R w1 represents a structure of the following formula: -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 )) n6 ) m4 -(O(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(Ra11 )) n5 O) m3 - -(C(R a8 )(R a9 )) n4 - ((C(R a10 )(R a11 )) n5 O) m3 - ((C(R a12 )(R a13 )) n6 O) m4 - -(C(R a8 )(R a9 )) n4 - ((C(R a10 )(R a11 )) n5 O) m3 - ((C(R a12 )(R a13 )) n6 O) m4 - ((C(R a14 )(R a15 )) n7 O) m5 - -(C(R a8 )(R a9 )) n4 - (N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 - -(C(R a8 )(R a9 )) n4 - (N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 - (N(R a7 )(C(R a12 )(R a13 )) n6 ) m4 - -(C(R a8 )(R a9 )) n4 - (N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 - (N(R a7 )(C(R a12 )(R a13)) n6 ) m4 -(N(R a7 )(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -((C(R a14 )(R a15 )) n7 N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 ))n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -(C(O)N(R a7 )- (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 ))m4 -((C(R a14 )(R a15 )) n7 - C(O)N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 ))n5-C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 O) m4 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -C(O)N(R a7 )-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 )m3 - -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -(O-(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -; -(C(R a8 )(R a9 ))n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -((C(R a12 )(R a13 ))) n6 -O) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -((C(R a12 )(R a13 )) n6 O) m4 -((C(R a14 )(R a15 )) n7 O) m5 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -N(R a7 )C(O)-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 )(R a9 )) n4 -(Arylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(Arylene-(C(R a10 )(R a11 )) n5 ) m3 -Arylene-(C(R a12 )(R a13 )) n6 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11) n5 -arylene) m3 -; -(C(R a8 )(R a9 ) n4 -((C(R a10 )(R a11 ) n5 -arylene) m3 -(C(R a12 )(R a13 ) n6 -arylene-; -(C(R a8 )(R a9 ) n4 -(heterocyclylene-(C(R a10 )(R a11 ) n5 ) m3 -; -(C(R a8 )(R a9 ) n4 -(heterocyclylene-(C(R a10 )(R a11 ) n5 ) m3 -(heterocyclylene-(C(R a12 )(R a13 ) n6 ) m4 -; -(C(R a8 )(R a9 ) n4 -((C(R a10 )(R a11 ) n5 -heterocyclylene) m3 -; -(C(R a8 )(R a9 ) n4 -((C(R a10 )(R a11 ) n5 -heterocyclylene) m3 -((C(R a12 )(R a13 ) m6 -heterocyclylene) m4 -; -(C(R a8 )(R a9 ) n4 -(heteroarylene-(C(R a10 )(R a11 ) n5 ) m3 -; -(C(R a8 )(R a9 ) n4-(heteroaryl-(C(R a10 )(R a11 )) n5 ) m3 -(heteroaryl-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heteroaryl) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -heteroaryl) m3 -((C(R a12 )(R a13 )) n6 -heteroaryl) m4 -; -(C(R a8 )(R a9 )) n4 -(cycloalkylene-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(cycloalkylene-(C(R a10 )(R a11 )) n5 ) m3 -(cycloalkylene-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -cycloalkylene) m3 -; or -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -cycloalkylene) m3- ((C(R a12 )(R a13 )) n6 - cycloalkylene) m4 -; wherein each R a7 independently represents H or C 1-3 alkyl; said cycloalkylene (e.g., C 3-20 cycloalkylene), said arylene (e.g., C 5-20 arylene), said heterocyclylene (e.g., 4- to 20-membered heterocyclylene), and said heteroarylene (e.g., 5- to 20-membered heteroarylene) are each independently optionally substituted with a substituent selected from the group consisting of deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; R a8 , R a9 , R a10 , R a11 , R a12 , R a13 , R a14 , and R a15 each independently represent H, deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof; and n4, n5, n6, n7, m3, m4, m5 are each independently selected from an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The total number of carbon atoms in each of the above-mentioned general formulae of alkylene, i.e., the sum of n4+n5*m3, the sum of n4+n5*m3+n6*m4, the sum of n4+n5*m3+n6*m4+n7*m5, is each independently an integer less than or equal to 20.

[0152] In some embodiments, examples of cycloalkylene in the general structure of R w1 in the general formula of LIN of the compound of formula (I) include, but are not limited to, C 3-20 cycloalkylene, C 3-15 cycloalkylene, and C 3-11Cycloalkylene, such as cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydro naphthylene, octahydrocyclopenta-dienylene, octahydro-lH-indenylene, 2,3-dihydro-lH-indenylene, spirocyclylene (e.g., C 5-15 spirocyclylene), adamantlylene, noradamantylidene, and norbornylidene. Cycloalkylene is optionally substituted with substituents selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0153] In some embodiments, the LIN of the compound of Formula (I) is substituted with one or more substituents selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C w1 Examples of arylene in the general structure of R 5-20 arylene, C 6-20 arylene, C 5-15 arylene, and C 6-15 arylene, such as phenylene or naphthylene. Arylene is optionally substituted with substituents selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1- 6alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0154] In some embodiments, the LIN of the compound of Formula (I) is substituted with one or more substituents selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, oxo, C w1Examples of heterocyclyl groups in the general structure of formula (I) include, but are not limited to, 4- to 20-membered, 4- to 15-membered, 4- to 12-membered, 4- to 11-membered, 4- to 10-membered, 4- to 9-membered, 4- to 8-membered, 4- to 7-membered, 4- to 6-membered, 5- to 15-membered, and 5- to 9-membered heterocyclyl groups, such as, for example, azetidinyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, oxepanyl, diazepanyl, diazepanyl, 6-azabicyclo[3.1.1]heptanyl, 2,5-diazabicyclo[2.2.1]heptanyl, 3,6-diazabicyclo[3.1.1]heptanyl, 3-azabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 3,8-diazabicyclo[3.2.1]octanyl, 2,5-diazabicyclo[2.2.2]octanyl, and 5- to 20-membered azaspiro cyclyl groups. The heterocyclyl group can be optionally substituted with substituents selected from the group consisting of deuterium, hydroxy, amino, thiol, nitro, halogen, cyano, oxo, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0155] In some embodiments, R w1Examples of heteroarylene groups in the general structure of LINinclude, but are not limited to, 5- to 20-membered heteroarylene groups, 5- to 15-membered, 5- to 10-membered, 5- to 9-membered, 5- to 8-membered, 5- to 7-membered, and 5- to 6-membered heteroarylene groups, such as, for example, oxazolylene, isoxazolylene, oxadiazolylene, thienylene, thiazolylene, isothiazolylene, thiadiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofurylene, isobenzofurylene, benzothienylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadia- zolylene, benzo[1,2,3]thiadia- zolylene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1 H-pyrrolo[3,2-b]pyridinylene, 1 H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1 -b]thiazolylene, or imidazo[2,1 -b]thiazolylene. The heteroarylene group is optionally substituted with substituents selected from the group consisting of deuterium, hydroxyl, amino, thiol, nitro, halogen, cyano, C 1-6 alkyl, haloC 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 3-6 cycloalkyl, haloC 3-6 cycloalkyl, deuterated C 3-6 cycloalkyl, 4- to 10-membered heterocyclyl, and any combination thereof.

[0156] In some embodiments, R w1 Examples of -O-(CH2)n- groups include, but are not limited to, the following groups: -0-CH2-, -0-(CH2)2-, -0-(CH2)3-, -0-(CH2)4-, -0-(CH2)5-, -0-(CH2)6-, -0-(CH2)7-, -0-(CH2)8-, -0-(CH2)9-, -0-(CH2) 10 -, -(CH2)1-0-, -(CH2)2-0-, -(CH2)3-0-, -(CH2)4-0-, -(CH2)5-0-, -(CH2)6-0-, -(CH2)7-0-, -(CH2)8-0-, -(CH2)9-0-, -(CH2) 10-O-、-CH2-O-CH2-、-CH2-O-(CH2)2-、-(CH2)1-O-(CH2)3-、-(CH2)1-O-(CH2)4-、-(CH2)1-O-(CH2)5-、-(CH2)1-O-(CH2)6-、-(CH2)1-O-(CH2)7-、-(CH2)1-O-(CH2)8-、-(CH2)1-O-(CH2)9-、-(CH2)1-O-(CH2) 10 -、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O-(CH2) 10-(CH2)3-S-(CH2)1-, -(CH2)3-S-(CH2)2-, -(CH2)3-S-(CH2)3-, -(CH2)3-S-(CH2)4-, -(CH2)3-S-(CH2)5-, -(CH2)3-S-(CH2)6-, -(CH2)3-S-(CH2)7-, -(CH2)4-S-(CH2)1-, -(CH2)4-S-(CH2)2-, -(CH2)4-S-(CH2)3-, -(CH2)4-S-(CH2)4-, -(CH2)4-S-(CH2)5-, -(CH2)4-S-(CH2)6-, -(CH2)5-S-(CH2)1-, -(CH2)5-S-(CH2)2-, -(CH2)5-S-(CH2)3-, -(CH2)5-S-(CH2)4-, -(CH2)5-S-(CH2)5-, -(CH2)6-S-(CH2)1-, -(CH2)6-S-(CH2)2-, -(CH2)6-S-(CH2)3-, -(CH2)6-S-(CH2)4-, -(CH2)7-S-(CH2)1-, -(CH2)7-S-(CH2)2-, -(CH2)7-S-(CH2)3-, -(CH2)8-S-(CH2)1-, -(CH2)8-S-(CH2)2-, -CH(CH3)-S-(CH2)1-, -CH(CH3)-S-(CH2)2-, -CH(CH3)-S-(CH2)3-, -CH(CH3)-S-(CH2)4-, -CH(CH3)-S-(CH2)5-, -CH(CH3)-S-(CH2)6-, -CH(CH3)-S-(CH2)7-, -CH(CH3)-S-(CH2)8-, -CH(CH3)-S-(CH2)9-, -CH(CH3)-S-(CH2) 10-CH2-(0(CH2)2)2-, -CH2-(0(CH2)2)3-, -CH2-(0(CH2)2)4-, -CH2-(0(CH2)2)5-, -CH2- (0(CH2)2)6-, -CH2-(0(CH2)2)7-, -CH2-(0(CH2)2)1-OCH2-, -CH2-(0(CH2)2)2-OCH2-, - CH2-(0(CH2)2)3-OCH2-, -CH2-(0(CH2)2)4-OCH2-, -CH2-(0(CH2)2)5-OCH2-, - (CH2)2-(0(CH2)2)2-, -(CH2)2-(0(CH2)2)3-, -(CH2)2-(0(CH2)2)4-, -(CH2)2-(0(CH2)2)5-, - (CH2)2-(0(CH2)2)6-, -(CH2)3-(0(CH2)2)2-, -(CH2)3-(0(CH2)2)3-, -(CH2)3-(0(CH2)2)4-, - (CH2)3-(0(CH2)2)5-, -(CH2)4-(0(CH2)2)2-, -(CH2)4-(0(CH2)2)3-, -(CH2)4-(0(CH2)2)4-, - (CH2)4-(0(CH2)2)5-, -CH2-(0(CH2)3)2-, -CH2-(0(CH2)3)3-, -CH2-(0(CH2)3)4-, - (CH2)2-(0(CH2)3)2-, -(CH2)2-(0(CH2)3)3-, -(CH2)2-(0(CH2)3)4-, -(CH2)3-(0(CH2)3)2-, - (CH2)3-(0(CH2)3)3-, -(CH2)3-(0(CH2)3)4-, -CH2-0-(CH2)2-0-(CH2)3-, -CH2-(0(CH2)2)2- (0(CH2)3)2-, (CH2)2-0-(CH2)2-0-(CH2)3-, -(CH2)2-(0(CH2)2)2-(0(CH2)3)2-, -(CH2)3- O-(CH2)2-0-(CH2)3-, -(CH2)3-(0(CH2)2)2-(0(CH2)3)2-, -CH2-0-(CH2)3-0-(CH2)2-, - CH2-(0(CH2)3)2-(0(CH2)2)2-, -(CH2)2-0-(CH2)3-0-(CH2)2-, -(CH2)2-(0(CH2)3)2- (0(CH2)2)2-, -CH2-(0(CH2)2)2-(0(CH2)2)2-, -CH2-(0(CH2)2)3-(0(CH2)2)2-, -CH2- (0(CH2)2)4-(0(CH2)2)2-, -CH2-(0(CH2)2)5-(0(CH2)2)2-, -CH2-(0(CH2)2)6-(0(CH2)2)2-, - CH2-(0(CH2)2)7-(0(CH2)2)2-, -CH2-(0(CH2)2)1-OCH2-(0(CH2)2)2-, -CH2-(0(CH2)2)2- OCH2-(0(CH2)2)2-, -CH2-(0(CH2)2)3-OCH2-(0(CH2)2)2-, -CH2-(0(CH2)2)4-OCH2- (0(CH2)2)2-, -CH2-(0(CH2)2)5-OCH2-(0(CH2)2)2-, -CH2-(0(CH2)2)6-OCH2-(0(CH2)2)2-, - CH2-(0(CH2)2)7-OCH2-(0(CH2)2)2-, -CH2-(0(CH2)2)1-OCH2-(0(CH2)2)3-, -CH2- (0(CH2)2)2-OCH2-(0(CH2)2)3-, -CH2-(0(CH2)2)3-OCH2-(0(CH2)2)3-, -CH2-(0(CH2)2)4- OCH2-(0(CH2)2)3-, -CH2-(0(CH2)2)5-OCH2-(0(CH2)2)3-, -CH2-(0(CH2)2)6-OCH2- (0(CH2)2)3-, -CH2-(0(CH2)2)7-OCH2-(0(CH2)2)3-, -CH2-(0(CH2)2)1-OCH2-(0(CH2)2)4-, - CH2-(0(CH2)2)2-OCH2-(0(CH2)2)4-, -CH2-(0(CH2)2)3-OCH2-(0(CH2)2)4-, -CH2- (0(CH2)2)4-OCH2-(0(CH2)2)4-, -CH2-(0(CH2)2)5-OCH2-(0(CH2)2)4-, -CH2- (0(CH2)2)6-OCH2-(0(CH2)2)4-, -CH2-(0(CH2)2)7-OCH2-(0(CH2)2)4-, -CH2--(CH2)3-0-(CH2)3-0-(CH2)2-, -(CH2)3-(0(CH2)3)2-(0(CH2)2)2-, -CH2-0-(CH2)2-0-CH2-, -(CH2)2-0-(CH2)2-0-CH2-, -(CH2)2-(0(CH2)2)2-0-(CH2)3-, -(CH2)2-(0(CH2)2)3-0-(CH2)3-, -(CH2)2-(0(CH2)2)4-0-(CH2)3-, -(CH2)5-(0(CH2)2)2-0-(CH2)5-, -(CH2)5-(0(CH2)2)2-0-(CH2)6-, -(CH2)1-N(R a7 -(CH2)1-, -(CH2)1-N(R a7 -(CH2)2-, -(CH2)1-N(R a7 -(CH2)3-, -(CH2)1-N(R a7 -(CH2)4-, -(CH2)1-N(R a7 -(CH2)5-, -(CH2)1-N(R a7 -(CH2)6-, -(CH2)1-N(R a7 -(CH2)7-, -(CH2)1-N(R a7 -(CH2)8-, -(CH2)1-N(R a7 -(CH2)9-, -(CH2)1-N(R a7 -(CH2) 10 -, -N(R a7 -(CH2)1-, -N(R a7 -(CH2)2-, -N(R a7 -(CH2)3-, -N(R a7 -(CH2)4-, -N(R a7 -(CH2)5-, -N(R a7 -(CH2)6-, -N(R a7 -(CH2)7-, -N(R a7 -(CH2)8-, -N(R a7 -(CH2)9-, -N(R a7 -(CH2) 10 -, -(CH2)2-N(R a7 -(CH2)1-, -(CH2)2-N(R a7 -(CH2)2-, -(CH2)2-N(R a7 -(CH2)3-, -(CH2)2-N(Ra7 -(CH2)4-, -(CH2)2-N(R a7 -(CH2)5-, -(CH2)2-N(R a7 -(CH2)6-, -(CH2)2-N(R a7 -(CH2)7-, -(CH2)2-N(R a7 -(CH2)8-, -(CH2)2-N(R a7 -(CH2)9-, -(CH2)2-N(R a7 -(CH2) 10 - -(CH2)3-N(R a7 -(CH2)1-, -(CH2)3-N(R a7 -(CH2)2-, -(CH2)3-N(R a7 -(CH2)3-, -(CH2)4-N(R a7 -(CH2)1-, -(CH2)4-N(R a7 -(CH2)2-, -(CH2)4-N(R a7 -(CH2)3-, -(CH2)4-N(R a7 -(CH2)4-, -(CH2)5-N(R a7 -(CH2)1-, -(CH2)5-N(R a7 -(CH2)2-, -(CH2)5-N(R a7 -(CH2)3-, -(CH2)5-N(R a7 -(CH2)4-, -(CH2)5-N(R a7 -(CH2)5-, -(CH2)6-N(R a7 -(CH2)1-, -(CH2)6-N(R a7 -(CH2)2-, -(CH2)6-N(R a7 -(CH2)3-, -(CH2)7-N(R a7 -(CH2)1-, -(CH2)7-N(R a7 -(CH2)2-, -(CH2)7-N(R a7 -(CH2)3-, -(CH2)8-N(R a7 -(CH2)1-, -(CH2)8-N(R a7 -(CH2)2-, -(CH2)8-N(R a7 -(CH2)3-, -CH(CH3)-N(R a7 -(CH2)1-, -CH(CH3)-N(Ra7 -(CH2)2-, -CH(CH3)-N(R a7 -(CH2)3-, -CH(CH3)-N(R a7 -(CH2)4-, -CH(CH3)-N(R a7 -(CH2)5-, -CH(CH3)-N(R a7 -(CH2)6-, -CH(CH3)-N(R a7 -(CH2)7-, -CH(CH3)-N(R a7 -(CH2)8-, -CH(CH3)-N(R a7 -(CH2)9-, -CH(CH3)-N(R a7 -(CH2) 10 ​​​​​​​​​, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O)NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC(O)(CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(CH2)4NHC(O)(CH2)8-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -phenylene-CH2-, -phenylene-(CH2)2-, -phenylene-(CH2)3-, -phenylene-(CH2)4-, -phenylene-(CH2)5-, -phenylene-(CH2)6-, -phenylene-(CH2)7-, -phenylene-(CH2)8-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1-,-(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene-(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -(CH2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, -(CH2)5-phenylene-(CH2)3-, -(CH2)5-phenylene-(CH2)4-, -(CH2)5-phenylene-(CH2)5-, -(CH2)5-phenylene-(CH2)6-, -(CH2)5-phenylene-(CH2)7-, -(CH2)5-phenylene-(CH2)8-, -(CH2)6-phenylene-(CH2)1-, -(CH2)6-phenylene-(CH2)2-, -(CH2)6-phenylene-(CH2)3-, -(CH2)6-phenylene-(CH2)4-, -(CH2)6-phenylene-(CH2)5-, -(CH2)6-phenylene-(CH2)6-, -(CH2)6-phenylene-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-, -(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-,-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7 )-CH2-phenylene-CH2-, -CH2-N(R a7-CH2-phenylene-(CH2)2-, -(CH2)2-N(R a7 -CH2-phenylene-(CH2)3-, -(CH2)2-N(R a7 -CH2-phenylene-(CH2)4-, -(CH2)2-N(R a7 -CH2-phenylene-(CH2)5-, -(CH2)2-N(R a7 -CH2-phenylene-(CH2)6-, -(CH2)2-N(R a7 -CH2-phenylene-(CH2)7-, -(CH2)2-N(R a7 -CH2-phenylene-(CH2)8-, -(CH2)3-N(R a7 -CH2-phenylene-CH2-, -(CH2)3-N(R a7 -CH2-phenylene-(CH2)2-, -(CH2)3-N(R a7 -CH2-phenylene-(CH2)3-, -(CH2)3-N(R a7 -CH2-phenylene-(CH2)8-, -(CH2)4-N(R a7 -CH2-phenylene-CH2-, -(CH2)4-N(R a7 -CH2-phenylene-(CH2)2-, -(CH2)4-N(R a7 -CH2-phenylene-(CH2)3-, -(CH2)4-N(R a7 -CH2-phenylene-(CH2)8-, -(CH2)5-N(R a7 -CH2-phenylene-(CH2)3-, -(CH2)5-N(R a7 -CH2-phenylene-(CH2)8-, -(CH2)6-N(R a7 -CH2-phenylene-(CH2)3-, -(CH2)6-N(R a7 -CH2-phenylene-(CH2)8-, -(CH2)7-N(R a7 -CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 -CH2-phenylene-CH2-, -(CH2)8-N(R a7 -CH2-phenylene-(CH2)2-, -(CH2)8-N(R a7 -CH2-phenylene-(CH2)3-, -(CH2)8-N(R a7 -CH2-phenylene-(CH2)4-, -(CH2)8-N(R a7)-CH2-phenylene-(CH2)5-, -(CH2)8-N(R a7-CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7-, -CH2-piperidinylene-(CH2)8-, -CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene-(CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene-(CH2)6-, -CH2-piperidinylene-(CH2)7-, -CH2-piperidinylene-(CH2)8-, -(CH2)2-piperidinylene-CH2-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2-piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, -(CH2)2-piperidinylene-(CH2)6-, -(CH2)2-piperidinylene-(CH2)7-, -(CH2)2-piperidinylene-(CH2)8-, -(CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene-(CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -(CH2)3-piperidinylene-(CH2)6-, -(CH2)3-piperidinylene-(CH2)7-, -(CH2)3-piperidinylene-(CH2)8-, -(CH2)4-piperidinylene-CH2-, -(CH2)4-piperidinylene-(CH2)2-, -(CH2)4-piperidinylene-(CH2)3-, -(CH2)4-piperidinylene-(CH2)4-, -(CH2)4-piperidinylene-(CH2)5-, -(CH2)4-piperidinylene-(CH2)6-, -(CH2)4-piperidinylene-(CH2)7-, -(CH2)4-piperidinylene-(CH2)8-, -(CH2)5-piperidinylene-CH2-, -(CH2)5-piperidinylene-(CH2)2-, -(CH2)5-piperidinylene-(CH2)3-, -(CH2)5-piperidinylene-(CH2)4-, -(CH2)5-piperidinylene-(CH2)5-, -(CH2)5-piperidinylene-(CH2)6-, -(CH2)5-piperidinylene-(CH2)7-, -(CH2)5-piperidinylene-(CH2)8-, -(CH2)6-piperidinylene-CH2-, -(CH2)6-piperidinylene-(CH2)2-, -(CH2)6-piperidinylene-(CH2)3-, -(CH2)6-piperidinylene-(CH2)4-, -(CH2)6-piperidinylene-(CH2)5-, -(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-CH2-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2)3-, -(CH2)7-piperidinylene-(CH2)4-, -(CH2)7-piperidinylene-(CH2)5-, -(CH2)7-piperidinylene-(CH2)6-, -(CH2)7-piperidinylene-(CH2)7-, -(CH2)7-piperidinylene-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, and -(CH2)8-piperidinylene-(CH2)8-;-(CH2)6-piperidinylene-(CH2)4-, -(CH2)6-piperidinylene-(CH2)5-, -(CH2)6-piperidinylene-(CH2)6-, -(CH2)6-piperidinylene-(CH2)7-, -(CH2)6-piperidinylene-(CH2)8-, -(CH2)7-piperidinylene-(CH2)1-, -(CH2)7-piperidinylene-(CH2)2-, -(CH2)7-piperidinylene-(CH2)3-, -(CH2)7-piperidinylene-(CH2)4-, -(CH2)7-piperidinylene-(CH2)8-, -(CH2)8-piperidinylene-CH2-, -(CH2)8-piperidinylene-(CH2)2-, -(CH2)8-piperidinylene-(CH2)3-, -(CH2)8-piperidinylene-(CH2)4-, -(CH2)8-piperidinylene-(CH2)5-, -(CH2)8-piperidinylene-(CH2)6-, -(CH2)8-piperidinylene-(CH2)7-, -N(R a7 )-CH2-piperidinylene-CH2-, -N(R a7 )-CH2-piperidinylene-(CH2)2-, -N(R a7 )-CH2-piperidinylene-(CH2)3-, -N(R a7 )-CH2-piperidinylene-(CH2)4-, -N(R a7 )-CH2-piperidinylene-(CH2)5-, -N(R a7 )-CH2-piperidinylene-(CH2)6-, -N(R a7 )-CH2-piperidinylene-(CH2)7-, -N(R a7 )-CH2-piperidinylene-(CH2)8-, -CH2-N(R a7 )-CH2-piperidinylene-CH2-, -CH2-N(R a7 )-CH2-piperidinylene-(CH2)2-, -CH2-N(R a7 )-CH2-piperidinylene-(CH2)3-, -CH2-N(R a7 )-CH2-piperidinylene-(CH2)4-, -CH2-N(R a7 )-CH2-piperidinylene-(CH2)5-, -CH2-N(R a7 )-CH2-piperidinylene-(CH2)6-, -CH2-N(R a7 )-CH2-piperidinylene-(CH2)7-, -CH2-N(R a7 )-CH2-piperidinylene-(CH2)8-, -CH2-N(R a7-(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7 -(CH2)2-piperidinylene-(CH2)2-, -CH2-N(R a7)-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R a7 )-CH2-piperidyl-(CH2)3-, -(CH2)5-N(R-CH2-piperidyl-(CH2)6-, -piperazinyl-CH2-, -piperazinyl-(CH2)2-, -piperazinyl-(CH2)3-, -piperazinyl-(CH2)4-, -piperazinyl-(CH2)5-, -piperazinyl-(CH2)6-, -piperazinyl-(CH2)7-, -piperazinyl-(CH2)8-, -CH2-piperazinyl-CH2-, -CH2-piperazinyl-(CH2)2-, -CH2-piperazinyl-(CH2)3-, -CH2-piperazinyl-(CH2)4-, -CH2-piperazinyl-(CH2)5-, -CH2-piperazinyl-(CH2)6-, -CH2-piperazinyl-(CH2)7-, -CH2-piperazinyl-(CH2)8-, -(CH2)2-piperazinyl-(CH2)1-, -(CH2)2-piperazinyl-(CH2)2-, -(CH2)2-piperazinyl-(CH2)3-, -(CH2)2-piperazinyl-(CH2)4-, -(CH2)2-piperazinyl-(CH2)5-, -(CH2)2-piperazinyl-(CH2)6-, -(CH2)2-piperazinyl-(CH2)7-, -(CH2)2-piperazinyl-(CH2)8-, -(CH2)3-piperazinyl-CH2-, -(CH2)3-piperazinyl-(CH2)2-, -(CH2)3-piperazinyl-(CH2)3-, -(CH2)3-piperazinyl-(CH2)4-, -(CH2)3-piperazinyl-(CH2)5-, -(CH2)3-piperazinyl-(CH2)6-, -(CH2)3-piperazinyl-(CH2)7-, -(CH2)3-piperazinyl-(CH2)8-, -(CH2)4-piperazinyl-CH2-, -(CH2)4-piperazinyl-(CH2)2-, -(CH2)4-piperazinyl-(CH2)3-, -(CH2)4-piperazinyl-(CH2)4-, -(CH2)4-piperazinyl-(CH2)5-, -(CH2)4-piperazinyl-(CH2)6-, -(CH2)4-piperazinyl-(CH2)7-, -(CH2)4-piperazinyl-(CH2)8-, -(CH2)5-piperazinyl-(CH2)1-, -(CH2)5-piperazinyl-(CH2)2-, -(CH2)5-piperazinyl-(CH2)3-, -(CH2)5-piperazinyl-(CH2)4-, -(CH2)5-piperazinyl-(CH2)5-, -(CH2)5-piperazinyl-(CH2)6-, -(CH2)5-piperazinyl-(CH2)7-, -(CH2)5-piperazinyl-(CH2)8-, -(CH2)6-piperazinyl-(CH2)1-, -(CH2)6-piperazinyl-(CH2)2-, -(CH2)6-piperazinyl-(CH2)3-,-(CH2)6-piperazinyl-(CH2)4-, -(CH2)6-piperazinyl-(CH2)5-, -(CH2)6-piperazinyl-(CH2)6-, -(CH2)6-piperazinyl-(CH2)7-, -(CH2)6-piperazinyl-(CH2)8-, -(CH2)7-piperazinyl-(CH2)1-, -(CH2)7-piperazinyl-(CH2)2-, -(CH2)7-piperazinyl-(CH2)2- Piperazinyl-(CH2)3-, -(CH2)7-piperazinyl-(CH2)4-, -(CH2)8-piperazinyl-CH2-, -(CH2)8-piperazinyl-(CH2)2-, -(CH2)8-piperazinyl-(CH2)3-, -(CH2)8-piperazinyl-(CH2)4-, -(CH2)8-piperazinyl-(CH2)5-, or -(CH2)8-piperazinyl-(CH2)6-; wherein each R, a7 Independently represent H or C 1-3 alkyl ； The phenylene, the piperazine group, and the piperidinyl group are each optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substitution with cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof. In this document, unless otherwise expressly indicated, any end of any of the above groups may be connected to the R of a compound of formula (I). a6 The other end is connected to ring A. 1 For example, the O in the -O-CH2- group can connect to the R in compound (I). a6 CH2 can connect to A of compound (I). 1 ,vice versa.

[0157] In some embodiments, when R in the general formula of LIN of compound (I) w2 and R w1 When all y1, y2, and y3 represent bonds, and when y1, y2, and y3 all represent integers 0, LIN represents a bond, meaning LIN does not exist. The R of compound (I) a6 R directly connected to PBM c Group.

[0158] In some embodiments, examples of LIN of the compound of Formula (I) include, but are not limited to, the following groups: C(O), C(O)NH, NHC(O), -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -, -(CH2)11-, -(CH2) 12 -, -(CH2) 13 -, -(CH2) 14 -, -(CH2) 15 -; -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10 -, -(CH2)1-O-, -(CH2)2-O-, -(CH2)3-O-, -(CH2)4-O-, -(CH2)5-O-, -(CH2)6-O-, -(CH2)7-O-, -(CH2)8-O-, -(CH2)9-O-, -(CH2) 10-O-, -CH2-O-CH2-, -CH2-O-(CH2)2-, -(CH2)I-O-(CH2)3-, -(CH2)I-O-(CH2)4-, -(CH2)I-O-(CH2)5-, -(CH2)I-O-(CH2)6-, -(CH2)I-O-(CH2)7-, -(CH2)I-O-(CH2)8-, -(CH2)2-O-(CH2)I-, -(CH2)2-O-(CH2)2-, -(CH2)2-O-(CH2)3-, -(CH2)2-O-(CH2)4-, -(CH2)2-O-(CH2)5-, -(CH2)2-O-(CH2)6-, -(CH2)2-O-(CH2)7-, -(CH2)2-O-(CH2)8-, -(CH2)3-O-(CH2)I-, -(CH2)3-O-(CH2)2-, -(CH2)3-O-(CH2)3-, -(CH2)3-O-(CH2)4-, -(CH2)3-O-(CH2)5-, -(CH2)3-O-(CH2)6-, -(CH2)3-O-(CH2)7-, -(CH2)4-O-(CH2)I-, -(CH2)4-O-(CH2)2-, -(CH2)4-O-(CH2)3-, -(CH2)4-O-(CH2)4-, -(CH2)4-O-(CH2)5-, -(CH2)4-O-(CH2)6-, -(CH2)5-O-(CH2)I-, -(CH2)5-O-(CH2)2-, -(CH2)5-O-(CH2)3-, -(CH2)5-O-(CH2)4-, -(CH2)5-O-(CH2)5-, -(CH2)6-O-(CH2)I-, -(CH2)6-O-(CH2)2-, -(CH2)6-O-(CH2)3-, -(CH2)6-O-(CH2)4-, -(CH2)7-O-(CH2)I-, -(CH2)7-O-(CH2)2-, -(CH2)7-O-(CH2)3-, -(CH2)8-O-(CH2)I-, -(CH2)8-O-(CH2)2-, -CH(CH3)-O-(CH2)I-, -CH(CH3)-O-(CH2)2-, -CH(CH3)-O-(CH2)3-, -CH(CH3)-O-(CH2)4-, -CH(CH3)-O-(CH2)5-, -CH(CH3)-O-(CH2)6-, -CH(CH3)-O-(CH2)7-, -CH(CH3)-O-(CH2)8-, -(O(CH2)2)2-, -(O(CH2)2)3-, -(O(CH2)2)4-, -(O(CH2)2)5-, -(O(CH2)2)6-,-CH2-(0(CH2)2)2-, -CH2-(0(CH2)2)3-, -CH2-(0(CH2)2)4-, -CH2-(0(CH2)2)5-, -CH2-(0(CH2)2)6-, -CH2-(0(CH2)2)1-0CH2-, -CH2-(0(CH2)2)2-0CH2-, -CH2-(0(CH2)2)3-0CH2-, -CH2-(0(CH2)2)4-0CH2-, -CH2-(0(CH2)2)5-0CH2-, -CH2-(0(CH2)2)6-0CH2-, -(CH2)2-(0(CH2)2)2-, -(CH2)2-(0(CH2)2)3-, -(CH2)2-(0(CH2)2)4-, -(CH2)2-(0(CH2)2)5-, -(CH2)2-(0(CH2)2)6-, -(CH2)3-(0(CH2)2)2-, -(CH2)3-(0(CH2)2)3-, -(CH2)3-(0(CH2)2)4-, -(CH2)3-(0(CH2)2)5-, -(CH2)4-(0(CH2)2)2-, -(CH2)4-(0(CH2)2)3-, -(CH2)4-(0(CH2)2)4-, -(CH2)4-(0(CH2)2)5-, -CH2-(0(CH2)3)2-, -CH2-(0(CH2)3)3-, -CH2-(0(CH2)3)4-, -(CH2)2-(0(CH2)3)2-, -(CH2)2-(0(CH2)3)3-, -(CH2)2-(0(CH2)3)4-, -(CH2)3-(0(CH2)3)2-, -(CH2)3-(0(CH2)3)3-, -CH2-0-(CH2)2-0-(CH2)3-, -CH2-(0(CH2)2)2-(0(CH2)3)2-, (CH2)2-0-(CH2)2-0-(CH2)3-, -(CH2)2-(0(CH2)2)2-(0(CH2)3)2-, -(CH2)3-0-(CH2)2-0-(CH2)3-, -(CH2)3-(0(CH2)2)2-(0(CH2)3)2-, -CH2-0-(CH2)3-0-(CH2)2-, -CH2-(0(CH2)3)2-(0(CH2)2)2-, (CH2)1-N(R a7 -(CH2)1-, -(CH2)1-N(R a7 -(CH2)2-, -(CH2)1-N(R a7 -(CH2)3-, -(CH2)1-N(R a7 -(CH2)4-, -(CH2)1-N(Ra7 -(CH2)5-, -(CH2)6-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7 -(CH2)3-, -(CH2)4-, a7 -(CH2)1-, -(CH2)2-, a7-(CH2)2-, -(CH2)7-N(R a7 -(CH2)3-, -(CH2)8-N(R a7 -(CH2)1-, -(CH2)8-N(R a7 -(CH2)2-, -(CH2)8-N(R a7 -(CH2)3-, -CH(CH3)-N(R a7 -(CH2)1-, -CH(CH3)-N(R a7 -(CH2)2-, -CH(CH3)-N(R a7 -(CH2)3-, -CH(CH3)-N(R a7 -(CH2)4-, -CH(CH3)-N(R a7 -(CH2)5-, -CH(CH3)-N(R a7)-(CH2)6-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2 )2C(O)NH(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(C H2)5C(O)NH(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2 NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3N HC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2) 2-Phenylidene-(CH2)3-, -(CH2)2-Phenylidene-(CH2)4-, -(CH2)2-Phenylidene-(CH2)5-, -(CH2)3-Phenylidene-CH2-, -(CH2)3-Phenylidene-(CH2)2-, -(CH2)3-Phenylidene-(CH2)3-, -(CH2)3-Phenylidene-(CH2)4-, -(CH2)3-Phenylidene-(CH2)5-, -(CH2)4-Phenylidene-CH2-, -(CH2)4-Phenylidene-(CH2)2-, -(CH2)4-Phenylidene-(CH2)3-, -(CH2)4-Phenylidene-(CH2)4-, -(CH2)4-Phenylidene-(CH2)5-,-CH2-piperidinylene-CH2-, -CH2-piperidinylene-(CH2)2-, -CH2-piperidinylene- (CH2)3-, -CH2-piperidinylene-(CH2)4-, -CH2-piperidinylene-(CH2)5-, -CH2-piperidinylene- (CH2)6-, -(CH2)2-piperidinylene-(CH2)1-, -(CH2)2-piperidinylene-(CH2)2-, -(CH2)2- piperidinylene-(CH2)3-, -(CH2)2-piperidinylene-(CH2)4-, -(CH2)2-piperidinylene-(CH2)5-, - (CH2)3-piperidinylene-CH2-, -(CH2)3-piperidinylene-(CH2)2-, -(CH2)3-piperidinylene- (CH2)3-, -(CH2)3-piperidinylene-(CH2)4-, -(CH2)3-piperidinylene-(CH2)5-, -CH2- piperazinylene-CH2-, -CH2-piperazinylene-(CH2)2-, -CH2-piperazinylene-(CH2)3-, -CH2- piperazinylene-(CH2)4-, -CH2-piperazinylene-(CH2)5-, -(CH2)2-piperazinylene-(CH2)1-, - (CH2)2-piperazinylene-(CH2)2-, -(CH2)2-piperazinylene-(CH2)3-, -(CH2)2-piperazinylene- (CH2)4-, -(CH2)2-piperazinylene-(CH2)5-, -(CH2)3-piperazinylene-CH2-, -(CH2)3- piperazinylene-(CH2)2-, -(CH2)3-piperazinylene-(CH2)3-, -(CH2)3-piperazinylene-(CH2)4-, - (CH2)3-piperazinylene-(CH2)5-, -(CH2)4-piperazinylene-CH2-, -(CH2)4-piperazinylene- (CH2)2-, -(CH2)4-piperazinylene-(CH2)3-, -(CH2)4-piperazinylene-(CH2)4-, -(CH2)4- piperazinylene-(CH2)5-, -(CH2)8-piperazinylene-CH2-, -(CH2)8-piperazinylene-(CH2)2-, - (CH2)8-piperazinylene-(CH2)3-, -(CH2)8-piperazinylene-(CH2)4-, or -(CH2)8- piperazinylene-(CH2)5; wherein the above groups are optionally substituted with a substituent selected from deuterium, C 1-6 alkyl, deuterated C 1-6 alkyl, halo C 1-6 alkyl, C 1-6 alkoxy, halogen, amino, hydroxyl, thiol, cyano, carboxyl, C 2-6 alkynyl, or C 2-6 alkenyl. Herein, unless explicitly indicated otherwise, either end of each of the above groups can be attached to Ra6 and the other end is connected to R c of PBM.

[0159] In some embodiments, examples of LIN of the compound of Formula (I) include, but are not limited to, the following groups: wherein the above groups are optionally substituted with a substituent selected from deuterium, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, C 1-6 alkoxy, halogen, amino, hydroxyl, thiol, cyano, carboxyl, C 2-6 alkynyl, or C 2-6 alkenyl. Herein, unless explicitly otherwise stated, either end of each of the above groups can be connected to R a6 and the other end is connected to R c of PBM.

[0160] In some embodiments, the compound of Formula (I) is also represented by the structure of Formula (I-1), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (I-6), Formula (I-7), Formula (I-8), Formula (I-9), or Formula (I-10): wherein Z, R a1 , R a2 , R a3 , R a4 , (R a5 ) m , L1, L2, R a6 , LIN, R c , X1, X2, X3, X4, R 1a , R 1b , (R 1c ) p1a , (R 1d ) p1b , ring A, ring B, ring C, X5, X6, X7, X8, X9, R 3a , R 3b , (R 3c ) p3a , (R 4a ) p4a , R 4b , R 5a , R 5b , R 5c , R 5d , (R 5e ) p5a , (R 5f ) p5b, (R 5g ) p5c , ring D, R 6a , R 6b , R x1 , (R 7a ) p7a , (R 7b ) p7b , R 8a , R 8b , (R 8c ) p8a , ring E, (R 8d ) p8b , R 9a , R 9b , ring F, (R 9c ) p9a , (R 9d ) p9b , (R 10a ) p10a , R 10b , R 10c , R 10d and R 10e are as defined above in the compound of formula (I) and in each subembodiment thereof.

[0161] In some embodiments, the following specific compounds of formula (I) and salts (including pharmaceutically acceptable salts, e.g., their hydrochloride salts), prodrugs, solvates, isotopically enriched analogs, polymorphs, stereoisomers (including enantiomers and diastereomers), or mixtures of stereoisomers, of the compounds of formula (I) of Table 1 below are provided: Compound of formula (II)

[0162] The present disclosure provides uses of a compound of formula (II) or a salt (including a pharmaceutically acceptable salt), stereoisomer (including an enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof: wherein Z represents C(O) or CH2; R a1 , R a2 , R a3 and R a4 are the same or different and each independently represents hydrogen, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl, such as halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl, such as perdeuterated-C 1-6 alkyl, perdeuterated-C 1-5 alkyl or perdeuterated-C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy, such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 alkoxy, such as halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), or deuterated-C 1-6 alkoxy; (R a5 ) m represents an isoinodoline ring to which it is attached optionally substituted by m R a5 each R a5 are the same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxy, thio, nitro, amino, cyano, C 1-6 alkyl, such as C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl, such as halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl, such as perdeuterated-C 1-6 alkyl, perdeuterated-C 1-5 alkyl or perdeuterated-C 1-4Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkoxy groups, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy), and halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, or deuterated C 1-6 Alkoxy; m represents an integer 0, 1, 2, or 3; L1 represents S or O; L2 represents a substituted or unsubstituted straight-chain or branched alkylene group (e.g., a substituted or unsubstituted straight-chain or branched C1-C...). 10 Alkylene), or L2 is absent; R E express: Among them, ring Y 1 Indicates arylene, heteroarylene, heterocyclic, or cycloalkylene, (R d1 ) n1 Represents ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each can independently represent deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, and C. 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C 1-3 Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy) or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4alkyl (e.g. C1-C6-alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C1-C6-alkyl (e.g. halo-C1-C4-alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C1-C6-alkyl (e.g. perdeuterated C1-C6-alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C1-C6-alkoxy (e.g. C1-C4-alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halo-C1-C6-alkoxy (e.g. halo-C1-C4-alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n2 denotes an integer between 0 and 20. 3 represents a nitrogen-containing heterocyclyl group, (R d2 ) n2 represents a ring Y 3 optionally substituted by n2 R d2 groups, each R d2 each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halo-C 1-6 alkoxy (e.g. halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2ClCH2-O-), and n2 denotes an integer between 0 and 20.

[0163] The compound of formula (II) provided by the present disclosure or a salt (including a pharmaceutically acceptable salt), a stereoisomer (including an enantiomer), a solvate, an isotopically enriched analogue, a prodrug or a polymorph thereof has CRBN binding force, helps to recruit substrate proteins, can be combined with CRBN E3 ubiquitin ligase as a molecular glue, and thus can be applied to a bifunctional protein degradation small molecule drug. The compound of formula (II) of the present disclosure has antitumor activity, or has good pharmacokinetic properties.

[0164] In some embodiments, the compound of formula (II) of the present disclosure or a salt (including a pharmaceutically acceptable salt), a stereoisomer (including an enantiomer), a solvate, an isotopically enriched analogue, a prodrug or a polymorph thereof can be used for preparing a bifunctional protein degradation small molecule drug of the present disclosure, i.e. a compound of formula (I) or a salt (including a pharmaceutically acceptable salt), a stereoisomer (including an enantiomer), a solvate, an isotopically enriched analogue, a prodrug or a polymorph thereof.

[0165] In some embodiments, Z of the compound of formula (II) represents C(O).

[0166] In some embodiments, Z of the compound of formula (II) represents CH2.

[0167] In some embodiments, L1of the compound of formula (II) represents S.

[0168] In some embodiments, L1of the compound of formula (II) represents O.

[0169] In some embodiments, R a1 , R a2 , R a3 and R a4 are the same or different and each independently represents hydrogen, deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), halogenated C 1-6 alkyl (e.g. halogenated C 1-4alkyl (e.g., C1-C5alkyl, C1-C3alkyl, C1-C2alkyl, or C1alkyl), C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., C 1-6 alkoxy (e.g., C

[0170] In some embodiments, R a1 , R a2 , R a3 , and R a4 represent hydrogen.

[0171] In some embodiments, m of the compound of Formula (II) represents the integer 0.

[0172] In some embodiments, m of the compound of Formula (II) represents the integer 1, 2, or 3.

[0173] In some embodiments, each R a5 are the same or different and each independently represents halogen (e.g., fluorine, chlorine, bromine, or iodine).

[0174] In some embodiments, L2of the compound of Formula (II) is substituted or unsubstituted straight-chained or branched alkylene. When L2is substituted or unsubstituted straight-chained or branched alkylene, the L2represents substituted or unsubstituted straight-chained or branched C1-C5alkylene, or substituted or unsubstituted straight-chained or branched C1-C3alkylene, etc. 10 alkylene, or substituted or unsubstituted straight-chained or branched C1-C5alkylene, or substituted or unsubstituted straight-chained or branched C1-C3alkylene, etc.

[0175] In some embodiments, when L2of the compound of Formula (II) is substituted or unsubstituted straight-chained or branched C1-C5alkylene, the straight-chained or branched C1-C5alkylene can be methylene, ethylene, propylene, n-propylene, i-propylene, butylene, n-butylene, i-butylene, t-butylene, s-butylene, 1-methyl-butylene, 1-ethyl-butylene, pentylene, n-pentylene, i-pentylene, neo-pentylene, or t-pentylene, etc.

[0176] In some embodiments, when L2of the compound of formula (II) is a substituted or unsubstituted straight or branched C1-C3alkylene, the straight or branched alkylene can be, for example, methylene, ethylene, propylene, or isopropylene.

[0177] In some embodiments, L2of the compound of formula (II) is selected from methylene.

[0178] In some embodiments, the substituents of the substituted L2of the compound of formula (II) are optionally selected from deuterium, halogen, cyano, nitro, hydroxyl, thiol, carbonyl, ester, imide, amino, phosphine, alkoxy, haloalkoxy, aryloxy, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, silyl, boryl, alkyl, cycloalkyl, alkenyl, aryl, aralkyl, aralkenyl, alkylaryl, alkylamino, aralkylamino, heteroarylamino, arylamino, arylphosphine, heteroaryl, acenyl, and the like, or any combination thereof. Alternatively, the substituents of the substituted L2may be, for example, one or more substituents selected from D (i.e., deuterium), halogen, hydroxyl, cyano, C1-C3alkyl, C1-C3alkoxy, trifluoromethyl, heterocyclyl (e.g., four- to eight-membered heterocyclyl), nitro, thiol, carbonyl, ester, imide, amino, phosphine, alkoxy, deuterated alkoxy, trifluoromethoxy, aryloxy, alkylthio, arylthio, alkylsulfonyl, arylsulfonyl, silyl, boryl, alkyl, deuterated alkyl, haloalkyl, amino-substituted alkylene, alkyl-NHC(O)-, alkyl-C(O)NH-, cycloalkyl, deuterated cycloalkyl, alkenyl, aryl, aralkyl, aralkenyl, alkylaryl, alkylamino, aralkylamino, heteroarylamino, arylamino, arylphosphine, heteroaryl, acenyl, oxo, or any combination thereof. Further alternatively, the substituents of the substituted L2may be, for example, selected from deuterium, halogen, nitro, thiol, hydroxyl, cyano, C1-C3alkyl, C1-C3alkoxy, halo-substituted C1-C3alkoxy, halo-substituted C1-C3alkyl, amino, silyl, boryl, or any combination thereof. Further alternatively, the “substituted” substituents may, for example, be selected from deuterium, F, Cl, methoxy, methyl, hydroxyl, or any combination thereof.

[0179] In some embodiments, L2of the compound of formula (II) is absent.

[0180] In some embodiments, R E represents: wherein ring Y 1 represents C5-C 30 arylene, 5- to 30-membered heteroarylene, 4- to 30-membered heterocyclylene, or C3-C 30 cycloalkylene, (R d1 )n1 represents a 4- to 30-membered nitrogen-containing heterocyclyl group, (R 1 optionally substituted by n1 R d1 groups, each R d1 each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl or hexyl), haloC 1-6 alkyl (e.g. haloC 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or t-butyloxy) or haloC 1-6 alkoxy (e.g. haloC 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), and n1 represents an integer from 0 to 20 (e.g. 0 to 10 or 0 to 5, e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20); w represents an integer 0 or 1 ; and ring Y 3 represents a 4- to 30-membered nitrogen-containing heterocyclyl group, (R d2 ) n2 represents a 4- to 30-membered nitrogen-containing heterocyclyl group, (R 3 optionally substituted by n2 R d2 groups, each R d2 each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3Alkyl groups, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, or hexyl; and halogenated C groups. 1-6 Alkyl groups (e.g., halogenated C) 1-4 Alkyl groups, such as F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2ClCH2-, and deuterated C. 1-6 Alkyl groups (e.g., fully deuterated C) 1-6 Alkyl, fully deuterated C 1-5 Alkyl or fully deuterated C 1-4 Alkyl groups, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 Alkoxy groups (e.g., C) 1-4 Alkyl groups (such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy, or tert-butyloxy) or halogenated C 1-6 Alkoxy groups (e.g., halogenated C) 1-4 Alkoxy groups, such as F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-, and n2 represents an integer from 0 to 20 (e.g., 0-10 or 0-5, such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20).

[0181] In some embodiments, the R of compound (II) E express: Among them, ring Y 1 Indicates C5-C 20 Aryl groups (e.g., C5-C) 15 arylene), 5 to 20 heteroarylene (e.g., 5 to 15 heteroarylene), 4 to 20 heterocyclic (e.g., 4 to 15 heterocyclic), or C3-C 20 Cycloalkylene (e.g., C3-C) 15 (R) d1 ) n1 Represents ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each can be independently represented as deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl (e.g., C10) 1-5 Alkyl, C 1-4 Alkyl or C1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl, such as halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl, such as perdeuterated-C 1-6 alkyl, perdeuterated-C 1-5 alkyl or perdeuterated-C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy, such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halo-C 1-6 alkoxy, such as halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), and n1 represents an integer from 0 to 20; w represents the integer 0 or 1 ; and ring Y 3 represents a 4- to 20-membered nitrogen-containing heterocyclyl group (e.g. a 4- to 15-membered nitrogen-containing heterocyclyl group), (R d2 ) n2 represents ring Y 3 optionally substituted by n2 R d2 groups, each R d2 each independently represents deuterium, halogen (e.g. fluorine, chlorine, bromine or iodine), hydroxy, mercapto, nitro, amino, cyano, oxo, C 1-6 alkyl, such as C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl, such as halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl, such as perdeuterated-C 1-6 alkyl, perdeuterated-C 1-5 alkyl or perdeuterated-C1-4 alkyl (e.g., CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., C 1-6 alkoxy (e.g., C 1-4 alkoxy (e.g., F3C-O-, FCH2-O-, F2CH-O-, ClCH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O-, or CH2ClCH2-O-), and n2 represents an integer from 0 to 20.

[0182] In some embodiments, R E ring Y 1non-limiting examples include, but are not limited to: azetidinylene, oxetidinylene, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, tetrahydrofuranylene, tetrahydropyranylene, dihydropyranylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, oxazolidinylene, thiazolidinylene, piperidinylene, piperazinylene, morpholinylene, thiomorpholinylene, dioxanylene, dioxolanylene, azepanylene, azocanylene, diazepanylene, diazocanylene, bridged heterocyclylene (e.g., 5- to 15-membered bridged heterocyclylene, such as azabicyclohexanylene, azabicycloheptanylene, or azabicyclooctanylene), or spiroheterocyclylene (e.g., 5- to 15-membered spiroheterocyclylene, such as 3-azaspiro[5.5]undecanylene or 7-azaspiro[3.5]nonanylene); or furanylene, oxanylene, isoxanylene, oxadiazanylene, thienylene, thiazanylene, isothiazanylene, thiadiazanylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzofuranylene, isobenzofuranylene, benzothiophenylene, indazolylene, benzimidazolylene, benzoxazolylene, benzisoxazolylene, benzothiazolylene, benzisothiazolylene, benzotriazolylene, benzo[2,1,3]oxadiazolylene, benzo[2,1,3]thiadiazolylene, benzo[1,2,3]thiadiazolylene, quinolinylene, isoquinolinylene, naphthidinylene, cinnolinylene, quinazolinylene, quinoxalinylene, phthalazinylene, pyrazolo[1,5-a]pyridinylene, pyrazolo[1,5-a]pyrimidinylene, imidazo[1,2-a]pyridinylene, 1H-pyrrolo[3,2-b]pyridinylene, 1H-pyrrolo[2,3-b]pyridinylene, pyrrolo[2,1-b]thiazolylene, and imidazo[2,1-b]thiazolylene; or cyclopropylylene, cyclobutylylene, cyclopentylylene, cyclopentenylylene, cyclohexylylene, cyclohexenylylene, cycloheptylylene, cyclooctanylene, decahydronaphthylylene, octahydrobenzo[a]cyclopentylylene, octahydro-1H-indenylene, spirocycloalkanylene (e.g., C5-C 15 spirocycloalkanylene, such as spiro[3.3]heptanylene, spiro[2.5]octanylene, spiro[3.5]nonanylene, spiro[4.4]nonanylene, spiro[4.5]decanylene, or spiro[5.5]undecanylene), or bridged cycloalkanylene (e.g., C5-C 15 bridged cycloalkanylene, such as adamantylylene, noradamantylylene, menthylylene, bicyclo[2.2.1]heptanylene, 2-oxobicyclo[2.2.1]heptanylene, or bicyclo[2.2.1]heptenylylene); or phenylylene or naphthylylene; wherein the ring Y 1 is optionally substituted with n1R d1 groups, each R d1each independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, deuterated C 1-6 alkyl, deuterated C 1-6 alkyl, deuterated C 1-6 alkyl, deuterated C n1 represents an integer from 0-20 (e.g., 0-10 or 0-5, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20).

[0183] In some embodiments, R E of ring Y 3 non-limiting examples of which include, but are not limited to: azetidinyl, diazetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, piperidinyl, tetrahydropyridinyl, piperazinyl, 1,2,3,4-tetrahydropyrazinyl, hexahydropyrimidinyl, hexahydropyridazinyl, morpholinyl, thiomorpholinyl, azepinyl, azocinyl, dioxanyl, azepinyl, azocinyl, diazepinyl, diazocinyl, nitrogen-containing bridged heterocyclyl (e.g., 5- to 20-membered nitrogen-containing bridged heterocyclyl, e.g., azabicyclo[3.1.1]heptanyl (e.g., 6-azabicyclo[3.1.1]heptanyl), azabicyclo[2.2.1]heptanyl, azabicyclo[3.2.1]octanyl (e.g., 3-azabicyclo[3.2.1]octanyl), azabicyclo[2.2.2]octanyl, diazabicyclo[3.1.1]heptanyl (e.g., 3,6-diazabicyclo[3.1.1]heptanyl), diazabicyclo[2.2.1]heptanyl (e.g., 2,5-diazabicyclo[2.2.1]heptanyl), diazabicyclo[3.2.1]octanyl (e.g., 3,8-diazabicyclo[3.2.1]octanyl), diazabicyclo[2.2.2]octanyl (e.g., 2,5-diazabicyclo[2.2.2]octanyl)), or 5- to 20-membered azaspiro cyclyl (e.g., azaspiro[2.3]hexanyl, azaspiro[3.3]heptanyl, azaspiro[2.4]heptanyl, azaspiro[3.4]octanyl, azaspiro[3.5]nonanyl, azaspiro[4.4]nonanyl, azaspiro[4.5]decanyl, azaspiro[5.5]undecanyl, diazaspiro[2.3]hexanyl, diazaspiro[3.3]heptanyl, diazaspiro[2.4]heptanyl, diazaspiro[3.4]octanyl, diazaspiro[3.5]nonanyl, diazaspiro[4.4]nonanyl, diazaspiro[4.5]decanyl, diazaspiro[5.5]undecanyl, octahydropyrrolo[c]pyrrolyl, octahydropyrrolo[3,4-c]pyrrolyl, or decahydronaphthyridinyl); wherein the ring Y 3 is optionally substituted with n2 Rd2 each R d2 each independently deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy or C 1-6 alkoxy; and n2 represents an integer from 0-20 (e.g., 0-10 or 0-5, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20).

[0184] In some embodiments, R E Non-limiting examples of R wherein R d3 , R d4 each independently is selected from hydrogen, deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl, deuterated C 1-6 alkyl, haloC 1-6 alkyl, haloC 1-6 alkoxy or C 1-6 alkoxy; and R d3 , R d4 are not simultaneously hydrogen.

[0185] In some embodiments, the compound of Formula (II) represents the structure of Formula (II-1), Formula (II-2), Formula (II-3), or Formula (II-4): wherein Z represents C(O) or CH2; R a1 , R a2 , R a3 and R a4 are the same or different and each independently represents hydrogen, deuterium, halogen (e.g., fluorine, chlorine, bromine, or iodine), C 1-6 alkyl (e.g., C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, t-butyl, pentyl, or hexyl), haloC 1-6 alkyl (e.g., haloC 1-4 alkyl, e.g., F3C-, FCH2-, F2CH-, ClCH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2-, or CH2ClCH2-), deuterated C 1-6 alkyl (e.g., perdeuterated C 1-6 alkyl, perdeuterated C1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 alkoxy (such as halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), or deuterated C 1-6 alkoxy; (R a5 ) m represents an isoinodoline ring optionally substituted with m R a5 groups, each R a5 is the same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxy, thio, nitro, amino, cyano, C 1-6 alkyl (such as C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl (such as halo-C 1-4 alkyl, such as F3C-, FCH2-, F2CH-, CICH2-, C12CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halo-C 1-6 alkoxy (such as halo-C 1-4 alkoxy, such as F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, C12CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), or deuterated C1-6 alkyl; m denotes an integer 0, 1, 2 or 3; L1denotes S or O; L2denotes a substituted or unsubstituted straight-chain or branched alkylene, or L2is absent; R E denotes: wherein ring Y 1 denotes arylene, heteroarylene, heterocyclylene, or cycloalkylene, (R d1 ) n1 denotes ring Y 1 optionally substituted by n1R d1 groups, each R d1 each independently denotes deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated C 1-6 alkyl (e.g. perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halo-C 1-6 alkoxy (e.g. halo-C 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), and n1denotes an integer from 0 to 20 (e.g. the integer 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not limited by any or automatically by the size of the building block); w denotes the integer 0 or 1 ; and ring Y 3 denotes a nitrogen-containing heterocyclyl, (R d2 ) n2 denotes ring Y 3 optionally substituted by n2Rd2 each R d2 each independently represents deuterium, halogen, hydroxyl, thiol, nitro, amino, cyano, oxo, C 1-6 alkyl (e.g. C 1-5 alkyl, C 1-4 alkyl or C 1-3 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halo-C 1-6 alkyl (e.g. halo-C 1-4 alkyl, e.g. F3C-, FCH2-, F2CH-, CICH2-, Cl2CH-, CF3CF2-, CF3CHF-, CHF2CF2-, CHF2CHF-, CF3CH2- or CH2CICH2-), deuterated-C 1-6 alkyl (e.g. perdeuterated-C 1-6 alkyl, perdeuterated-C 1-5 alkyl or perdeuterated-C 1-4 alkyl, e.g. CD3, CD3CD2-, CD3CD2CD2-, etc.), C 1-6 alkoxy (e.g. C 1-4 alkoxy, e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy) or halo-C 1-6 alkoxy (e.g. halo-C 1-4 alkoxy, e.g. F3C-O-, FCH2-O-, F2CH-O-, CICH2-O-, Cl2CH-O-, CF3CF2-O-, CF3CHF-O-, CHF2CF2-O-, CHF2CHF-O-, CF3CH2-O- or CH2CICH2-O-), and n2 represents an integer from 0 to 20 (e.g. the integer 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20. The number of substituents is in principle not limited by any restriction or automatically by the size of the building block).

[0186] In some embodiments, the following specific compounds of Formula (II) of Table 2 below and salts (including pharmaceutically acceptable salts, e.g. their hydrochloride salts), prodrugs, solvates, isotopically enriched analogs, polymorphs, stereoisomers (including enantiomers and diastereomers), or mixtures of stereoisomers thereof are provided: Table 2 Compounds of the present disclosure II. Other forms of the compounds (including salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs of the compounds)

[0187] The compounds of the present disclosure have the structure of any one of Formula (I), Formula (I-l), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (I-6), Formula (I-7), Formula (I-8), Formula (I-9), Formula (I-10), Formula (II), Formula (II-l), Formula (II-2), Formula (II-3), or Formula (II-4). Unless otherwise indicated, when reference is made to a compound of the present disclosure, it is intended to include compounds of any one of Formula (I), Formula (I-l), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (I-6), Formula (I-7), Formula (I-8), Formula (I-9), Formula (I-10), Formula (II), Formula (II-l), Formula (II-2), Formula (II-3), or Formula (II-4), as well as specific compounds falling within the scope of these general formulas.

[0188] It is recognized that the compounds of the present disclosure, including compounds of Formula (I), Formula (I-l), Formula (I-2), Formula (I-3), Formula (I-4), Formula (I-5), Formula (I-6), Formula (I-7), Formula (I-8), Formula (I-9), Formula (I-10), Formula (II), Formula (II-l), Formula (II-2), Formula (II-3), or Formula (II-4), can have a stereochemical configuration, and thus can exist in more than one stereoisomeric form. The present disclosure is also directed to compounds having a stereochemical configuration that are optically enriched, such as about greater than 90% ee, such as about 95% ee or 97% ee, or greater than 99% ee, as well as mixtures thereof, including racemic mixtures. As used herein, "optically enriched" means that a mixture of enantiomers consists of a substantially greater proportion of one enantiomer, and can be described by the enantiomeric excess (ee %). Purification of isomers and separation of mixtures of isomers can be achieved by standard techniques known in the art (e.g., column chromatography, preparative TLC, preparative HPLC, asymmetric synthesis (e.g., by using chiral intermediates), and / or chiral resolution, etc.).

[0189] In some embodiments, there are also provided polymorphic forms of the compounds of the present disclosure or salts of the compounds of the present disclosure. The salts of the compounds of the present disclosure can be pharmaceutically acceptable salts, including but not limited to hydrohalides (including hydrochlorides, hydrobromides), sulfates, maleates, sulfonates, citrates / citrates, lactates, lactobionates, L-tartrates, fumarates, L-malates, L-lactates, a-ketoglutarates, hippurates, D-glucuronates, D-gluconates, a-D-glucoheptonates, glycolates, mucates, L-ascorbates, orotate, picrates, glycines, alanines, arginates, cinnamates, laurates, pamoates, sebacates, benzenesulfonates, methanesulfonates, ethanesulfonates, ethanedisulfonates, formates, acetates, 2,2-dichloroacetates, pivalates, propionates, valerates, palmitates, triphenylacetates, 2-ethyl-butandioates, iodates, nicotinates, L-pyroglutamates, L-prolinates, ferulates, 2-hydroxyethanesulfonates, nitrates, gentisates, cholate, salicylates, terephthalates, glutarates, adipates, stearates, oleates, undecylenates, camphorates, camphorsulfonates, dodecylsulfonates, phosphates, thiocyanates, dihydrogen phosphates, pyrophosphates, metaphosphates, oxalates, carbonates, malonates, benzoates, mandelates, succinates, pyruvates, p-chlorobenzenesulfonates, 1,5-napthalene disulfonates, 3-hydroxy-2-naphthoates, 1-hydroxy-2-naphthoates, 2-naphthoates, trifluoroacetates, glycolates, hippurates, or p-toluenesulfonates, and the like. The compounds of the present disclosure can exist in unsolvated or solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In some embodiments, the compounds of the present disclosure can be prepared as prodrugs or prodrugs. Prodrugs are converted into the parent drugs in the body to form the active drug metabolite(s). In some embodiments, there are also provided isotopically-labeled compounds of the present disclosure, examples of isotopes include deuterium (D or 2 H) III. Pharmaceutical Compositions / Formulations

[0190] In some embodiments, the present disclosure provides a pharmaceutical composition comprising, as an active ingredient, a compound of the present disclosure (a compound of Formula (I)) or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomeric forms), or mixture of stereoisomers thereof, and at least one pharmaceutically acceptable carrier.

[0191] In some embodiments, the pharmaceutically acceptable carrier includes, but is not limited to, fillers, stabilizers, dispersing agents, suspending agents, diluents, excipients, thickening agents, coloring agents, solvents or encapsulating materials. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, including the compounds useful in the present disclosure, and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, for example sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laureate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents, phosphate buffered saline solutions; polyoxyethylene, polyvinylpyrrolidone, polyacrylamide, poloxamer; and other non-toxic compatible substances used in pharmaceutical formulations.

[0192] The pharmaceutical compositions described herein further include at least one second therapeutic agent, such as an anti-cancer agent. The second therapeutic agent can be used in combination with the compound of Formula (I) described herein to treat a disease or disorder described herein. The second therapeutic agent includes, but is not limited to, a chemotherapeutic agent, an immunotherapeutic agent, a gene therapy agent, and the like.

[0193] The pharmaceutical compositions described herein comprising a compound of the present disclosure (a compound of Formula (I)) or a pharmaceutically acceptable salt thereof as an active ingredient can be prepared into a suitable formulation form according to a suitable administration route (including, but not limited to, intranasal administration, inhalation administration, topical administration, oral administration, oral mucosal administration, rectal administration, pleural cavity administration, peritoneal administration, vaginal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrathecal administration, and intravenous administration), such as a spray formulation, a patch, a tablet (e.g., a conventional tablet, a dispersible tablet, an oral disintegrating tablet), a capsule (e.g., a soft capsule, a hard capsule, an enteric capsule), a sugar-coated pill, a buccal tablet, a powder, a granule, a powder injection, a suppository, or a liquid formulation (e.g., a suspension (e.g., an aqueous or oily suspension), a solution, an emulsion, or a syrup), or a conventional injection form such as a sterile injection solution (e.g., a sterile injection solution prepared using water, Ringer's solution or isotonic sodium chloride solution, etc. as a carrier or solvent according to a method known in the art) or a lyophilized composition. The compound of the present disclosure (a compound of Formula (I)) can also be prepared into a conventional, dispersible, chewable, oral rapid disintegrating or fast dissolving formulation, or a sustained release or controlled release capsule as needed by a person skilled in the art.

[0194] The compounds of the present disclosure (compounds of Formula (I)) as active ingredients are contained in a pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a subject a therapeutically effective amount for the indication being treated without causing serious toxic effects in the subject being treated. The active compounds for all diseases or conditions mentioned herein are administered in a dosage of, for example, about 5 ng / kg to 500 mg / kg of the subject's body weight per day, about 10 ng / kg to 300 mg / kg of the subject's body weight per day, for example, 0.1 to 100 mg / kg of the subject's body weight per day, or 0.5 to about 25 mg / kg of the subject's body weight per day.

[0195] The compounds of the present disclosure (compounds of Formula (I)), or pharmaceutically acceptable salts thereof, can be conveniently administered in any appropriate formulation, the specifications of which include, but are not limited to, less than 1 mg, 1 mg to 3000 mg, 5 mg to 1000 mg, for example, 5 to 500 mg, 25 to 250 mg of active ingredient per unit dosage form. IV. Kits / Package

[0196] The compounds of the present disclosure (compounds of Formula (I)), or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof, are useful as medicaments. The medicaments of the present disclosure or the pharmaceutical compositions of the present disclosure can be present in a kit / package. The kit / package can include a package or container. The package or container includes, but is not limited to, ampoules, blister packs, pharmaceutical bottles made of plastic, vials, pharmaceutical bottles made of glass, containers, syringes, laminated soft-packaged containers, co-extruded film infusion containers, test tubes, and dispensing devices, etc. The kit / package can contain instructions for use of the product. V. Methods and Uses

[0197] The compounds of Formula (I) described herein, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof, can be used as a medicament. In particular, the compounds of Formula (I) described herein, or pharmaceutically acceptable salts, solvates, isotopically enriched analogs, polymorphs, prodrugs, stereoisomers (including enantiomers), or mixtures of stereoisomers thereof, can be used in the manufacture of a medicament for the treatment and / or prevention of a disease or condition selected from the group consisting of a neoplasm, an infectious disease, an autoinflammatory disease, an inflammatory disease, an autoimmune disease, a neurological disease, a respiratory disease, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, a cardiovascular disease, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, alopecia seborrheica, hirsutism, a skin disease, functional uterine bleeding, anemia, pediatric aplastic anemia, endometriosis, polycystic ovary syndrome, and a thyroid disease. In some embodiments, the disease or condition includes, but is not limited to, myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, burning myeloma; myelofibrosis; myeloid disease; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including chronic myelogenous leukemia, B-cell chronic lymphocytic leukemia, anemia associated with leukemia, acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), monocytic leukemia, myelomonocytic leukemia, acute lymphoblastic leukemia (ALL), acute T-lymphoblastic leukemia, T-lymphoblastic leukemia, chronic lymphocytic leukemia (CLL); lymphoma, including diffuse large B-cell lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin's lymphoma, refractory B-cell non-Hodgkin's lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin's lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; brain glioma; astrocytoma; glioma; peripheral neuroepithelioma; ovarian cancer; bronchial cancer; prostate cancer;breast cancer, including triple negative breast cancer, sporadic breast cancer, breast ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancer; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; large intestine adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcoma, including rhabdomyosarcoma, various adipose-derived tumors, Ewing / PNETs, and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; cholangiocarcinoma; bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulceration, Kawasaki disease, polymyositis / dermatomyositis, Sjogren syndrome, atopic dermatitis, hidradenitis suppurativa; keratoconjunctivitis sicca; autoinflammatory diseases, including gout, etc.; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS, COVID-19 novel coronavirus infection, gram-negative bacterial infection, gram-positive bacterial infection, tuberculosis, etc.; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; cachexia and multiple organ failure due to septic shock; acute liver failure; functional uterine bleeding; anemia; pediatric aplastic anemia; endometriosis; polycystic ovary syndrome; thyroid disease; cardiovascular disease (e.g., coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin disease (e.g., acne); Kennedy disease; seborrhea; and hirsutism.

[0198] Methods for preventing and / or treating a disease or condition in a subject include administering to the subject a therapeutically effective amount of a compound of formula (I) of this disclosure, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the disease or condition includes, but is not limited to, tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular diseases, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, dysfunctional uterine bleeding, anemia, childhood aplastic anemia, endometriosis, polycystic ovary syndrome, and thyroid diseases. In some implementations, the disease or condition includes, but is not limited to: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, and smoldering multiple myeloma; myelofibrosis; bone marrow diseases; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including chronic myeloid leukemia, B-cell chronic lymphocytic leukemia, leukemia-associated anemia, acute myeloid leukemia (AML), and chronic myeloid leukemia. Blood disorders (CML), monocytic leukemia, myeloid monocytic leukemia, acute lymphoblastic leukemia (ALL), acute T-cell lymphoblastic leukemia, T-cell lymphoblastic leukemia, chronic lymphocytic leukemia (CLL); lymphomas, including diffuse large B-cell lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma. slymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; intestinal cancer; brain glioma; astrocytic glioblastoma; glial tumor; peripheral neuroepithelioma; ovarian cancer; bronchial cancer; prostate cancer; breast cancer, including triple-negative breast cancer, sporadic breast cancer, breast ductal carcinoma, and patients with Cowden disease; pancreatic cancer; central nervous system cancer; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; large intestine adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcoma, including rhabdomyosarcoma, various adipose-derived tumors, Ewing sarcoma / primitive neuroectodermal tumor (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; cholangiocarcinoma; bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulceration, Kawasaki disease, polymyositis / dermatomyositis, Sjogren syndrome, atopic dermatitis, hidradenitis suppurativa; keratoconjunctivitis sicca; autoinflammatory diseases, including gout and the like; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS, COVID-19 novel coronavirus infection, gram-negative bacterial infection, gram-positive bacterial infection, tuberculosis, and the like; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; cachexia and multiple organ failure due to septic shock; acute liver failure; functional uterine bleeding; anemia; pediatric aplastic anemia; endometriosis; polycystic ovary syndrome; thyroid disease; cardiovascular disease (e.g., coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin disease (e.g., acne); Kennedy disease; alopecia seborrheica; and hirsutism.

[0199] In a method for preventing and / or treating a disease or disorder in a subject, a therapeutically effective amount of a compound of Formula (I) described in the disclosure, or a pharmaceutical composition described in the disclosure comprising a compound of Formula (I) as an active ingredient is administered to the subject by at least one administration route selected from the group consisting of intranasal administration, inhalation administration, topical administration, oral administration, buccal administration, rectal administration, pleural cavity administration, peritoneal administration, intramuscular administration, subcutaneous administration, transdermal administration, epidural administration, intrathecal administration, and intravenous administration.

[0200] The compound of Formula (II) described in the disclosure, or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers thereof, is a novel CRBN E3 ubiquitin ligase ligand, which can bind to CRBN E3 ligase as a molecular glue. The compound of Formula (II) described in the disclosure, or a pharmaceutically acceptable salt, solvate, isotopically enriched analog, polymorph, prodrug, stereoisomer (including enantiomer), or mixture of stereoisomers thereof, has CRBN binding ability, helps to recruit substrate proteins, and can be used to prepare the bifunctional protein degradation small molecule drug of the disclosure, i.e., the compound of Formula (I) or a salt (including a pharmaceutically acceptable salt), stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph thereof.

[0201] The term "treatment" or "treatment" refers to the administration of a compound of the disclosure (a compound of Formula (I)) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of the disclosure (a compound of Formula (I)) or a pharmaceutically acceptable salt thereof as an active ingredient to a subject to slow down (reduce) the development of an undesired disease or disorder (e.g., a tumor). The beneficial or desired clinical outcomes of the disclosure include, but are not limited to, alleviating symptoms, reducing the severity of the disease, stabilizing the state of the disease, delaying or slowing down the progression of the disease, improving or alleviating the condition, and relieving the disease. [0...

Claims

1. A compound of formula (I) or a salt thereof, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug, or polymorph: PBM-LIN-ULM (I) PBM represents the target portion of a protein that can bind to it, and PBM is covalently linked to ULM via the LIN group; ULM represents the ligand moiety capable of binding to E3 ubiquitin ligases, and is represented by the following formula (ULM): in Z represents C(O) or CH2; R a1 R a2 R a3 and R a4 The same or different and each independently represents hydrogen, deuterium, halogen, and carbon. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 alkoxy or halogenated C 1-6 Alkoxy; (R a5 ) m This indicates that the isoindoline ring connected to it is optionally surrounded by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, and C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 alkoxy or halogenated C 1-6 Alkoxy; m represents an integer 0, 1, 2, or 3; L1 represents S or O; L2 represents a substituted or unsubstituted straight-chain or branched alkylene group, or L2 is not present; R a6 express: Among them, ring Y 1 Indicates arylene, heteroarylene, heterocyclic, or cycloalkylene, (R d1 ) n1 Represents ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each can independently represent deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy groups, and n1 represents integers from 0 to 20; w represents an integer 0 or 1; Y-shaped ring 2 Indicates a nitrogen-containing heterocyclic sub-heterocyclic group, (R d2 ) n2 Represents ring Y 2 Optionally, it can be used by n2 R d2 Group substitution, each R d2 Each can independently represent deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 alkoxy groups, and n2 represent integers from 0 to 20; and The symbol ** indicates the connection point with LIN; and LIN represents a key or a structure like the following: Where R w2 Connect to PBM, R w1 Connect R a6 ; R w2 Represents the bond, C(O), C(O)NH, or NHC(O); Each ring A 1 The same or different and each independently represents a heterocyclic group, a cycloalkyl group, an aryl group, or a heteroaryl group, where y1 represents an integer 0, 1, 2, or 3, (R y1 ) a1 Indicates each ring A 1 Independently and optionally by a1 R y1 Group substitution, each R y1 Independent of deuterium and C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 alkenyl, and a1 represent integers from 0 to 10; Each ring A 2 The same or different and each independently represents a heterocyclic group, a cycloalkyl group, an aryl group, or a heteroaryl group, where y2 represents the integer 0, 1, 2, or 3, (R y2 ) a2 Indicates each ring A 2 Each can be independently and optionally controlled by a2 R y2 Group substitution, each R y2 Each independently constitutes deuterium and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 alkenyl, and a2 represent integers from 0 to 10; Each ring A 3 The same or different and each independently represents a heterocyclic group, a cycloalkyl group, an aryl group, or a heteroaryl group; y3 represents an integer 0, 1, 2, or 3; (R y3 ) a3 Indicates each ring A 3 Independently and optionally by a3 R y3 Group substitution, each R y3 Independent of deuterium and C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl and a3 represent integers from 0 to 10; R w1 Denotes a bond, or a C-chain of alternative substitutions, either straight or branched. 1-20 Alkylene, wherein the straight-chain or branched C 1-20 Any one or more methylene groups in the main carbon chain backbone of the alkylene group may optionally be replaced by one or more groups selected from the following: R a R b And any combination thereof, each group R a Each is independently selected from O, C(O), OC(O), S, S(O), S(O)2, and S(O)2N(R). a7 ), N(R a7 S(O)2、C(O)N(R) a7 ), N(R a7 C(O), N(R) a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each can be represented independently as H or C. 1-3 Alkyl groups, and when the straight-chain or branched C 1-20 Any two or more methylene groups in the main carbon chain backbone of an alkylene group are separated by two or more R groups. a During substitution, each group R a They are not directly connected to each other; each group R b Each is independently selected from optionally substituted cycloalkylene, optionally substituted arylene, optionally substituted heterocyclic, optionally substituted heteroaryl, alkynylene, alkenylene, and any combination thereof.

2. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the PBM represents a small molecule ligand binding to the following proteins: epidermal growth factor receptor (EGFR), cyclin-dependent kinase 4 / 6 (CDK4 / 6), androgen receptor (AR), anaplastic lymphoma kinase (ALK), interleukin-1 receptor-associated kinase 4 (IRAK4), or breakpoint cluster region (BCR)-Abelson leukemia virus (ABL) (BCR-ABL) tyrosine kinase.

3. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the PBM comprises a structure selected from the following formulas: in In formula (PBM-1), X1 represents CR 1e or fragments Where the symbol # represents the connection point of N adjacent to X1, the symbol ## represents the connection point of X2, and each R 1e Each can be used independently to represent deuterium, hydrogen, halogen, and carbon. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-deuterated C 1-6 Alkyl or -C(O)NR 1f R 1g , where R 1f R 1g The same or different and each independently represents hydrogen and C. 1-6 Alkyl or deuterated C 1-6 Alkyl, and R 1f R 1g They are not both hydrogen; In equation (PBM-1), X2 represents N or CR 1h , where R 1h Represents hydrogen, deuterium, halogens, and carbon. 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; X3 and X4 each independently represent CH or N; R 1a Indicates a heteroaryl group with a bond or optional substitution (e.g., a halogenated or deuterium-substituted heteroaryl group); R 1b Indicates hydrogen, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, or optionally substituted C 3-12 cycloalkyl; In equation (PBM-1), (R) 1c ) p1a This indicates that the pyridine ring connected to it may optionally be p1a R 1c Replace, each R 1c The same or different and each independently represents deuterium, halogen, and carbon. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy group, p1a represents the integer 0, 1, 2 or 3; In equation (PBM-1), (R) 1d ) p1b This indicates that the nitrogen-containing bicyclic heteroaryl ring connected to it is optionally replaced by p1b R 1d Replace, each R 1d The same or different and each independently represents deuterium, halogen, and carbon. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 alkoxy group, p1b represents the integer 0 or 1; In equation (PBM-2), ring A represents C. 6-10 aryl or 5- to 20-membered heteroaryl (e.g., 5- to 20-membered heteroaryl comprising one or two 5- to 7-membered rings and 1 to 4 heteroatoms selected from N, O, and S), wherein ring A is optionally surrounded by one or more R 2a Replacement, and each R 2a The same or different, and each independently, are deuterium, halogen, hydroxyl, cyano, amino, nitro, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 2-6 alkenyl, or C 2-6 alkynyl group; In equation (PBM-2), ring B represents C. 3-15 Cycloalkyl or 4- to 20-membered heterocyclic groups (e.g., 4- to 20-membered heterocyclic groups containing 1 to 4 heteroatoms selected from N, O, and S), wherein the ring B is optionally separated by one or more R... 2b Replacement, and each R 2b The same or different, and each independently, are deuterium, halogen, hydroxyl, cyano, amino, nitro, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; In formula (PBM-2), the ring C represents a 5- to 20-membered heteroaryl group (e.g., a 5- to 20-membered monocyclic or bicyclic heteroaryl group containing 1-4 heteroatoms selected from N, O, and S), wherein the ring C is optionally separated by one or more R atoms. 2c Replacement, and each R 2c The same or different, and each independently, are deuterium, halogen, hydroxyl, cyano, amino, nitro, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; In formula (PBM-3), X5, X6, X7, X8, and X9 may be the same or different and each independently represents N or CH; R 3a The methylene group represents a bonded or optionally substituted methylene group (e.g., a halogen-substituted methylene group); R 3b -C(O)N(R) 3f )R 3e -N(R) 3f )C(O)R 3e -S(O)2N(R) 3f )R 3e -N(R) 3f )S(O)2R 3e -S(O)2R 3e or -P(O)(R 3e )2, where each R 3e The same or different and each independently represents C. 1-6 Alkyl or deuterated C 1-6 Alkyl groups, each R 3f Each can be independently represented as hydrogen or C. 1-6 alkyl; In formula (PBM-3), (R) 3c ) p3a This indicates that the six-membered ring containing X6 and X7 connected to it can optionally be p3a R 3c Replace, each R 3c The same or different and each independently represents deuterium, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; p3a represents the integer 0, 1, 2, 3 or 4; R 3d This indicates deuterium, halogen, hydroxyl, amino, cyano, and C. 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; In formula (PBM-4), (R) 4a ) p4a This indicates that the benzene ring it is attached to is surrounded by p4a R atoms. 4a Replace, each R 4a The same or different and each independently represents deuterium, halogen, hydroxyl, C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, NO2, NH2, or cyano groups; p4a represents the integer 0, 1, 2, 3, 4 or 5; R 4b C indicates whether it is substituted or not substituted. 3-15 Cycloalkyl groups, such as cyclopentyl; R in equation (PBM-5) 5a R 5b R 5c Each can be represented independently as CH or N; R 5d -C(O)NHR 5h -NHC(O)R 5h -S(O)2NHR 5h -NHS(O)2R 5h -S(O)2R 5h or -P(O)(R 5h )2, where each R 5h The same or different and each independently represents C. 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; (R 5e ) p5a Indicates p5a substituents R 5e Each R 5e The same or different and each independently represents halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; p5a represents the integer 0, 1, 2, 3 or 4; (R 5f ) p5b Indicates p5b substituents R 5f Each R 5f The same or different and each independently represents halogen, hydroxyl, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; p5b represents the integer 0, 1, or 2; (R 5g ) p5c This indicates that the benzene ring connected to it may optionally be p5c R 5g Replacement, and each R 5g Each can be independently represented by halogen, hydroxyl, cyano, amino, nitro, or C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; p5c represents the integer 0, 1, 2, 3 or 4; In formula (PBM-6), ring D represents a 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, O, and S. R 6b This indicates optional substituted 5- to 15-membered heteroaryl, optional substituted 5- to 15-membered heterocyclic, deuterium, halogen, hydroxyl, cyano, amino, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; R 6a Indicates hydrogen, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; R in equation (PBM-7) x1 Represents a bond or C(O), or R x1 It represents -C(O)NH-R x2 -C(O)-***, where the symbol *** indicates that it is related to R c The connection point, and R x2 C represents optional substitution 3-15 Cycloalkylene; (R 7a ) p7a This indicates that the 1H-pyrrolo[2,3-b]pyridine ring connected to it is optionally replaced by a p7a R 7a Replacement, and each R 7a Each can be independently represented by cyano, halogen, hydroxyl, amino, nitro, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1- 6-alkoxy group and p7a represent integers 0, 1, 2, 3, 4 or 5; (R 7b ) p7b This indicates that the pyridine ring connected to it is optionally replaced by p7b R 7b Replacement, and each R 7b Each can be independently represented by cyano, halogen, hydroxyl, nitro, or C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy or NR 7c R 7d , where R 7c R 7d The same or different and each independently represents hydrogen and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, optional substituted C 3-15 Cycloalkyl or optionally substituted 4- to 15-membered heterocyclic groups, and p7b represents the integer 0, 1, 2 or 3; R in equation (PBM-8) 8a Indicates N or CH; R 8b It represents NHC(O), C(O)NH, NHS(O)2 or S(O)2NH; (R 8c ) p8a Indicates that it is connected to R 8a The six-membered ring is p8a R 8c Replace, each R 8c The same or different and each independently represents halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkyl group, and p8a represents an integer 0, 1, 2, 3 or 4; Cyclic E represents a 5- to 15-membered heteroaryl group, (R 8d ) p8b This indicates that the ring E connected to it can optionally be p8b R. 8d Replace, each R 8d The same or different and each independently represents halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, hydroxyl substituted C 1-6 alkyl and amino substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy or optional substituted C 3-15 Cycloalkyl, and p8b represents the integer 0, 1, 2 or 3; R in equation (PBM-9) 9a It represents -NHC(O)- or -C(O)NH-; R 9b Represents -NH-, -N(C 1-6 alkyl)- or ethynyl group; In formula (PBM-9), ring F represents a 5- to 20-membered monocyclic, bicyclic, or polycyclic heteroaryl group containing 1-4 heteroatoms selected from N, O, and S. 9c ) p9a This indicates that the ring F can be optionally divided by p9a R. 9c Replacement, and each R 9c The same or different, and each independently, represent optional substituted 5- to 15-membered heteroaryl, deuterium, halogen, hydroxyl, cyano, amino, NO2, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Alkoxy; p9a represents the integer 0, 1, 2, or 3; In formula (PBM-9), each (R) 9d ) p9b Each of the benzene rings to which it is attached represents an independent and optional p9b R group. 9d Replace, each R 9d The same or different and each independently represents deuterium, halogen, hydroxyl, cyano, amino, NO2, and C. 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; Each p9b may be the same or different and each independently represents the integer 0, 1, 2, 3 or 4; In formula (PBM-10), (R) 10a ) p10a This indicates that the benzene ring connected to it is surrounded by p10a R 10a Replace, each R 10a The same or different and each independently represents deuterium, halogen, hydroxyl, cyano, amino, NO2, and C. 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; p10a represents the integer 1, 2, 3, 4 or 5; R 10b Indicates halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl or halogenated C 1-6 alkyl; R 10c It represents -NHC(O)- or -C(O)NH-; R 10d and R 10e Each can independently represent N or CH; and R in each general formula c Each independently represents a bond, -O-, -N(R) d )-, -NHC(O)-*, -C(O)NH-*, -N(R d )-R f -N(R e -*、-R f -C(O)NH-*、-R f -NHC(O)-*、-R f -C(O)O-*、-R f -OC(O)-*, -C(O)O-*, -OC(O)-*, -R f -、-R f -N(R d -*、-OR f -N(R d )-*、 Among them, each ring W 1 The same or different and each independently represents a nitrogen-containing heterocyclic group, cycloalkyl group, aryl group, or heteroaryl group, t1 represents an integer 0, 1, or 2, (R c1 ) m1 Indicates each ring W 1 Each can be independently and optionally assigned to m1 R c1 Group substitution, each R c1 Independent of deuterium and C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl or R c4 -R c3 -, where R c3 It is an optional replacement for C 1-6 Alkylene or optionally substituted C 2-6 Ideonyl, R c4 Indicates halogen, R c5 R c6 N-, hydroxyl, carboxyl, ethynyl or vinyl, wherein R c5 and R c6 The same or different and each independently represents hydrogen or C. 1-3 Alkyl groups, and m1 represents integers from 0 to 20; Each ring W 2 The same or different and each independently represents a nitrogen-containing heterocyclic group, cycloalkyl group, aryl group, or heteroaryl group, t2 represents an integer 0 or 1, (R c2 ) m2 Indicates each ring W 2 Each can be independently and optionally assigned to m2 R c2 Group substitution, each R c2 Each independently constitutes deuterium and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl or R c8 -R c7 -, where R c7 It is an optional replacement for C 1-6 Alkylene or optionally substituted C 2-6 Ideonyl, R c8 Indicates halogen, R c9 R c10 N-, hydroxyl, carboxyl, ethynyl or vinyl, wherein R c9 and R c10 The same or different and each independently represents hydrogen or C. 1-3 Alkyl groups, and m2 represents integers from 0 to 20; and R d and R e Each can be independently represented as hydrogen or C. 1-6 Alkyl, R f and R g Each independently represents an optional substitution of C. 1-6 Alkylene or optionally substituted C 2-6 The subalkenyl group, and the symbol * indicates the connection point with LIN.

4. The compound of formula (I) as claimed in claim 3, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the PBM represents one of the following structures: Where R c As defined in claim 3.

5. The compound of formula (I) as described in claim 3, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein... The R c Each independently represents a bond, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, or -NH-, or R c Each can be represented independently as follows: -N(R d )-、-N(R d )-R f -N(R e )-*、-R f -C(O)NH-*、-R f -NHC(O)-*、-R f -C(O)O-*、-R f -OC(O)-*、-R f -、-R f -N(R d )-*、-O-R f -N(R d )-*、 Among them, each ring W 1 The same or different and each independently represents a 4- to 20-membered nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene, C 5-20 arylene, or 5- to 20-membered heteroarylene, t1 represents an integer 0, 1, or 2, (R c1 ) m1 Indicates each ring W 1 Each can be independently and optionally assigned to m1 R c1 Group substitution, each R c1 Each independently constitutes deuterium and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl, or R c4 -R c3 -, where R c3 It is an optional replacement for C 1-6 Alkylene or optionally substituted C 2-6 Ideonyl, R c4 Indicates halogen, R c5 R c6 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c5 and R c6 The same or different and each independently represents hydrogen or C. 1-3 Alkyl groups, and m1 represents integers from 0 to 20; Each ring W 2 The same or different and each independently represents a 4- to 20-membered nitrogen-containing heterocyclic group, C 3-20 Cycloalkylene, C 5-20 arylene, or 5- to 20-membered heteroarylene, t2 represents an integer 0 or 1, (R c2 ) m2 Indicates each ring W 2 Each can be independently and optionally assigned to m2 R c2 Group substitution, each R c2 Each independently constitutes deuterium and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl, or R c8 -R c7 -, where R c7 It is an optional replacement for C 1-6 Alkylene or optionally substituted C 2-6 Ideonyl, R c8 Indicates halogen, R c9 R c10 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c9 and R c10 The same or different and each independently represents hydrogen or C. 1-3 Alkyl groups, and m2 represents integers from 0 to 20; and R d and R e Each can be independently represented as hydrogen or C. 1-6 Alkyl, R f and R g Each independently represents an optional substitution of C. 1-6 Alkylene or optionally substituted C 2-6 alkenyl; The C 1-6 Alkylene and C 2-6 Each of the alkenyl groups is independently and optionally selected from one or more groups selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Substitution of alkoxy groups; and The symbol * indicates the connection point with LIN.

6. The compound of formula (I) as described in any one of claims 3-5, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein... Each ring W 1 The same or different and each independently represents a 4- to 15-membered nitrogen-containing heterocyclic group, C 3-15 Cycloalkylene, 6- to 15-membered arylene, or 5- to 15-membered heteroarylene, for example Piperidinyl, Piperazinyl, Morpholinyl, Azahexacyclic Butyl, Pyrrolidine, Imidazolyl, Pyrazolyl, Ixazolyl, Ixazolyl, Thiazolyl, Thionomorpholinyl, Azahexacyclic Heptyl, Diazahexacyclic Heptyl, Azahexacyclic Octyl, Diazahexacyclic Octyl, Azabicyclo[3.1.1]Heptane, Azabicyclo[2.2.1]Heptane, Azabicyclo[3.2.1]Octanyl, Azabicyclo[2.2.2]Octanyl, Diazabicyclo[3.1.1]Heptane, Diazabicyclo[2.2.1]Heptane, Diazabicyclo[ 3.2.1] Octaneylidene, diazabicyclo[2.2.2] Octaneylidene, 3-azaspiro[5.5] Undecaneylidene, 8-azaspiro[4.5] Decaneylidene, 2-oxo-8-azaspiro[4.5] Decaneylidene, 3-methyl-2-oxo-8-azaspiro[4.5] Decaneylidene, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydrocyclopentadienylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclic, adamantylene Alkyl, adamantylene, norborneolyl, phenylene, naphthylene, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thiopheneylene, thiazolylene, isothiazolylene, thiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyrazinylene, indoleylene, isindoleylene, benzofuranylene, isobenzofuranylene, benzothiopheneylene, indoleylene, benzimidazole subunit, benzoxazole subunit, benzisoxazole subunit, benzothiazolyl subunit, benzothiazolyl subunit, benzisoxazole subunit, benzothiazolyl subunit, benzothiazolyl, benzotriazole subunit, benzo[] [2,1,3]oxadiazole subunit, benzo[2,1,3]thiadiazole subunit, benzo[1,2,3]thiadiazole subunit, quinoline, isoquinoline, naphthinyl, cinnamoline, quinoline, quinoline, quinolineyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl subunit, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridinyl subunit, 1H-pyrrolo[3,2-b]pyridinyl subunit, 1H-pyrrolo[2,3-b]pyridinyl subunit, pyrrolo[2,1-b]thiazole subunit, or imidazo[2,1-b]thiazole subunit, or Among them, each ring W 1 Each can be independently and optionally assigned to m1 R c1 Group substitution, each R c1 Independent of deuterium and C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl, or R c4 -R c3 -, where R c3 It is an optional replacement for C 1-6 Alkylene or optionally substituted C 2-6 Ideonyl, R c4 Indicates halogen, R c5 R c6 N-, hydroxyl, carboxyl, ethynyl or vinyl, wherein R c5 and R c6 The same or different and each independently represents hydrogen or C. 1-3 Alkyl groups, and the C 1-6 alkylene and the C 2-6 Each of the alkenyl groups is independently and optionally selected from one or more groups selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Substituents of alkoxy groups, and m1 representing an integer from 0 to 20; and / or Each ring W 2 The same or different and each independently represents a 4- to 15-membered nitrogen-containing heterocyclic group, C 3-15 Cycloalkylene, 6- to 15-membered arylene, or 5- to 15-membered heteroarylene, for example, Piperidinyl, Piperazinyl, Morpholinyl, Azahexacyclic Butyl, Pyrrolidine, Imidazolyl, Pyrazolyl, Ixazolyl, Ixazolyl, Thiazolyl, Thionomorpholinyl, Azahexacyclic Heptyl, Diazahexacyclic Heptyl, Azahexacyclic Octyl, Diazahexacyclic Octyl, Azabicyclo[3.1.1]Heptane, Azabicyclo[2.2.1]Heptane, Azabicyclo[3.2.1]Octanyl, Azabicyclo[2.2.2]Octanyl, Diazabicyclo[3.1.1]Heptane, Diazabicyclo[2.2.1]Heptane, Diazabicyclo[ 3.2.1] Octaneylidene, diazabicyclo[2.2.2] Octaneylidene, 3-azaspiro[5.5] Undecaneylidene, 8-azaspiro[4.5] Decaneylidene, 2-oxo-8-azaspiro[4.5] Decaneylidene, 3-methyl-2-oxo-8-azaspiro[4.5] Decaneylidene, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydrocyclopentadienylene, octahydro-1H-indenylene, 2,3-dihydro-1H-indenylene, spirocyclic, adamantylene Alkyl, adamantylene, norborneolyl, phenylene, naphthylene, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thiopheneylene, thiazolylene, isothiazolylene, thiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyrazinylene, indoleylene, isindoleylene, benzofuranylene, isobenzofuranylene, benzothiopheneylene, indoleylene, benzimidazole subunit, benzoxazole subunit, benzisoxazole subunit, benzothiazolyl subunit, benzothiazolyl subunit, benzisoxazole subunit, benzothiazolyl subunit, benzothiazolyl, benzotriazole subunit, benzo[] [2,1,3]oxadiazole subunit, benzo[2,1,3]thiadiazole subunit, benzo[1,2,3]thiadiazole subunit, quinoline, isoquinoline, naphthinyl, cinnamoline, quinoline, quinoline, quinolineyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl subunit, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridinyl subunit, 1H-pyrrolo[3,2-b]pyridinyl subunit, 1H-pyrrolo[2,3-b]pyridinyl subunit, pyrrolo[2,1-b]thiazole subunit, or imidazo[2,1-b]thiazole subunit, or Among them, each ring W 2 Each can be independently and optionally assigned to m2 R c2 Group substitution, each R c2 Independent of deuterium and C 1-6 Alkyl, deuterated C 1- 6-alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl, or R c8 -R c7 -, where R c7 It is an optional replacement for C 1-6 Alkylene or optionally substituted C 2-6 Ideonyl, R c8 Indicates halogen, R c9 R c10 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c9 and R c10 The same or different and each independently represents hydrogen or C. 1-3 Alkyl groups, and the C 1-6 alkylene and the C 2-6 Each of the alkenyl groups is independently and optionally replaced by one or more deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C group, etc. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 The alkoxy group is substituted, and m2 represents an integer from 0 to 20.

7. The compound of formula (I) as claimed in any one of claims 3-5, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein in R c Parts of the general formulas Represents the following groups: Each of the aforementioned groups may optionally be further selected from one or more elements chosen from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl, R c12 -R c11 Substitution by substituents of , or any combination thereof, wherein R c11 It is an optional replacement for C 1- 6-alkylene or optionally substituted C 2-6 Ideonyl, R c12 Indicates halogen, R c13 R c14 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c13 and R c14 The same or different and each independently represents hydrogen or C. 1-3 Alkyl, the C 1-6 Alkylene and C 2-6 Each of the alkenyl groups is independently and optionally selected from one or more groups selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Substitution of alkoxy groups.

8. The compound of formula (I) as claimed in any one of claims 3-5, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein R c Represents the following groups: a key, -O-, -NHC(O)-*, -C(O)NH-*, -C(O)O-*, -OC(O)-*, -CH2C(O)O-*, -CH2OC(O)-*, -NH-, -N(CH3)-, -NH-CH2-*, -N(CH3)-CH2-*, -N(CH3)-(CH2)2-N(CH3)-*, -N(CH3)-(CH2)3-N(CH3)-*, -NH-(CH2)2-N(CH3)-*, -N(CH3)-(CH2)3-NH-*, -CH2-NHC(O)-*, -CH2-C(O)NH-*, -CH2-NH-*, -O-(CH2)2-N(CH3)-*, -O-(CH2)2-NH-*, or -CH2-N(CH3)-*, or Each of the aforementioned groups may optionally be further selected from one or more elements chosen from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, C 2-6 alkynyl group, C 2-6 Alkenyl, optional deuterated C 3-6 cycloalkyl, R c12 -R c11 - or any combination of substituents thereof, wherein R c11 It is an optional replacement for C 1-6 Alkylene or optionally substituted C 2-6 Ideonyl, R c12 Indicates halogen, R c13 R c14 N-, hydroxyl, carboxyl, ethynyl, or vinyl, wherein R c13 and R c14 The same or different and each independently represents hydrogen or C. 1-3 Alkyl, the C 1-6 Alkylene and C 2-6 Each of the alkenyl groups is independently and optionally selected from one or more groups selected from deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 alkoxy or halogenated C 1-6 Substituents of alkoxy groups; and the symbol * indicates the connection point with LIN.

9. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the ULM represents a structure of formula (ULM-1-1), (ULM-1-2), (ULM-1-3), or (ULM-1-4): Among them, Z and R a1 R a2 R a3 R a4 、(R a5 ) m L1, L2 and R a6 As defined in claim 1.

10. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the ULM represents a structure of formula (ULM-2-1), (ULM-2-2), (ULM-2-3), or (ULM-2-4): Among them, Z, (R) a5 ) m L1, L2 and R a6 As defined in claim 1.

11. The compound of formula (I) as claimed in claim 1, 9, or 10, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein... L2 represents a substituted or unsubstituted straight-chain or branched C1-C5 alkylene group, or L2 is absent; and / or The ring Y 1 Indicates C5-C 30 arylene, 5 to 30-membered heteroarylene, 4 to 30-membered heterocyclic, or C3-C 30 Cycloalkylene, (R d1 ) n1 Represents ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 alkoxy group, and n1 represent integers from 0 to 20; and / or The ring Y 2 Indicates 4 to 30 nitrogen-containing heterocyclic groups, (R d2 ) n2 Represents ring Y 2 Optionally, it can be used by n2 R d2 Group substitution, each R d2 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy, and n2 represent integers from 0 to 20.

12. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein... (i) The ring Y 1 Indicates C5-C 20 arylene, 5 to 20-membered heteroarylene, 4 to 20-membered heterocyclic, or C3-C 20 cycloalkylene; for example, the cyclo-Y 1 express: Azahexacyclobutyl, oxohexacyclobutyl, pyrrolidine, imidazoalkyl, pyrazolidine, tetrahydrofuranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolidine, thiazoalkyl, piperidinyl, piperazine, morpholinyl, thiomorpholinyl, dioxazolidinyl, dioxazolidinyl, heptyl, octyl, dioxazolidinyl, octyl, bridged heterocyclic (e.g., 5- to 15-membered bridged heterocyclic, such as azabicyclohexyl, azabicycloheptyl, or azabicyclooctyl), or spirohexacyclic (e.g., 5- to 15-membered spirohexacyclic, such as 3-azaspiro[5.5]undecyl or 7-azaspiro[3.5]nonyl); or Isofuranyl, Isooxazolyl, Isooxazolyl, Isodiazoleyl, Isothienyl, Isothiazolyl, Isothiazolyl, Isothiadiazoleyl, Ipyrroloyl, Imizolyl, Isopyrazolyl, Ipyridinyl, Iridazinyl, Iridolyl, Isoindolyl, Ibenzofuranyl, Isobenzofuranyl, Ibenzothienyl, Iridazoleyl, Ibenzimidazoleyl, Ibenzooxazolyl, Ibenzoisooxazolyl, Ibenzothiazolyl, Ibenzotriazoleyl, Ibenzo[2,1,3]oxadiazoleyl , benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolineyl, isoquinolineyl, naphthinyl, cinnamolineyl, quinolineyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidineyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazoleyl and imidazo[2,1-b]thiazoleyl; or Cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydro-1H-indenylene, spirocycloalkylene (e.g., C5-C) 15 Spirocycloalkyl, such as spiro[3.3]heptanediol, spiro[2.5]octanediol, spiro[3.5]nonanediol, spiro[4.4]nonanediol, spiro[4.5]decanediol, or spiro[5.5]undecanediol), or bridged cycloalkyl (e.g., C5-C). 15 Subbridged cycloalkyl groups, such as adamantylene, noradamantylene, borneolyl, bicyclo[2.2.1]heptane, 2-oxobicyclo[2.2.1]heptane, or bicyclo[2.2.1]heptene; or Phenylidene or naphthylene; The ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy; n1 represents an integer from 0 to 20; or (ii) The ring Y 2 This represents a 4- to 20-membered nitrogen-containing heterocyclic group; for example, the cyclic Y... 2 express: Azahexacyclobutyl, diazahexacyclobutyl, pyrrolidine, imidazoalkyl, pyrazolidine, oxazolidine, thiazoalkyl, piperidinyl, tetrahydropyridinyl, piperazinyl, 1,2,3,4-tetrahydropyrazinyl, hexahydropyrimidinyl, hexahydropyridazinyl, morpholinyl, thiomorpholinyl, zazaheptanyl, zazaheptanyl, dioxacyclohexyl, zazaheptanyl, diazaheptanyl, dioxacyclooctaneyl, nitrogen-containing bridged heterocyclic groups (e.g., 5 to 20-membered nitrogen-containing bridged heterocyclic groups). Cyclic groups, such as azabicyclo[3.1.1]heptane group (e.g., 6-azabicyclo[3.1.1]heptane group), azabicyclo[2.2.1]heptane group, azabicyclo[3.2.1]octane group (e.g., 3-azabicyclo[3.2.1]octane group), azabicyclo[2.2.2]octane group, diazabicyclo[3.1.1]heptane group (e.g., 3,6-diazabicyclo[3.1.1]heptane group), diazabicyclo[2.2.1]heptane group (e.g., 2,5-diazabicyclo[2.1.1]heptane group). 2.1] heptanediol), diazabicyclo[3.2.1] octanediol (e.g., 3,8-diazabicyclo[3.2.1] octanediol), diazabicyclo[2.2.2] octanediol (e.g., 2,5-diazabicyclo[2.2.2] octanediol)), or 5 to 20 azinoniden (e.g., azinoniden[2.3] hexanediol, azinoniden[3.3] heptanediol, azinoniden[2.4] heptanediol, azinoniden[3.4] octanediol, azinoniden[3.5] nonanediol, azinoniden[4.4] nonanediol Alkyl group, azaspiro[4.5]decane group, azaspiro[5.5]undecane group, diazaspiro[2.3]hexane group, diazaspiro[3.3]heptane group, diazaspiro[2.4]heptane group, diazaspiro[3.4]octane group, diazaspiro[3.5]nonane group, diazaspiro[4.4]nonane group, diazaspiro[4.5]decane group, diazaspiro[5.5]undecane group, octahydrocyclopentano[c]pyrrole group, octahydropyrrolo[3,4-c]pyrrole group or decahydronaphthidine group); The ring Y 2 Optionally, it can be used by n2 R d2 Group substitution, each R d2 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 alkoxy groups; and n2 represents an integer between 0 and 20. (iii) The L2 represents methylene, ethylene, propylene or isopropylene, or L2 is not present.

13. The compound of formula (I) as described in any one of claims 1-12, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein... (i)R a6 express: Where R d3、 R d4 Each is independently selected from hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy; and R d3、 R d4 Not simultaneously hydrogen; and / or (ii) Each ring A 1 The same or different and each independently represents 4- to 20-membered subheterocyclic groups, C 3-20 Cycloalkylene, C 5-20 arylene, or 5- to 20-membered heteroarylene, such as each ring A 1 Each is expressed independently: Azahexacyclobutyl, diazahexacyclobutyl, oxadicyclobutyl, pyrrolidine, imidazoalkyl, pyrazolidine, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolidine, thiazoalkyl, piperidinyl, tetrahydropyridinyl, piperazine, 1,2,3,4-tetrahydropyrazine, hexahydropyrimidinyl, hexahydropyridazine, morpholinyl, thiomorpholinyl, etc. Azaheptanyl, azaheptanyl, dioxanecyclohexyl, azaheptanyl, azaheptanyl, dioxanecycloheptanyl, dioxanecycloheptanyl, azabicyclo[3.1.1]heptane (e.g., 6-azabicyclo[3.1.1]heptane), azabicyclo[2.2.1]heptane, azabicyclo[3.2.1]octane (e.g., 3-azabicyclo[3.2.1]) Octane derivatives), azabicyclo[2.2.2]octane derivatives, azabicyclo[3.1.1]heptane derivatives (e.g., 3,6-diazabicyclo[3.1.1]heptane derivatives), azabicyclo[2.2.1]heptane derivatives (e.g., 2,5-diazabicyclo[2.2.1]heptane derivatives), azabicyclo[3.2.1]octane derivatives (e.g., 3,8-diazabicyclo[3.2.1]octane derivatives). Alkyl group), diazabicyclo[2.2.2]octane group (e.g., 2,5-diazabicyclo[2.2.2]octane group), 5 to 20 nucleotide azaspirocyclic group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclopentenyl group, cyclohexyl group, cyclohexenyl group, cycloheptyl group, cyclooctyl group, decahydronaphthyl group, octahydrocyclopentadienyl group, octahydro-1H-indenyl group, 2,3-dihydro-1H-indenyl group, C 5-15 Spirocyclohexyl, adamantylene, norbornelyl, phenylene, naphthylene, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thiopheneylene, thiazolylene, isothiazolylene, thiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyrazinylene, indoleylene, isindoleylene, benzofuranylene, isobenzofuranylene, benzothiopheneylene, indoleylene, benzimidazole subunit, benzoxazole subunit, benziisoxazole subunit, benzothiazole subunit, benziisothiazole subunit, benzotriazole subunit Benzo[2,1,3]oxadiazole subunit, benzo[2,1,3]thiadiazole subunit, benzo[1,2,3]thiadiazole subunit, quinoline, isoquinoline, naphthidyl, cinnamoline, quinoline, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazole subunit, or imidazo[2,1-b]thiazole subunit, or y1 represents the integer 0, 1, 2 or 3, (R y1 ) a1 This indicates that each ring A1 can be independently and optionally controlled by a1 R. y1 Group substitution, each R y1 Each independently constitutes deuterium and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 alkenyl, and a1 represent integers from 0 to 10; and / or (iii) Each ring A 2 The same or different and each independently represents 4- to 20-membered subheterocyclic groups, C 3-20 Cycloalkylene, C 5-20 arylene, or 5- to 20-membered heteroarylene, such as each ring A 2 Each is expressed independently: Azahexacyclobutyl, diazahexacyclobutyl, oxadicyclobutyl, pyrrolidine, imidazoalkyl, pyrazolidine, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolidine, thiazoalkyl, piperidinyl, tetrahydropyridinyl, piperazine, 1,2,3,4-tetrahydropyrazine, hexahydropyrimidinyl, hexahydropyridazine, morpholinyl, thiomorpholinyl, etc. Azaheptanyl, azaheptanyl, dioxanecyclohexyl, azaheptanyl, azaheptanyl, dioxanecycloheptanyl, dioxanecycloheptanyl, azabicyclo[3.1.1]heptane (e.g., 6-azabicyclo[3.1.1]heptane), azabicyclo[2.2.1]heptane, azabicyclo[3.2.1]octane (e.g., 3-azabicyclo[3.2.1]) Octane derivatives), azabicyclo[2.2.2]octane derivatives, azabicyclo[3.1.1]heptane derivatives (e.g., 3,6-diazabicyclo[3.1.1]heptane derivatives), azabicyclo[2.2.1]heptane derivatives (e.g., 2,5-diazabicyclo[2.2.1]heptane derivatives), azabicyclo[3.2.1]octane derivatives (e.g., 3,8-diazabicyclo[3.2.1]octane derivatives). Alkyl group), diazabicyclo[2.2.2]octane group (e.g., 2,5-diazabicyclo[2.2.2]octane group), 5 to 20 nucleotide azaspirocyclic group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclopentenyl group, cyclohexyl group, cyclohexenyl group, cycloheptyl group, cyclooctyl group, decahydronaphthyl group, octahydrocyclopentadienyl group, octahydro-1H-indenyl group, 2,3-dihydro-1H-indenyl group, C 5-15 Spirocyclohexyl, adamantylene, norbornelyl, phenylene, naphthylene, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thiopheneylene, thiazolylene, isothiazolylene, thiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyrazinylene, indoleylene, isindoleylene, benzofuranylene, isobenzofuranylene, benzothiopheneylene, indoleylene, benzimidazole subunit, benzoxazole subunit, benziisoxazole subunit, benzothiazole subunit, benziisothiazole subunit, benzotriazole subunit Benzo[2,1,3]oxadiazole subunit, benzo[2,1,3]thiadiazole subunit, benzo[1,2,3]thiadiazole subunit, quinoline, isoquinoline, naphthidyl, cinnamoline, quinoline, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazole subunit, or imidazo[2,1-b]thiazole subunit, or y2 represents the integer 0, 1, 2, or 3, (R y2 ) a2 Indicates each ring A 2 Each can be independently and optionally controlled by a2 R y2 Group substitution, each R y2 Each independently constitutes deuterium and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 alkenyl, and a2 represent integers from 0 to 10; and / or (iv) Each ring A 3 The same or different and each independently represents 4- to 20-membered subheterocyclic groups, C 3-20 Cycloalkylene, C 5-20 arylene, or 5- to 20-membered heteroarylene, such as each ring A 3 Each is expressed independently: Azahexacyclobutyl, diazahexacyclobutyl, oxadicyclobutyl, pyrrolidine, imidazoalkyl, pyrazolidine, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolidine, thiazoalkyl, piperidinyl, tetrahydropyridinyl, piperazine, 1,2,3,4-tetrahydropyrazine, hexahydropyrimidinyl, hexahydropyridazine, morpholinyl, thiomorpholinyl, etc. Azaheptanyl, azaheptanyl, dioxanecyclohexyl, azaheptanyl, azaheptanyl, dioxanecycloheptanyl, dioxanecycloheptanyl, azabicyclo[3.1.1]heptane (e.g., 6-azabicyclo[3.1.1]heptane), azabicyclo[2.2.1]heptane, azabicyclo[3.2.1]octane (e.g., 3-azabicyclo[3.2.1]) Octane derivatives), azabicyclo[2.2.2]octane derivatives, azabicyclo[3.1.1]heptane derivatives (e.g., 3,6-diazabicyclo[3.1.1]heptane derivatives), azabicyclo[2.2.1]heptane derivatives (e.g., 2,5-diazabicyclo[2.2.1]heptane derivatives), azabicyclo[3.2.1]octane derivatives (e.g., 3,8-diazabicyclo[3.2.1]octane derivatives). Alkyl group), diazabicyclo[2.2.2]octane group (e.g., 2,5-diazabicyclo[2.2.2]octane group), 5 to 20 nucleotide azaspirocyclic group, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclopentenyl group, cyclohexyl group, cyclohexenyl group, cycloheptyl group, cyclooctyl group, decahydronaphthyl group, octahydrocyclopentadienyl group, octahydro-1H-indenyl group, 2,3-dihydro-1H-indenyl group, C 5-15 Spirocyclohexyl, adamantylene, norbornelyl, phenylene, naphthylene, furanylene, oxazolylene, isoxazolylene, oxadiazolylene, thiopheneylene, thiazolylene, isothiazolylene, thiazolylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyrazinylene, indoleylene, isindoleylene, benzofuranylene, isobenzofuranylene, benzothiopheneylene, indoleylene, benzimidazole subunit, benzoxazole subunit, benziisoxazole subunit, benzothiazole subunit, benziisothiazole subunit, benzotriazole subunit Benzo[2,1,3]oxadiazole subunit, benzo[2,1,3]thiadiazole subunit, benzo[1,2,3]thiadiazole subunit, quinoline, isoquinoline, naphthidyl, cinnamoline, quinoline, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidine subunit, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazole subunit, or imidazo[2,1-b]thiazole subunit, or y3 represents the integer 0, 1, 2, or 3, (R y3 ) a3 Indicates each ring A 3 Each can be independently and optionally controlled by a3 R y3 Group substitution, each R y3 Each independently constitutes deuterium and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl, and a3 represent integers from 0 to 10; and / or (v)R w1 Denotes a bond, or a C-chain of alternative substitutions, either straight or branched. 1-20 Alkylene, wherein the straight-chain or branched C 1-20 Any one or more methylene groups in the main carbon chain backbone of the alkylene group may optionally be replaced by one or more groups selected from the following: R a R b And any combination thereof, each group R a Each is independently selected from O, C(O), OC(O), S, S(O), S(O)2, and S(O)2N(R). a7 ), N(R a7 S(O)2、C(O)N(R) a7 ), N(R a7 C(O), N(R) a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each can be represented independently as H or C. 1-3 Alkyl groups, and when the straight-chain or branched C 1-20 Any two or more methylene groups in the main carbon chain backbone of an alkylene group are separated by two or more R groups. a During substitution, each group R a They are not directly connected to each other; each group R b Each is independently selected from optional substituted cycloalkylene groups (e.g., optional substituted C14 groups). 3-20 Cycloalkylene, optionally substituted arylene (e.g., optionally substituted C464), 5-20 arylene), optionally substituted heterocyclic groups (e.g., optionally substituted 4- to 20-membered heterocyclic groups), optionally substituted heteroarylene groups (e.g., optionally substituted 5- to 20-membered heteroarylene groups), alkynyl groups (e.g., C... 2-6 (e.g., C-ynyl), (e.g., C-yl) 2-6 (alkenyl groups) and any combination thereof, wherein the cycloalkyl group, the aryl group, the heterocyclic group, and the heteroaryl group are each independently and optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substituents of cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof, and the C-chain of said straight or branched groups. 1-20 One or more hydrogen atoms in the alkylene group may optionally be selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, or halogenated C. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substitution with cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof.

14. The compound of formula (I) as claimed in any one of claims 1-13, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the portion in the general formula LIN express: The aforementioned groups may optionally be selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl substituent substitution; and / or R w1 Indicates key, or R w1 express: -C 1-15 alkylene-; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -(R a (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -((C(R a14 )(R a15 )) n7 R a ) m5 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -(R b (C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -((C(R a14 )(R a15 )) n7 R b ) m5 -; -(C(R a8 )(R a9 )) n4 -(R a -R b -(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R a (C(R a1 0)(R a11 )) n5 ) m3 -(R b (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(R b -R a -(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(R b (C(R a10 )(R a11 )) n5 ) m3 -(R a (C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -R a -R b ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R a ) m3 -((C(R a12 )(R a13 )) n6 R b ) m4 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -R b -R a ) m3 -;or -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 R b ) m3 -((C(R a12 )(R a13 )) n6 R a ) m4 -; in, Each group R a Independently selected from O, C(O), OC(O), S, S(O), S(O)2, S(O)2N(R) a7 ), N(R a7 S(O)2、C(O)N(R) a7 ), N(R a7 C(O), N(R) a7 ) and N(R a7 )C(O)N(R a7 ), where each R a7 Each can be represented independently as H or C. 1-3 Alkyl groups; R groups b Independently selected from optional substituted cycloalkylene groups (e.g., optional substituted C14-C ... 3-20 Cycloalkylene, optionally substituted arylene (e.g., optionally substituted C464), 5-20 arylene), optionally substituted heterocyclic groups (e.g., optionally substituted 4- to 20-membered heterocyclic groups), optionally substituted heteroarylene groups (e.g., 5- to 20-membered heteroarylene groups), alkynyl groups (e.g., C... 2-6 (e.g., C-ynyl), (e.g., C-yl) 2-6 (alkenyl groups) and any combination thereof, wherein the cycloalkyl group, the aryl group, the heterocyclic group, and the heteroaryl group are each independently and optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substituents of cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof; R a8 R a9 R a10 R a11、 R a12 R a13 R a14 and R a15 Each of these groups independently represents H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, and halogenated C. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Cycloalkyl groups, 4- to 10-membered heterocyclic groups, and any combination thereof; and n4, n5, n6, n7, m3, m4, m5 are each independently selected from the integers 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and The C 1-15 Any one or more hydrogen atoms in the main carbon chain skeleton of the alkylene group may optionally be replaced by substituents selected from the following: deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, halogenated C. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof.

15. The compound of formula (I) as claimed in any one of claims 1-13, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein R w1 The structure of the following expression is represented as: -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(O(C(R a10 )(R a11 )) n5 ) m3 -(O(C(R a12 )(R a13 )) n6 ) m4 -(O(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -((C(R a12 )(R a13 )) n6 O) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 O) m3 -((C(R a12 )(R a13 )) n6 O) m4 -((C(R a14 )(R a15 )) n7 O) m5 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -(N(R a7 )(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )(C(R a10 )(R a11 )) n5 ) m3 -(N(R a7 )(C(R a12 )(R a13 )) n6 ) m4 -(N(R a7 )(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 N(R a7 )) m4 -((C(R a14 )(R a15 )) n7 N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(C(O)N(R a7 )-(C(R a12 )(R a13 )) n6 ) m4 -(C(O)N(R a7 )-(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 )) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 -C(O)N(R a7 )) m4 -((C(R a14 )(R a15 )) n7 -C(O)N(R a7 )) m5 -; -(C(R a8 )(R a9 )) n4 -(C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -C(O)N(R a7 )) m3 -((C(R a12 )(R a13 )) n6 O) m4 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -C(O)N(R a7 )-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 ))) n6 ) m4 -; -(C(R a8 )(R a9 )) n4 -(N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 ) m3 -(O-(C(R a12 )(R a13 )) n6 ) m4 -(O-(C(R a14 )(R a15 )) n7 ) m5 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)-(C(R a10 )(R a11 )) n5 -(O(C(R a12 )(R a13 )) n6 ) m3 -; -(C(R a8 )(R a9 )) n4 -N(R a7 )C(O)N(R a7 )-(C(R a10 )(R a11 )) n5 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -((C(R a12 )(R a13 ))) n6 -O) m4 -; -(C(R a8 )(R a9 )) n4 -((C(R a10 )(R a11 )) n5 -N(R a7 )C(O)) m3 -((C(R a12 )(R a13 )) n6 O) m4 -((C(R a14 )(R a15 )) n7 O) m5 -; -(C(R a8 )(R a9 )) n4 -(C(R a10 )(R a11 )) n5 -N(R a7 )C(O)-((C(R a12 )(R a13 )) n6 O) m3 -; -(C(R a8 (R) a9 )) n4 -(Asaryl-(C(R) a10 (R) a11 )) n5 ) m3 -; -(C(R a8 (R) a9 )) n4 -(Asaryl-(C(R) a10 (R) a11 )) n5 ) m3 -Asaryl-(C(R) a12 (R) a13 )) n6 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -Aspartic) m3 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -Aspartic) m3 -(C(R a12 (R) a13 )) n6 -Asaryl-; -(C(R a8 (R) a9 )) n4 -(heterocyclic group-(C(R)) a10 (R) a11 )) n5 ) m3 -; -(C(R a8 (R) a9 )) n4 -(heterocyclic group-(C(R)) a10 (R) a11 )) n5 ) m3 -(heterocyclic group-(C(R)) a12 (R) a13 )) n6 ) m4 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -heterocyclic group) m3 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -heterocyclic group) m3 -((C(R a12 (R) a13 )) n6 -heterocyclic group) m4 -; -(C(R a8 (R) a9 )) n4 -(hybridyl-(C(R) a10 (R) a11 )) n5 ) m3 -; -(C(R a8 (R) a9 )) n4 -(hybridyl-(C(R) a10 (R) a11 )) n5 ) m3 -(hybridyl-(C(R) a12 (R) a13 )) n6 ) m4 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -heteroaryl) m3 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -heteroaryl) m3 -((C(R a12 (R) a13 )) n6 -heteroaryl) m4 -; -(C(R a8 (R) a9 )) n4 -(cycloalkylene-(C(R) a10 (R) a11 )) n5 ) m3 -; -(C(R a8 (R) a9 )) n4 -(cycloalkylene-(C(R) a10 (R) a11 )) n5 ) m3 -(cycloalkylene-(C(R) a12 (R) a13 )) n6 ) m4 -; -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -cycloalkylene) m3 -;or -(C(R a8 (R) a9 )) n4 -((C(R a10 (R) a11 )) n5 -cycloalkylene) m3 -((C(R a12 (R) a13 )) n6 -cycloalkylene) m4 -; Among them, each R a7 Independently represent H or C 1-3 alkyl; The cycloalkylene (e.g., C) 3-20 cycloalkylene), said arylene (e.g., C10) 5-20 The arylene group (e.g., 4- to 20-membered heterocyclic group) and the heteroarylene group (e.g., 5- to 20-membered heteroarylene group) are optionally selected independently from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substituents of cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof; R a8 R a9 R a10 R a11、 R a12 R a13 R a14 and R a15 Each of the following groups can be independently represented: H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, and halogenated C. 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Cycloalkyl groups, 4- to 10-membered heterocyclic groups, and any combination thereof; and n4, n5, n6, n7, m3, m4, m5 are each independently selected from the integers 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

16. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein R w1 express: -CH2-、-(CH2)2-、-(CH2)3-、-(CH2)4-、-(CH2)5-、-(CH2)6-、-(CH2)7-、-(CH2)8-、-(CH2)9-、-(CH2) 10 -、-(CH2)11-、-(CH2) 12 -、-(CH2) 13 -、-(CH2) 14 -、-(CH2) 15 -; -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10 -、-(CH2)1-O-、-(CH2)2-O-、-(CH2)3-O-、-(CH2)4-O-、-(CH2)5-O-、-(CH2)6-O-、-(CH2)7-O-、-(CH2)8-O-、-(CH2)9-O-、-(CH2) 10 -O-,-CH2-O-CH2-,-CH2-O-(CH2)2-,-(CH2) l -O-(CH2)3-,-(CH2)1-O-(CH2)4-,-(CH2)1-O-(CH2)5-,-(CH2)1-O-(CH2)6-,-(CH2)1-O-(CH2)7-,-(CH2)1-O-(CH2)8-,-(CH2)1-O-(CH2)9-,-(CH2)1-O-(CH2) 10 -、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)2-O-(CH2)9-、-(CH2)2-O-(CH2) 10 -、-(CH2)3-O-(CH2)1-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2)5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH 2)4-O-(CH2)3-,-(CH2)4-O-(CH2)4-,-(CH2)4-O-(CH2)5-,-(CH2)4-O-(CH2)6-,-(CH2)5-O-(CH2)1-,-(CH2)5-O-(CH2)2-,-(CH2)5-O-(CH2)3-,-(CH2)5-O-(CH2)4-,-(CH2)5-O-(CH2)5-,-(CH2)6-O-( CH2)1-、-(CH2)6-O-(CH2)2-、-(CH2)6-O-(CH2)3-、-(CH2)6-O-(CH2)4-、-(CH2)7-O-(CH2)1-、-(CH2)7-O-(CH2)2-、-(CH2)7-O-(CH2)3-、-(CH2)8-O-(CH2)1-、-(CH2)8-O-(CH2)2-、-CH(CH3)-O-(CH2)1- -CH(CH3)-O-(CH2)2-, -CH(CH3)-O-(CH2)3-, -CH(CH3)-O-(CH2)4-, -CH(CH3)-O-(CH2)5-, -CH(CH3)-O-(CH2)6-, -CH(CH3)-O-(CH2)7-, -CH(CH3)-O-(CH2)8-, -CH(CH3)-O-(CH2)9-, -CH(CH3)-O-(CH2) 10 -、-(O(CH2)2)2-、-(O(CH2)2)3-、-(O(CH2)2)4-、-(O(CH2)2)5-、-(O(CH2)2)6-、-(O(CH2)2)7-、-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2 )2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)7-、-CH2- (O(CH2)2)1-OCH2-、-CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-C H2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-(CH2)2-(O(CH2)2)2-、 -(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(C H2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2 )3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4- (O(CH2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2-(O(CH2)3)2-、-( CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-(CH2)3-(O(CH2)3)4-、-CH2-O-(CH2)2-O-(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2 )2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)2-O-(CH2)3-O-(CH2)2-、-(CH2)2-(O(CH2)3)2-(O(CH2)2)2-、-(CH2)3-O-(CH2)3-O-(CH2)2-、-(CH2)3-(O(CH2)3)2-(O(CH2)2)2-、-CH2-O-(CH2)2-O-CH2-、-(CH2)2-O-(CH2)2-O-CH2-、-(CH2)2-(O(CH2)2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)3-O-(CH2)3-、-(CH2)2-(O(CH2)2)4-O-(CH2)3-、-(CH2)5-(O(CH2)2)2-O-(CH2)5-、-(CH2)5-(O(CH2)2)2-O-(CH2)6-、-(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-(CH2)1-N(R a7 )-(CH2)7-、-(CH2)1-N(R a7 )-(CH2)8-、-(CH2)1-N(R a7 )-(CH2)9-、-(CH2)1-N(R a7 )-(CH2) 10 -、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)7-、-N(R a7 )-(CH2)8-、-N(R a7 )-(CH2)9-、-N(R a7 )-(CH2) 10 -、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)7-、-(CH2)2-N(R a7 )-(CH2)8-、-(CH2)2-N(R a7 )-(CH2)9-、-(CH2)2-N(R a7 )-(CH2) 10 -、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2) l -、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-、-CH(CH3)-N(R a7 )-(CH2)7-、-CH(CH3)-N(R a7 )-(CH2)8-、-CH(CH3)-N(R a7 )-(CH2)9-、-CH(CH3)-N(R a7 )-(CH2) 10 -, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2)2C(O)NH (CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(CH2)5C(O) NH(CH2)5-, -(CH2)6C(O)NH(CH2)7-, -(CH2)6C(O)NH(CH2)6-, -(CH2)7C(O)NH(CH2)7-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(C H2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH 2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3NHC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)6NHC(O)( CH2)7-, -(CH2)6NHC(O)(CH2)6-, -(CH2)7NHC(O)(CH2)7-, -(CH2)4NHC(O)(CH2)8-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -phenylene-C H2-, -phenylene-(CH2)2-, -phenylene-(CH2)3-, -phenylene-(CH2)4-, -phenylene-(CH2)5-, -phenylene-(CH2)6-, -phenylene-(CH2)7-, -phenylene-(CH2)8-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -CH2-phenylene-(CH2)7-, -CH2-phenylene-(CH2)8-, -(CH2)2-phenylene-(CH2)1--(CH2)2-phenylene-(CH2)2-, -(CH2)2-phenylene-(CH2)3-, -(CH2)2-phenylene-(CH2)4-, -(CH2)2-phenylene-(CH2)5-, -(CH2)2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)7-, -(CH2)2-phenylene-(CH2)8-, -(CH2)3-phenylene-CH2-, -(CH2)3-phenylene-(CH2)2-, -(CH2)3-phenylene-(CH2)3-, -(CH2)3-phenylene-(CH2)4-, -(CH2)3-phenylene-(CH2)5-, -(CH2)3-phenylene -(CH2)6-, -(CH2)3-phenylene-(CH2)7-, -(CH2)3-phenylene-(CH2)8-, -(CH2)4-phenylene-CH2-, -(CH2)4-phenylene-(CH2)2-, -(CH2)4-phenylene-(CH2)3-, -(CH2)4-phenylene-(CH2)4-, -(CH2)4-phenylene-(CH2)5-, -(CH2)4-phenylene-(CH2)6-, -(CH2)4-phenylene-(CH2)7-, -(CH2)4-phenylene-(CH2)8-, -(CH2)5-phenylene-(CH2)1-, -(CH2)5-phenylene-(CH2)2-, - (CH2)5-Phenylidene-(CH2)3-, -(CH2)5-Phenylidene-(CH2)4-, -(CH2)5-Phenylidene-(CH2)5-, -(CH2)5-Phenylidene-(CH2)6-, -(CH2)5-Phenylidene-(CH2)7-, -(CH2)5-Phenylidene-(CH2)8-, -(CH2)6-Phenylidene-(CH2)1-, -(CH2)6-Phenylidene-(CH2)2-, -(CH2)6-Phenylidene-(CH2)3-, -(CH2)6-Phenylidene-(CH2)4-, -(CH2)6-Phenylidene-(CH2)5-, -(CH2)6-Phenylidene-(CH2)6-, -(CH2)6-Phenylidene-(CH2)6- Phenylacet-(CH2)7-, -(CH2)6-phenylene-(CH2)8-, -(CH2)7-phenylene-(CH2)1-, -(CH2)7-phenylene-(CH2)2-, -(CH2)7-phenylene-(CH2)3-, -(CH2)7-phenylene-(CH2)4-, -(CH2)7-phenylene-(CH2)8-, -(CH2)8-phenylene-CH2-, -(CH2)8-phenylene-(CH2)2-, -(CH2)8-phenylene-(CH2)3-, -(CH2)8-phenylene-(CH2)4-, -(CH2)8-phenylene-(CH2)5-, -(CH2)8-phenylene-(CH2)6-,-(CH2)8-phenylene-(CH2)7-,-N(R, a7 )-CH2-phenylene-CH2-、-N(R a7 )-CH2-phenylene-(CH2)2-、-N(R a7 )-CH2-phenylene-(CH2)3-、-N(R a7 )-CH2-phenylene-(CH2)4-、-N(R a7 )-CH2-phenylene-(CH2)5-、-N(R a7 )-CH2-phenylene-(CH2)6-、-N(R a7 )-CH2-phenylene-(CH2)7-、-N(R a7 )-CH2-phenylene-(CH2)8-、-CH2-N(R a7 )-CH2-phenylene-CH2-、-CH2-N(R a7 )-CH2-phenylene-(CH2)2-、-CH2-N(R a7 )-CH2-phenylene-(CH2)3-、-CH2-N(R a7 )-CH2-phenylene-(CH2)4-、-CH2-N(R a7 )-CH2-phenylene-(CH2)5-、-CH2-N(R a7 )-CH2-phenylene-(CH2)6-、-CH2-N(R a7 )-CH2-phenylene-(CH2)7-、-CH2-N(R a7 )-CH2-phenylene-(CH2)8-、-CH2-N(R a7 )-(CH2)2-phenylene-CH2-、-CH2-N(R a7 )-(CH2)2-phenylene-(CH2)2-、-CH2-N(R a7 )-(CH2)2-phenylene-(CH2)3-、-CH2-N(R a7 )-(CH2)2-phenylene-(CH2)4-、-CH2-N(R a7 )-(CH2)2-phenylene-(CH2)5-、-CH2-N(R a7 )-(CH2)2-phenylene-(CH2)6-、-CH2-N(R a7 )-(CH2)2-phenylene-(CH2)7-、-CH2-N(R a7 )-(CH2)2-phenylene-(CH2)8-、-(CH2)2-N(R a7 )-CH2-phenylene-CH2-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)2-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)4-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)5-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)6-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)7-、-(CH2)2-N(R a7 )-CH2-phenylene-(CH2)8-、-(CH2)3-N(R a7 )-CH2-phenylene-CH2-、-(CH2)3-N(R a7 )-CH2-phenylene-(CH2)2-、-(CH2)3-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)3-N(R a7 )-CH2-phenylene-(CH2)8-、-(CH2)4-N(R a7 )-CH2-phenylene-CH2-、-(CH2)4-N(R a7 )-CH2-phenylene-(CH2)2-、-(CH2)4-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)4-N(R a7 )-CH2-phenylene-(CH2)8-、-(CH2)5-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)5-N(R a7 )-CH2-phenylene-(CH2)8-、-(CH2)6-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)6-N(R a7 )-CH2-phenylene-(CH2)8-、-(CH2)7-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)8-N(R a7 )-CH2-phenylene-CH2-、-(CH2)8-N(R a7 )-CH2-phenylene-(CH2)2-、-(CH2)8-N(R a7 )-CH2-phenylene-(CH2)3-、-(CH2)8-N(R a7 )-CH2-phenylene-(CH2)4-、-(CH2)8-N(R a7 )-CH2-phenylene-(CH2)5-、-(CH2)8-N(R a7 -CH2-Phenylidene-(CH2)6-, -piperidinyl-CH2-, -piperidinyl-(CH2)2-, -piperidinyl-(CH2)3-, -piperidinyl-(CH2)4-, -piperidinyl-(CH2)5-, -piperidinyl-(CH2)6-, -piperidinyl-(CH2)7-, -piperidinyl-(CH2)8-, -CH2-piperidinyl-CH2-, -CH2-piperidinyl-(CH2)2-, -CH2-piperidinyl-(CH2)3-, -CH2-piperidinyl-(CH2)4-, -CH2-piperidinyl-(CH2)5-, -CH2-piperidinyl-(CH2)6-, -CH2-piperidinyl-(CH2)7- -CH2-piperidinyl-(CH2)8-, -(CH2)2-piperidinyl-(CH2)1-, -(CH2)2-piperidinyl-(CH2)2-, -(CH2)2-piperidinyl-(CH2)3-, -(CH2)2-piperidinyl-(CH2)4-, -(CH2)2-piperidinyl-(CH2)5-, -(CH2)2-piperidinyl-(CH2)6-, -(CH2)2-piperidinyl-(CH2)7-, -(CH2)2-piperidinyl-(CH2)8-, -(CH2)3-piperidinyl-CH2-, -(CH2)3-piperidinyl-(CH2)2-, -(CH2)3-piperidinyl-(CH2)3-, -( CH2)3-piperidinyl-(CH2)4-, -(CH2)3-piperidinyl-(CH2)5-, -(CH2)3-piperidinyl-(CH2)6-, -(CH2)3-piperidinyl-(CH2)7-, -(CH2)3-piperidinyl-(CH2)8-, -(CH2)4-piperidinyl-CH2-, -(CH2)4-piperidinyl-(CH2)2-, -(CH2)4-piperidinyl-(CH2)3-, -(CH2)4-piperidinyl-(CH2)4-, -(CH2)4-piperidinyl-(CH2)5-, -(CH2)4-piperidinyl-(CH2)6-, -(CH2)4-piperidinyl-(CH2)7-, -( CH2)4-piperidinyl-(CH2)8-, -(CH2)5-piperidinyl-(CH2)1-, -(CH2)5-piperidinyl-(CH2)2-, -(CH2)5-piperidinyl-(CH2)3-, -(CH2)5-piperidinyl-(CH2)4-, -(CH2)5-piperidinyl-(CH2)5-, -(CH2)5-piperidinyl-(CH2)6-, -(CH2)5-piperidinyl-(CH2)7-, -(CH2)5-piperidinyl-(CH2)8-, -(CH2)6-piperidinyl-(CH2)1-, -(CH2)6-piperidinyl-(CH2)2-, -(CH2)6-piperidinyl-(CH2)3--(CH2)6-piperidinyl-(CH2)4-, -(CH2)6-piperidinyl-(CH2)5-, -(CH2)6-piperidinyl-(CH2)6-, -(CH2)6-piperidinyl-(CH2)7-, -(CH2)6-piperidinyl-(CH2)8-, -(CH2)7-piperidinyl-(CH2)1-, -(CH2)7-piperidinyl-(CH2)2-, -(CH2)7-piperidinyl-(CH2)3-, -(CH2)7-piperidinyl -(CH2)4-, -(CH2)7-piperidinyl-(CH2)8-, -(CH2)8-piperidinyl-CH2-, -(CH2)8-piperidinyl-(CH2)2-, -(CH2)8-piperidinyl-(CH2)3-, -(CH2)8-piperidinyl-(CH2)4-, -(CH2)8-piperidinyl-(CH2)5-, -(CH2)8-piperidinyl-(CH2)6-, -(CH2)8-piperidinyl-(CH2)7-, -N(R, a7 )-CH2-piperidine-CH2-,-N(R a7 )-CH2-piperidine-(CH2)2-、-N(R a7 )-CH2-piperidine-(CH2)3-、-N(R a7 )-CH2-piperidine-(CH2)4-,-N(R a7 )-CH2-piperidinyl-(CH2)5-、-N(R a7 )-CH2-piperidine-(CH2)6-、-N(R a7 )-CH2-piperidine-(CH2)7-、-N(R a7 )-CH2-piperidine-(CH2)8-、-CH2-N(R a7 )-CH2-piperidine-CH2-,-CH2-N(R a7 )-CH2-piperidine-(CH2)2-, -CH2-N(R a7 )-CH2-piperidine-(CH2)3-、-CH2-N(R a7 )-CH2-piperidinyl-(CH2)4-, -CH2-N(R a7 )-CH2-piperidine-(CH2)5-,-CH2-N(R a7 )-CH2-piperidinyl-(CH2)6-,-CH2-N(R a7 )-CH2-piperidine-(CH2)7-,-CH2-N(R a7 )-CH2-piperidine-(CH2)8-、-CH2-N(R a7 )-(CH2)2-piperidine-CH2-,-CH2-N(R a7 )-(CH2)2-piperidine-(CH2)2-、-CH2-N(R a7 )-(CH2)2-piperidine-(CH2)3-、-CH2-N(R a7 )-(CH2)2-piperidine-(CH2)4-、-CH2-N(R a7 )-(CH2)2-piperidine-(CH2)5-、-CH2-N(R a7 )-(CH2)2-piperidine-(CH2)6-,-CH2-N(R a7 )-(CH2)2-piperidine-(CH2)7-、-CH2-N(R a7 )-(CH2)2-piperidine-(CH2)8-、-(CH2)2-N(R a7 )-CH2-piperidine-CH2-、-(CH2)2-N(R a7 )-CH2-piperidine-(CH2)2-、-(CH2)2-N(R a7 )-CH2-piperidine-(CH2)3-、-(CH2)2-N(R a7 )-CH2-piperidine-(CH2)4-、-(CH2)2-N(R a7 )-CH2-piperidine-(CH2)5-、-(CH2)2-N(R a7 )-CH2-piperidinyl-(CH2)6-、-(CH2)2-N(R a7 )-CH2-piperidine-(CH2)7-、-(CH2)2-N(R a7 )-CH2-piperidine-(CH2)8-,-(CH2)3-N(R a7 )-CH2-piperidine-CH2-、-(CH2)3-N(R a7 )-CH2-piperidine-(CH2)2-,-(CH2)3-N(R a7 )-CH2-piperidine-(CH2)3-、-(CH2)3-N(R a7 )-CH2-piperidinyl-(CH2)8-,-(CH2)4-N(R a7 )-CH2-piperidine-CH2-、-(CH2)4-N(R a7 )-CH2-piperidine-(CH2)2-,-(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)3-,-(CH2)4-N(R a7 )-CH2-piperidinyl-(CH2)8-,-(CH2)5-N(R a7 )-CH2-piperidine-(CH2)3-,-(CH2)5-N(R a7 )-CH2-piperidinyl-(CH2)8-,-(CH2)6-N(R a7 )-CH2-piperidine-(CH2)3-,-(CH2)6-N(R a7 )-CH2-piperidinyl-(CH2)8-,-(CH2)7-N(R a7 )-CH2-piperidine-(CH2)3-、-(CH2)8-N(R a7 )-CH2-piperidine-CH2-、-(CH2)8-N(R a7 )-CH2-piperidine-(CH2)2-、-(CH2)8-N(R a7 )-CH2-piperidine-(CH2)3-、-(CH2)8-N(R a7 )-CH2-piperidinyl-(CH2)4-,-(CH2)8-N(R a7 )-CH2-piperidine-(CH2)5-,-(CH2)8-N(R a7 -CH2-piperazinyl-(CH2)6-, -piperazinyl-CH2-, -piperazinyl-(CH2)2-, -piperazinyl-(CH2)3-, -piperazinyl-(CH2)4-, -piperazinyl-(CH2)5-, -piperazinyl-(CH2)6-, -piperazinyl-(CH2)7-, -piperazinyl-(CH2)8-, -CH2-piperazinyl-CH2-, -CH2-piperazinyl-(CH2)2-, -CH2-piperazinyl-(CH2)3-, -CH2-piperazinyl-(CH2)4-, -CH2-piperazinyl-(CH2)5-, -CH2-piperazinyl-(CH2)6-, -CH2-piperazinyl-(CH2)7 -, -CH2-piperazinyl-(CH2)8-, -(CH2)2-piperazinyl-(CH2)1-, -(CH2)2-piperazinyl-(CH2)2-, -(CH2)2-piperazinyl-(CH2)3-, -(CH2)2-piperazinyl-(CH2)4-, -(CH2)2-piperazinyl-(CH2)5-, -(CH2)2-piperazinyl-(CH2)6-, -(CH2)2-piperazinyl-(CH2)7-, -(CH2)2-piperazinyl-(CH2)8-, -(CH2)3-piperazinyl-CH2-, -(CH2)3-piperazinyl-(CH2)2-, -(CH2)3-piperazinyl-(CH2)3-, -( CH2)3-piperazinyl-(CH2)4-, -(CH2)3-piperazinyl-(CH2)5-, -(CH2)3-piperazinyl-(CH2)6-, -(CH2)3-piperazinyl-(CH2)7-, -(CH2)3-piperazinyl-(CH2)8-, -(CH2)4-piperazinyl-CH2-, -(CH2)4-piperazinyl-(CH2)2-, -(CH2)4-piperazinyl-(CH2)3-, -(CH2)4-piperazinyl-(CH2)4-, -(CH2)4-piperazinyl-(CH2)5-, -(CH2)4-piperazinyl-(CH2)6-, -(CH2)4-piperazinyl-(CH2)7-, -( CH2)4-piperazinyl-(CH2)8-, -(CH2)5-piperazinyl-(CH2)1-, -(CH2)5-piperazinyl-(CH2)2-, -(CH2)5-piperazinyl-(CH2)3-, -(CH2)5-piperazinyl-(CH2)4-, -(CH2)5-piperazinyl-(CH2)5-, -(CH2)5-piperazinyl-(CH2)6-, -(CH2)5-piperazinyl-(CH2)7-, -(CH2)5-piperazinyl-(CH2)8-, -(CH2)6-piperazinyl-(CH2)1-, -(CH2)6-piperazinyl-(CH2)2-, -(CH2)6-piperazinyl-(CH2)3--(CH2)6-piperazinyl-(CH2)4-, -(CH2)6-piperazinyl-(CH2)5-, -(CH2)6-piperazinyl-(CH2)6-, -(CH2)6-piperazinyl-(CH2)7-, -(CH2)6-piperazinyl-(CH2)8-, -(CH2)7-piperazinyl-(CH2)1-, -(CH2)7-piperazinyl-(CH2)2-, -(CH2)7-piperazinyl-(CH2)2- Zimine-(CH2)3-, -(CH2)7-piperazinyl-(CH2)4-, -(CH2)8-piperazinyl-CH2-, -(CH2)8-piperazinyl-(CH2)2-, -(CH2)8-piperazinyl-(CH2)3-, -(CH2)8-piperazinyl-(CH2)4-, -(CH2)8-piperazinyl-(CH2)5-, or -(CH2)8-piperazinyl-(CH2)6-; Among them, each R a7 Independently represent H or C 1-3 alkyl; The phenylene, the piperazine group, and the piperidinyl group are each optionally selected from deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, oxo, C 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, C 3-6 cycloalkyl, halogenated C 3-6 cycloalkyl, deuterated C 3-6 Substitution with cycloalkyl, 4- to 10-membered heterocyclic groups and any combination thereof.

17. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein... LIN represents: a bond, C(O), C(O)NH, NHC(O), -CH2-, -(CH2)2-, -(CH2)3-, -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, -(CH2)8-, -(CH2)9-, -(CH2) 10 -, -(CH2)11-, -(CH2) 12 -, -(CH2) 13 -, -(CH2) 14 -, -(CH2) 15 -; -O-CH2-, -O-(CH2)2-, -O-(CH2)3-, -O-(CH2)4-, -O-(CH2)5-, -O-(CH2)6-, -O-(CH2)7-, -O-(CH2)8-, -O-(CH2)9-, -O-(CH2) 10 -, -(CH2)1-O-, -(CH2)2-O-, -(CH2)3-O-, -(CH2)4-O-, -(CH2)5-O-, -(CH2)6-O-, -(CH2)7-O-, -(CH2)8-O-, -(CH2)9-O-, -(CH2) 10 -O-,-CH2-O-CH2-,-CH2-O-(CH2)2-,-(CH2)1-O-(CH2)3-,-(CH2)1-O-(CH2)4-,-(CH2)1-O-(CH2)5-,-(CH2)1-O-(CH2)6-,-(CH2)1-O-(CH2)7-,-( CH2)1-O-(CH2)8-、-(CH2)2-O-(CH2)1-、-(CH2)2-O-(CH2)2-、-(CH2)2-O-(CH2)3-、-(CH2)2-O-(CH2)4-、-(CH2)2-O-(CH2)5-、-(CH2)2-O-(CH2)6-、-(CH2)2-O-(CH2)7-、-(CH2)2-O-(CH2)8-、-(CH2)3-O-(CH2)2-、-(CH2)3-O-(CH2)3-、-(CH2)3-O-(CH2)4-、-(CH2)3-O-(CH2 )5-、-(CH2)3-O-(CH2)6-、-(CH2)3-O-(CH2)7-、-(CH2)4-O-(CH2)1-、-(CH2)4-O-(CH2)2-、-(CH2)4-O-(CH2)3-、-(CH2)4-O-(CH2)4-、-(CH2)4-O-(C H2)5-、-(CH2)4-O-(CH2)6-、-(CH2)5-O-(CH2)1-、-(CH2)5-O-(CH2)2-、- (CH2)5-O-(CH2)3-、-(CH2)5-O-(CH2)4-、-(CH2)5-O-(CH2)5-、-(CH2)6-O -(CH2)1-,-(CH2)6-O-(CH2)2-,-(CH2)6-O-(CH2)3-,-(CH2)6-O-(CH2)4-,-(CH2)7-O-(CH2)1-,-(CH2)7-O-(CH2)2-,-(CH2)7-O-(CH2)3-,-(CH2)8-O-(CH2)1-,-(CH2)8-O-(CH2)2-,-CH(CH3)-O-(CH2)1-,-CH(CH3)-O-(CH2)2-,-CH(CH3)-O-(CH2)3-,-CH(CH3)-O-(CH2)4-,-CH(CH3)-O-(CH2)5 -CH(CH3)-O-(CH2)6-,-CH(CH3)-O-(CH2)7-,-CH(CH3)-O-(CH2)8-,-(O(CH2)2)2-,-(O(CH2)2)3-,-(O(CH2)2)4-,-(O(CH2)2)5-,-(O(CH2)2)6-,-CH2-(O(CH2)2)2-、-CH2-(O(CH2)2)3-、-CH2-(O(CH2)2)4-、-CH2-(O(CH2)2)5-、-CH2-(O(CH2)2)6-、-CH2-(O(CH2)2)1-OCH2-、 -CH2-(O(CH2)2)2-OCH2-、-CH2-(O(CH2)2)3-OCH2-、-CH2-(O(CH2)2)4-OCH2-、-CH2-(O(CH2)2)5-OCH2-、-CH2-(O(CH2)2)6-OCH 2-、-(CH2)2-(O(CH2)2)2-、-(CH2)2-(O(CH2)2)3-、-(CH2)2-(O(CH2)2)4-、-(CH2)2-(O(CH2)2)5-、-(CH2)2-(O(CH2)2)6-、-(CH2)3-(O(CH2)2)2-、-(CH2)3-(O(CH2)2)3-、-(CH2)3-(O(CH2)2)4-、-(CH2)3-(O(CH2)2)5-、-(CH2)4-(O(CH2)2)2-、-(CH2)4-(O(C H2)2)3-、-(CH2)4-(O(CH2)2)4-、-(CH2)4-(O(CH2)2)5-、-CH2-(O(CH2)3)2-、-CH2-(O(CH2)3)3-、-CH2-(O(CH2)3)4-、-(CH2)2- (O(CH2)3)2-、-(CH2)2-(O(CH2)3)3-、-(CH2)2-(O(CH2)3)4-、-(CH2)3-(O(CH2)3)2-、-(CH2)3-(O(CH2)3)3-、-CH2-O-(CH2)2-O -(CH2)3-、-CH2-(O(CH2)2)2-(O(CH2)3)2-、(CH2)2-O-(CH2)2-O-(CH2)3-、-(CH2)2-(O(CH2)2)2-(O(CH2)3)2-、-(CH2)3-O-(CH2)2-O-(CH2)3-、-(CH2)3-(O(CH2)2)2-(O(CH2)3)2-、-CH2-O-(CH2)3-O-(CH2)2-、-CH2-(O(CH2)3)2-(O(CH2)2)2-、(CH2)1-N(R、 a7 )-(CH2)1-、-(CH2)1-N(R a7 )-(CH2)2-、-(CH2)1-N(R a7 )-(CH2)3-、-(CH2)1-N(R a7 )-(CH2)4-、-(CH2)1-N(R a7 )-(CH2)5-、-(CH2)1-N(R a7 )-(CH2)6-、-N(R a7 )-(CH2)1-、-N(R a7 )-(CH2)2-、-N(R a7 )-(CH2)3-、-N(R a7 )-(CH2)4-、-N(R a7 )-(CH2)5-、-N(R a7 )-(CH2)6-、-(CH2)2-N(R a7 )-(CH2)1-、-(CH2)2-N(R a7 )-(CH2)2-、-(CH2)2-N(R a7 )-(CH2)3-、-(CH2)2-N(R a7 )-(CH2)4-、-(CH2)2-N(R a7 )-(CH2)5-、-(CH2)2-N(R a7 )-(CH2)6-、-(CH2)3-N(R a7 )-(CH2)1-、-(CH2)3-N(R a7 )-(CH2)2-、-(CH2)3-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)1-、-(CH2)4-N(R a7 )-(CH2)2-、-(CH2)4-N(R a7 )-(CH2)3-、-(CH2)4-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)1-、-(CH2)5-N(R a7 )-(CH2)2-、-(CH2)5-N(R a7 )-(CH2)3-、-(CH2)5-N(R a7 )-(CH2)4-、-(CH2)5-N(R a7 )-(CH2)5-、-(CH2)6-N(R a7 )-(CH2)1-、-(CH2)6-N(R a7 )-(CH2)2-、-(CH2)6-N(R a7 )-(CH2)3-、-(CH2)7-N(R a7 )-(CH2)1-、-(CH2)7-N(R a7 )-(CH2)2-、-(CH2)7-N(R a7 )-(CH2)3-、-(CH2)8-N(R a7 )-(CH2)1-、-(CH2)8-N(R a7 )-(CH2)2-、-(CH2)8-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)1-、-CH(CH3)-N(R a7 )-(CH2)2-、-CH(CH3)-N(R a7 )-(CH2)3-、-CH(CH3)-N(R a7 )-(CH2)4-、-CH(CH3)-N(R a7 )-(CH2)5-、-CH(CH3)-N(R a7 )-(CH2)6-, -C(O)NHCH2-, -C(O)NH(CH2)2-, -C(O)NH(CH2)3-, -C(O)NH(CH2)4-, -C(O)NH(CH2)5-, -CH2C(O)NHCH2-, -(CH2)2C(O)NH(CH2)2-, -(CH2 )2C(O)NH(CH2)3-, -(CH2)2C(O)NH(CH2)4-, -(CH2)2C(O)NH(CH2)5-, -(CH2)3C(O)NH(CH2)3-, -(CH2)3C(O)NH(CH2)4-, -(CH2)4C(O)NH(CH2)4-, -(C H2)5C(O)NH(CH2)5-, -(CH2)2C(O)NH(CH2)2-O-(CH2)2-, -NHC(O)CH2-, -NHC(O)(CH2)2-, -NHC(O)(CH2)3-, -NHC(O)(CH2)4-, -NHC(O)(CH2)5-, -CH2 NHC(O)CH2-, -(CH2)2NHC(O)(CH2)2-, -(CH2)2NHC(O)(CH2)3-, -(CH2)2NHC(O)(CH2)4-, -(CH2)2NHC(O)(CH2)5-, -(CH2)3NHC(O)(CH2)3-, -(CH2)3N HC(O)(CH2)4-, -(CH2)4NHC(O)(CH2)4-, -(CH2)5NHC(O)(CH2)5-, -(CH2)2NHC(O)(CH2)2-O-(CH2)2-, -(CH2)4NHC(O)CH2-, -CH2-phenylene-CH2-, -CH2-phenylene-(CH2)2-, -CH2-phenylene-(CH2)3-, -CH2-phenylene-(CH2)4-, -CH2-phenylene-(CH2)5-, -CH2-phenylene-(CH2)6-, -(CH2)2-phenylene-(CH2)1-, -(CH2)2-phenylene-(CH2)2-, -(CH2) 2-Phenylidene-(CH2)3-, -(CH2)2-Phenylidene-(CH2)4-, -(CH2)2-Phenylidene-(CH2)5-, -(CH2)3-Phenylidene-CH2-, -(CH2)3-Phenylidene-(CH2)2-, -(CH2)3-Phenylidene-(CH2)3-, -(CH2)3-Phenylidene-(CH2)4-, -(CH2)3-Phenylidene-(CH2)5-, -(CH2)4-Phenylidene-CH2-, -(CH2)4-Phenylidene-(CH2)2-, -(CH2)4-Phenylidene-(CH2)3-, -(CH2)4-Phenylidene-(CH2)4-, -(CH2)4-Phenylidene-(CH2)5-,-CH2-piperidinyl-CH2-, -CH2-piperidinyl-(CH2)2-, -CH2-piperidinyl-(CH2)3-, -CH2-piperidinyl-(CH2)4-, -CH2-piperidinyl-(CH2)5-, -CH2-piperidinyl-(CH2)6-, -(CH2)2-piperidinyl-(CH2)1-, -(CH2)2-piperidinyl-(CH2)2-, -(CH2)2-piperidinyl-(CH2)3-, -(CH2)2-piperidinyl-(CH2)4-, -(CH2)2-piperidinyl-( CH2)5-, -(CH2)3-piperidinyl-CH2-, -(CH2)3-piperidinyl-(CH2)2-, -(CH2)3-piperidinyl-(CH2)3-, -(CH2)3-piperidinyl-(CH2)4-, -(CH2)3-piperidinyl-(CH2)5-, -CH2-piperazinyl-CH2-, -CH2-piperazinyl-(CH2)2-, -CH2-piperazinyl-(CH2)3-, -CH2-piperazinyl-(CH2)4-, -CH2-piperazinyl-(CH2)5-, -(CH2)2 -piperazinyl-(CH2)1-, -(CH2)2-piperazinyl-(CH2)2-, -(CH2)2-piperazinyl-(CH2)3-, -(CH2)2-piperazinyl-(CH2)4-, -(CH2)2-piperazinyl-(CH2)5-, -(CH2)3-piperazinyl-CH2-, -(CH2)3-piperazinyl-(CH2)2-, -(CH2)3-piperazinyl-(CH2)3-, -(CH2)3-piperazinyl-(CH2)4-, -(CH2)3-piperazinyl-(CH2)5-, -(C H2)4-piperazinyl-CH2-, -(CH2)4-piperazinyl-(CH2)2-, -(CH2)4-piperazinyl-(CH2)3-, -(CH2)4-piperazinyl-(CH2)4-, -(CH2)4-piperazinyl-(CH2)5-, -(CH2)8-piperazinyl-CH2-, -(CH2)8-piperazinyl-(CH2)2-, -(CH2)8-piperazinyl-(CH2)3-, -(CH2)8-piperazinyl-(CH2)4-, or -(CH2)8-piperazinyl-(CH2)5-; or LIN means: The aforementioned groups may optionally be selected from deuterium, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, halogen, amino, hydroxyl, mercapto, cyano, carboxyl, C 2-6 alkynyl or C 2-6 Alkenyl substituent substitution.

18. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, is also represented by a structure of formula (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), (I-7), (I-8), (I-9), or (I-10): Among them, Z and R a1 R a2 R a3 R a4 、(R a5 ) m L1, L2, R a6 LIN, R c X1, X2, X3, X4, R 1a R 1b 、(R 1c ) p1a 、(R 1d ) p1b Ring A, Ring B, Ring C, X5, X6, X7, X8, X9, R 3a R 3b 、(R 3c ) p3a 、(R 4a ) p4a R 4b R 5a R 5b R 5c R 5d 、(R 5e ) p5a 、(R 5f ) p5b 、(R 5g ) p5c , ring D, R 6a R 6b R x1 、(R 7a ) p7a 、(R 7b ) p7b R 8a R 8b 、(R 8c ) p8a Ring E, (R) 8d ) p8b R 9a R 9b , ring F, (R 9c ) p9a 、(R 9d ) p9b 、(R 10a ) p10a R 10b R 10c R 10d and R 10e As defined in claim 3.

19. The compound of formula (I) as claimed in claim 1, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, selected from the compounds in Table 1.

20. The compound of formula (I) as claimed in any one of claims 1 to 19, or its salts, enantiomers, stereoisomers, solvates, or polymorphs thereof, wherein the compound is a hydrohalate (including hydrochloride, hydrobromide), sulfate, maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-glucose, α-D-glucohepanoate, glycolate, mucilage, L-ascorbate, orotate, picrate, glycinate, alanineate, arginineate, cinnamate, laurate, permethrin, sebate, benzenesulfonate, methanesulfonate, ethanesulfonate, ethanedisulfonate, formate, acetate, 2,2- Dichloroacetate, trimethylacetate, propionate, valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulic acid, 2-hydroxyethanesulfonate, nitrate, gentianate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecenoate, camphorate, camphor sulfonate, dodecyl sulfonate, phosphate, thiocyanate, dihydrophosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthoate, 1-hydroxy-2-naphthoate, 2-naphthalenesulfonate, trifluoroacetate, hydroxyacetate, or p-toluenesulfonate.

21. A pharmaceutical composition comprising: The compound of formula (I) as described in any one of claims 1 to 20, or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug or polymorph thereof, and at least one pharmaceutically acceptable carrier. And optionally include at least one additional therapeutic agent, such as an anticancer agent.

22. A medicine box or reagent kit comprising: The compound of formula (I) as claimed in any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof; or The pharmaceutical composition as claimed in claim 21.

23. The compound of formula (I) as claimed in any one of claims 1 to 20, or its salt, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, for the treatment and / or prevention of diseases or conditions selected from: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular diseases, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, dysfunctional uterine bleeding, anemia, childhood aplastic anemia, endometriosis, polycystic ovary syndrome, and thyroid diseases.

24. The compound of formula (I) as claimed in claim 23, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow diseases; myelodysplastic syndromes (MDS); previously treated myelodysplastic syndromes; transplant-related cancers; neutropenia; leukemia, including chronic myeloid leukemia, B-cell chronic lymphocytic leukemia, leukemia-associated anemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), monocytic leukemia, myeloid monocytic leukemia, acute lymphoblastic leukemia (ALL), acute T-lymphocytic leukemia, T-lymphocytic leukemia, chronic lymphocytic leukemia (CLL); lymphoma, including diffuse large B-cell lymphoma. Follicular lymphoma, non-Hodgkin lymphoma, Hodgkin lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary Primary mediastinal large B-cell lymphoma, relapsed transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory transformed non-Hodgkin lymphoma; thyroid cancer; melanoma; lung cancer, including lung adenocarcinoma, lung squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; bowel cancer; glioma; glioblastoma; neurotrophic glioma; Peripheral neuroepithelial tumor; ovarian cancer; bronchial cancer; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and Cowden's disease; pancreatic cancer; central nervous system cancers; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcoma, including rhabdomyosarcoma, various adipose-derived tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct carcinoma; Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa; keratoconjunctivitis sicca; autoinflammatory diseases, including gout; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS, and COVID-19. Viral infections, Gram-negative bacterial infections, Gram-positive bacterial infections, tuberculosis, etc.; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; multiple organ failure due to cachexia and septic shock; acute liver failure; functional uterine bleeding; anemia; aplastic anemia in children; endometriosis; polycystic ovary syndrome; thyroid diseases; cardiovascular diseases (e.g., coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin diseases (e.g., acne); Kennedy's disease; seborrheic alopecia; and hirsutism.

25. The use of any compound of formula (I) as described in any one of claims 1 to 20, or its salts, enantiomers, stereoisomers, solvates, isotope-enriched analogs, prodrugs, or polymorphs, in the preparation of a medicament for the treatment and / or prevention of diseases or conditions selected from: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular diseases, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, dysfunctional uterine bleeding, anemia, childhood aplastic anemia, endometriosis, polycystic ovary syndrome, and thyroid diseases.

26. A method of treating or preventing a disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as described in any one of claims 1 to 20, or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph thereof, wherein the disease or condition is selected from: tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, cardiovascular diseases, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin diseases, dysfunctional uterine bleeding, anemia, childhood aplastic anemia, endometriosis, polycystic ovary syndrome, and thyroid diseases.

27. The use as described in claim 25 or the method as described in claim 26, wherein the disease or condition is selected from the group consisting of: myeloma, including multiple myeloma, plasma cell myeloma, smoldering myeloma, smoldering multiple myeloma; myelofibrosis; bone marrow diseases; myelodysplastic syndrome (MDS); previously treated myelodysplastic syndrome; transplant-related cancer; neutropenia; leukemia, including chronic myeloid leukemia, B-cell chronic lymphocytic leukemia, leukemia-associated anemia, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), monocytic leukemia, myeloid monocytic leukemia, acute lymphoblastic leukemia (ALL), acute T-lymphoblastic leukemia, T-lymphoblastic leukemia, chronic lymphocytic leukemia (CLL); lymphoma, including diffuse large B-cell lymphoma, non-Hodgkin lymphoma, etc. Chigkin's lymphoma, anaplastic lymphoma, anaplastic large cell lymphoma, immunoblastic T-cell lymphoma, CD20-positive lymphoma, mantle cell lymphoma, follicular lymphoma (FL), Burkitt's lymphoma, marginal zone lymphoma (MZL), primary lymphoma, B-cell lymphoma, relapsed B-cell non-Hodgkin's lymphoma, relapsed diffuse large B-cell lymphoma, relapsed mediastinal large B-cell lymphoma, primary mediastinal large B-cell lymphoma Large B-cell lymphoma, relapsed-transformed non-Hodgkin lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-cell lymphoma, refractory primary mediastinal large B-cell lymphoma, refractory-transformed non-Hodgkin lymphoma; thyroid cancer; melanoma; lung cancer, including adenocarcinoma, squamous cell carcinoma, non-small cell lung cancer, and small cell lung cancer; inflammatory myofibroblastic tumor; colorectal cancer; bowel cancer; glioma; glioblastoma; neurotrophic glioma; Peripheral neuroepithelial tumor; ovarian cancer; bronchial cancer; prostate cancer; breast cancer, including triple-negative breast cancer, incidental breast cancer, ductal carcinoma, and Cowden's disease; pancreatic cancer; central nervous system cancers; neuroblastoma; extramedullary plasmacytoma; plasmacytoma; gastric cancer; gastrointestinal stromal tumor; esophageal cancer; colorectal adenocarcinoma; esophageal squamous cell carcinoma; liver cancer; renal cell carcinoma; bladder cancer; endometrial cancer; uterine cancer; head and neck cancer; brain cancer; oral cancer; sarcoma, including rhabdomyosarcoma, various adipose-derived tumors, Ewing sarcoma / primitive neuroectodermal tumors (Ewing / PNETs), and leiomyosarcoma; urothelial carcinoma; basal cell carcinoma; oral squamous cell carcinoma; bile duct carcinoma; Bone cancer; cervical cancer; skin cancer; Richter syndrome (RS); sepsis syndrome; autoimmune diseases, including rheumatoid arthritis, autoimmune encephalomyelitis, ankylosing spondylitis, psoriasis, systemic lupus erythematosus, multiple sclerosis, recurrent oral ulcers, Kawasaki disease, polymyositis / dermatomyositis, Sjögren's syndrome, atopic dermatitis, hidradenitis suppurativa; keratoconjunctivitis sicca; autoinflammatory diseases, including gout; inflammatory diseases, including Crohn's disease and ulcerative colitis, pneumonia, osteoarthritis, synovitis, systemic inflammatory response syndrome, airway inflammation, bronchitis; cerebral malaria; infectious diseases, including viral pneumonia, AIDS, and COVID-19. Viral infections, Gram-negative bacterial infections, Gram-positive bacterial infections, tuberculosis, etc.; septic shock; bacterial meningitis; chronic obstructive pulmonary disease; asthma; hemorrhagic shock; organ (including kidney, heart, lung) or tissue transplant rejection; diabetes; sarcoidosis; adult respiratory distress syndrome; multiple organ failure due to cachexia and septic shock; acute liver failure; functional uterine bleeding; anemia; aplastic anemia in children; endometriosis; polycystic ovary syndrome; thyroid diseases; cardiovascular diseases (e.g., coronary heart disease, congestive heart failure, myocardial infarction, atherosclerosis); skin diseases (e.g., acne); Kennedy's disease; seborrheic alopecia; and hirsutism.

28. Use of a compound of formula (II) or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph as described in claim 1 for the preparation of a compound of formula (I) or a salt thereof, enantiomer, stereoisomer, solvate, isotope-enriched analog, prodrug, or polymorph as described in claim 1: in Z represents C(O) or CH2; R a1 R a2 R a3 and R a4 The same or different and each independently represents hydrogen, deuterium, halogen, and carbon. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 alkoxy or halogenated C 1-6 Alkoxy; (R a5 ) m This indicates that the isoindoline ring connected to it is optionally surrounded by m R a5 Replace, each R a5 The same or different and each independently represents deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, and C. 1-6 Alkyl, Halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy, deuterated C 1-6 alkoxy or halogenated C 1-6 Alkoxy; m represents an integer 0, 1, 2, or 3; L1 represents S or O; L2 represents a substituted or unsubstituted straight-chain or branched alkylene group, or L2 is not present; R E express: Among them, ring Y 1 Indicates arylene, heteroarylene, heterocyclic, or cycloalkylene, (R d1 ) n1 Represents ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each can independently represent deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy groups, and n1 represents integers from 0 to 20; w represents an integer 0 or 1; and Y-shaped ring 3 Indicates a nitrogen-containing heterocyclic group, (R d2 ) n2 Represents ring Y 3 Optionally, it can be used by n2 R d2 Group substitution, each R d2 Each can independently represent deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, and C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy, and n2 represent integers from 0 to 20.

29. The use as described in claim 28, wherein the compound of formula (II) or its salts, enantiomers, stereoisomers, solvates, isotope-enriched analogs, prodrugs, or polymorphs are also compounds of formula (II-1), (II-2), (II-3), or (II-4): Among them, Z and R a1 R a2 R a3 R a4 、(R a5 ) m L1, L2 and R E As defined in claim 21.

30. The use as described in claim 28 or 29, wherein (i) L2 represents a substituted or unsubstituted straight-chain or branched C1-C5 alkylene group, or L2 is absent; and / or (ii) The ring Y 1 Indicates C5-C 30 arylene, 5 to 30-membered heteroarylene, 4 to 30-membered heterocyclic, or C3-C 30 Cycloalkylene, (R d1 ) n1 Represents ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 alkoxy group, and n1 represent integers from 0 to 20; and / or (iii) The ring Y 3 Indicates 4 to 30 nitrogen-containing heterocyclic groups, (R d2 ) n2 Represents ring Y 3 Optionally, it can be used by n2 R d2 Group substitution, each R d2 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy, and n2 represent integers from 0 to 20.

31. The use as described in claim 28, wherein (i) The ring Y 1 Indicates C5-C 20 arylene, 5 to 20% heteroarylene, 4 to 20% heterocyclic, or C3-C 20 cycloalkylene; for example, the cyclo-Y 1 express: Azahexacyclobutyl, oxohexacyclobutyl, pyrrolidine, imidazoalkyl, pyrazolidine, tetrahydrofuranyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiophenyl, tetrahydrothiaranyl, oxazolidine, thiazoalkyl, piperidinyl, piperazine, morpholinyl, thiomorpholinyl, dioxazolidinyl, dioxazolidinyl, heptyl, octyl, dioxazolidinyl, octyl, bridged heterocyclic (e.g., 5- to 15-membered bridged heterocyclic, such as azabicyclohexyl, azabicycloheptyl, or azabicyclooctyl), or spirohexacyclic (e.g., 5- to 15-membered spirohexacyclic, such as 3-azaspiro[5.5]undecyl or 7-azaspiro[3.5]nonyl); or Isofuranyl, Isooxazolyl, Isooxazolyl, Isodiazoleyl, Isothienyl, Isothiazolyl, Isothiazolyl, Isothiadiazoleyl, Ipyrroloyl, Imizolyl, Isopyrazolyl, Ipyridinyl, Iridazinyl, Iridolyl, Isoindolyl, Ibenzofuranyl, Isobenzofuranyl, Ibenzothienyl, Iridazoleyl, Ibenzimidazoleyl, Ibenzooxazolyl, Ibenzoisooxazolyl, Ibenzothiazolyl, Ibenzotriazoleyl, Ibenzo[2,1,3]oxadiazoleyl , benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazolyl, quinolineyl, isoquinolineyl, naphthinyl, cinnamolineyl, quinolineyl, quinoxalinyl, phthalazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidineyl, imidazo[1,2-a]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl, pyrrolo[2,1-b]thiazoleyl and imidazo[2,1-b]thiazoleyl; or Cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene, cyclooctylene, decahydronaphthylene, octahydro-1H-indenylene, spirocycloalkylene (e.g., C5-C) 15 Spirocycloalkyl, such as spiro[3.3]heptanediol, spiro[2.5]octanediol, spiro[3.5]nonanediol, spiro[4.4]nonanediol, spiro[4.5]decanediol, or spiro[5.5]undecanediol), or bridged cycloalkyl (e.g., C5-C). 15 Subbridged cycloalkyl groups, such as adamantylene, noradamantylene, borneolyl, bicyclo[2.2.1]heptane, 2-oxobicyclo[2.2.1]heptane, or bicyclo[2.2.1]heptene; or Phenylidene or naphthylene; The ring Y 1 Optionally, it can be used by n1 R d1 Group substitution, each R d1 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy; n1 represents an integer from 0 to 20; and / or (ii) The ring Y 3 This represents a 4- to 20-membered nitrogen-containing heterocyclic group; for example, the cyclic Y... 3 express: Azacyclobutyl, diazacyclobutyl, pyrrolyl, imidazoalkyl, pyrazolyl, oxazolyl, thiazoalkyl, piperidinyl, tetrahydropyridinyl, piperazinyl, 1,2,3,4-tetrahydropyrazinyl, hexahydropyrimidinyl, hexahydropyridazinyl, morpholinyl, thiomorpholinyl, azacycloheptyl, azacyclooctyl, dioxacyclohexyl, azacycloheptyl, azacyclooctyl, diazacycloheptyl, diazacyclooctyl, nitrogen-bridged heterocyclic groups (e.g., 5 to 20-membered nitrogen-bridged heterocyclic groups, e.g., azabicyclo[] 3.1.1]Heptyl (e.g., 6-azabicyclo[3.1.1]heptyl), azabicyclo[2.2.1]heptyl, azabicyclo[3.2.1]octyl (e.g., 3-azabicyclo[3.2.1]octyl), azabicyclo[2.2.2]octyl, diazabicyclo[3.1.1]heptyl (e.g., 3,6-diazabicyclo[3.1.1]heptyl), diazabicyclo[2.2.1]heptyl (e.g., 2,5-diazabicyclo[2.2.1]heptyl) Heptyl), diazabicyclo[3.2.1]octyl (e.g., 3,8-diazabicyclo[3.2.1]octyl), diazabicyclo[2.2.2]octyl (e.g., 2,5-diazabicyclo[2.2.2]octyl)), or 5 to 20 azirheptocycloyl (e.g., azirhepto[2.3]hexyl, azirhepto[3.3]heptyl, azirhepto[2.4]heptyl, azirhepto[3.4]octyl, azirhepto[3.5]nonyl, azirhepto[4.4]nonane alkyl, azaspiro[4.5]decyl, azaspiro[5.5]undecyl, diazaspiro[2.3]hexyl, diazaspiro[3.3]heptyl, diazaspiro[2.4]heptyl, diazaspiro[3.4]octyl, diazaspiro[3.5]nonyl, diazaspiro[4.4]nonyl, diazaspiro[4.5]decyl, diazaspiro[5.5]undecyl, octahydrocyclopentano[c]pyrroleyl, octahydropyrrolo[3,4-c]pyrroleyl or decahydronaphthidyl); The ring Y 3 Optionally, it can be used by n2 R d2 Group substitution, each R d2 Each of these groups can be independently classified as deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, or C. 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 alkoxy groups; and n2 represents an integer from 0 to 20; and / or (iii) The L2 represents methylene, ethylene, propylene or isopropylene, or L2 is not present.

32. The use as described in claim 28, wherein R E Selected from: in, R d3 R d4 Each is independently selected from hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, oxo, C 1-6 Alkyl, deuterated C 1-6 Alkyl, Halogenated C 1-6 Alkyl, Halogenated C 1-6 Alkoxy or C 1-6 Alkoxy; and R d3 R d4 They are not both hydrogen.

33. The use as described in claim 28, wherein the compound of formula (II) is selected from: 3-(5-(azacyclobutane-3-ylthio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(pyrrolidine-3-ylthio)isoindololin-2-yl)piperidin-2,6-dione; 3-(1-oxo-5-(piperidin-4-ylthio)isoindoline-2-yl)piperidin-2,6-dione; 3-(5-(azacycloheptane-4-ylthio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(4-(azacyclobutane-3-ylthio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(6-(azacyclobutane-3-ylthio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(7-(azacyclobutane-3-ylthio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((7-azaspiro[3.5]nonane-2-yl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((3-azaspiro[5.5]undecane-9-yl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((octahydrocyclopentano[c]pyrrolo-5-yl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((3,3-difluoropiperidin-4-yl)thio)-1-oxoisoindoline-2-yl)piperidin-2,6-dione; 3-(5-((3-azabicyclo[3.2.0]heptane-6-yl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((3-azabicyclo[3.1.0]hexane-6-yl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-(((3-azabicyclo[3.1.1]heptane-1-yl)methyl)thio)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-(((5-(azacyclobutane-3-yl)pyridin-3-yl)methyl)thio)-1-oxoisoindoline-2-yl)piperidin-2,6-dione; 3-(5-(azacyclobutane-3-yloxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(pyrrolidine-3-yloxy)isoindoline-2-yl)piperidine-2,6-dione; 3-(1-oxo-5-(piperidin-4-yloxy)isoindoline-2-yl)piperidin-2,6-dione; 3-(5-(azacycloheptane-4-yloxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(4-(azacyclobutane-3-yloxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(6-(azacyclobutane-3-yloxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(7-(azacyclobutane-3-yloxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((7-azaspiro[3.5]nonane-2-yl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((octahydrocyclopentano[c]pyrrolo-5-yl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((3-azaspiro[5.5]undecane-9-yl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((3,3-difluoropiperidin-4-yl)oxy)-1-oxoisoindoline-2-yl)piperidin-2,6-dione; 3-(5-((3-azabicyclo[3.2.0]heptane-6-yl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((3-azabicyclo[3.1.0]hexane-6-yl)oxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione; 3-(5-((3-azabicyclo[3.1.1]heptane-1-yl)methoxy)-1-oxoisoindololin-2-yl)piperidine-2,6-dione; and 3-(5-((5-(azacyclobutane-3-yl)pyridin-3-yl)methoxy)-1-oxoisoindoline-2-yl)piperidine-2,6-dione.

34. The use as described in claim 28, wherein the salt of the compound of formula (II) is a hydrohalate (including hydrochloride, hydrobromide), sulfate, maleate, sulfonate, citrate / citrate, lactate, lactobionate, L-tartrate, fumarate, L-malate, L-lactate, α-ketoglutarate, hippurate, D-glucuronate, D-glucose, α-D-glucohepanoate, glycolate, mucilage, L-ascorbate, orotic acid salt, picrate, glycine salt, alanine salt, arginine salt, cinnamate, laurate, permethrin, sebate, benzenesulfonate, methanesulfonate, ethanesulfonate, ethanedisulfonate, formate, acetate, 2,2-dichloroacetate, trimethylacetate, propionate. Valerate, palmitate, triphenylacetate, 2-ethyl-succinate, iodate, nicotinate, L-pyroglutamate, L-proline, ferulic acid, 2-hydroxyethanesulfonate, nitrate, gentianate, cholate, salicylate, terephthalate, glutarate, adipate, stearate, oleate, undecenoate, camphorate, camphor sulfonate, dodecyl sulfonate, phosphate, thiocyanate, dihydrophosphate, pyrophosphate, metaphosphate, oxalate, carbonate, malonate, benzoate, mandelate, succinate, pyruvate, pyruvate, p-chlorobenzenesulfonate, 1,5-naphthalenedisulfonate, 3-hydroxy-2-naphthalenecarboxate, 1-hydroxy-2-naphthalenecarboxate, 2-naphthalenesulfonate, succinate, trifluoroacetate, hippurate, hydroxyacetate, or p-toluenesulfonate.

Images